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ABSTRACT 
Abnormalities in brain development and maladaptive plasticity are thought to underlay a 
range of neurodevelopmental and neurological disabilities and disorders, such as autism 
spectrum disorders, schizophrenia and learning disability. Though many transcription factors 
are known to control important diverse aspects of embryonic development, the molecular 
mechanisms by which these factors coordinate processes such as neuronal differentiation 
remain unclear. Thus, there is a need to identify genes and pathways involved in these 
processes. Myelin transcription factor 1- like (MYT1L) has a property to convert fibroblast to 
neurons and it is specifically expressed in the brain. Since the fundamental steps in neural 
development and MYT1L gene are highly conserved in vertebrates, we anticipated that 
interference with its function may result in obvious phenotypes. To understand the role of 
MYT1L in the vertebrate development, we first examined its expression patterns in the 
zebrafish and mouse. We reported myt1l first manifestation in the telencephalon region 
around 24h post-fertilisation and gradual increase of its mRNA levels during fish 
embryogenesis. We have also examined mRNA levels of this gene in mouse brain and found 
Myt1l most prominent role just before birth, when neural development is most active. To 
investigate the role of MYT1L during neural differentiation we used lentiviral-mediated gene 
silencing of this transcription factor in human neural stem cells. Subsequent microarray 
analyses revealed a list of potential targets of MYT1L, most of which were down-regulated 
upon MYT1L silencing, suggesting that the expression of those genes is mediated by MYT1L. 
The analyses of gene expression patterns during stem cells development have revealed that 
Myocyte Enhancer factor 2 (MEF2A)-specific binding site is present in most of genes co-
expressed with MYT1L. We hypothesised, that MEF2A may regulate the expression of MYT1L 
and MYT1L co-expressed genes. By examining the consequences of MEF2A down-regulation in 
neuronal stem cells we discovered that MYT1L expression was negatively regulated upon 
MEF2A silencing. Differential gene expression analyses revealed that the majority of genes 
deregulated upon knock-down of MEF2A were also de-regulated by knock-down of MYT1L, 
suggesting that both genes operate through similar or possibly the same regulatory pathways. 
Therefore, the findings presented throughout this thesis contribute towards a better 
understanding of MYT1L role, function and its molecular mechanisms involved in the neural 
development. Further work is required to provide a greater understanding of MYT1L 
involvement in normal brain growth and maturation and the collective results might help to 
unravel molecular mechanisms underlying neurodevelopmental disorders and possibly help in 
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1. Introduction  
Over the last decades, remarkable progress has been made in the field of neurobiology. In 
particular, advances in molecular biology have furthered our knowledge and understanding of 
how the brain develops and nerve cells communicate and how these internal cellular and 
molecular mechanisms relate to behaviour. In addition, the completion of the Human Genome 
Project and 'HapMap', have laid grounds for discovery of new genes for complex disorders.  
Molecular genetics methods, such as genome-wide gene expression analysis, next generation 
sequencing, linkage and association studies will help us to understand genetic aspects of 
psychiatric diseases and integrate this findings to serve patients (Avramopoulos, 2010).  
Genetic and inherited components have been found for nearly all behavioural disorders, such 
as autism (Bailey et al., 1995; E. M. Morrow et al., 2008; Sutcliffe, 2008; Szatmari et al., 2007), 
schizophrenia (Bergen et al., 2012; Hamshere et al., 2013; Ripke et al., 2013), attention-
deficit/hyperactivity disorder (ADHD) (Faraone et al., 2005; Silberg et al., 1996; Smalley et al., 
2002; Smith et al., 2003; Stevenson, 1992) or intellectual disabilities (de Ligt et al., 2012; Gécz, 
Shoubridge, & Corbett, 2009; Plomin, Owen, & McGuffin, 1994; Rauch et al., 2012). 
Furthermore, genes and genetic mechanisms that may contribute to neurological disorders 
have been identified.  
Besides this progress in the field of human genetics, the possibility to study model organisms, 
such as zebrafish, mice and primates, has allowed us to further our understanding of how 
different genes contribute to neurological abnormalities.  
 
1.1. Normal brain development  
Several major processes must be specifically coordinated during normal brain development. 
Any disruptions, due to either genetic or environmental factors, can result in cognitive deficits, 
leading to neurodevelopmental and psychiatric disorders, such as autism spectrum disorder 
(ASD) and schizophrenia (Ronan, Wu, & Crabtree, 2013). 






Figure 1.1. Major events in human brain development and times of their occurrence (picture from 
(Andersen, 2003).  
 
1.1.1. Neurulation 
Human brain development begins with the formation of the neural tube (neurulation) at 
gestational week three (Stiles & Jernigan, 2010). This consists of a primary and secondary 
stage, resulting in the formation of the central nervous system and spinal cord.  
Primary neurulation spans from approximately the 18th gestation day to the end of the fourth 
week of gestation and it refers to the formation of the neural tube (Fotos, Olson, & Kanekar, 
2011). This process is regulated by multiple genes and it involves complex morphogenetic 
events, orchestrated by cell proliferation, changes in cell adhesion and apoptosis (Back & 
Plawner, 2012). The nervous system originates from the dorsal point of the embryo as a neural 
plate which consists of tissue that differentiated in the middle of the ectoderm.  At 
approximately day 18 of gestation the notochord and chordal mesoderm induce formation of 
the neural plate. Continuous induction directed by chordal mesoderm leads to dorsal closure 
of the neural plate and formation of the neural tube, which gives rise to the central nervous 
system (CNS). Disturbances during the events of primary neurulation are associated with a 




paired-box 3 (PAX3) gene, in which any perturbations can lead to errors in neural tube closure 
(Sarnat, 2008).  
Central to the fusion of the neural tube are two signalling molecules: bone morphogenetic 
proteins (BMPs) and Sonic hedgehog (Shh). They influence and induce the alar (a dorsal 
portion)  and the basal (a ventral portion) plates that later form brain stem and spinal cord 
(Back & Plawner, 2012). Absence of sonic hedgehog will result in holoprosencephaly. The 
development and closure of the neural tube is usually completed by 28 days post-conception 
and failure of the posterior neural tube to close can result in spina bifida, while defects in the 
closure of the anterior neural tube could result in anencephaly (Blom, Shaw, den Heijer, & 
Finnell, 2006).   
As the neural folds fuse, a population of specialised cells is formed from ectodermal cells on 
both sides of the neural tube. These cells form neural crest and they migrate shortly after the 
closure of the neural tube. They are precursor cells to melanocytes in the skin, facial 
connectivity tissues, sensory, sympathetic and parasympethtic ganglia, Schwann’s cells and 
enteric neurons (Back & Plawner, 2012; B. K. Hall, 2008). 
The process of secondary neurulation refers to the formation of the neural tube in the sacral 
and caudal regions from the caudal cell mass. At gestational days 41 to 51, the secondary 
neural tube and the central canal begins to regress together with the disappearance of the 
embryonic tail.  
 
1.1.2. Prosencephalon development 
The prosencephalon refers to the telencephalon and the diencephalon, future forebrain (Back 
& Plawner, 2012). The diencephalon later develops into the thalamus, hypothalamus and 
epithalamus, while the telencephalon gives rise to the cerebral hemispheres. Formation of the 
prosencephalon begins at the rostral part of the neural tube, peaking at 5-6 weeks after 
conception. The next stage, called prosencephalic cleavage, includes horizontal cleavage 
(formation of paired optic vesicles, olfactory bulbs and tracks), sagittal cleavage (to form the 
paired cerebral hemispheres, lateral ventricles and basal ganglia) and transverse cleavage (to 
separate the telencephalon from the diencephalon) (J. J. Volpe, 2000). During the next 2-3 
months the midline prosencephalon develops to create the corpus callosum, the optic nerve 




can lead to a number of defects including holoprosencephaly which  is a severe foetal brain 
malformation caused by a failure of cleavage of prosencephalon (Cohen Jr & Sulik, 1992) 
 
1.1.3. Development of the cerebellum  
The cerebellum is one of the most extensively studied parts of the brain. It integrates motor 
control with sensory perception, motor learning and cognition (C. C. Bell, 2002; Curtis C. Bell, 
Han, & Sawtell, 2008; Ito, 2002). The cerebellum is derived from the dorsal part of the anterior 
hindbrain and it develops over an extended period of time, starting at the early embryonic 
stage through to the first postnatal years. Its development begins after closure of the neural 
tube, and happens concurrently with prosencephalic development (ten Donkelaar & Lammens, 
2009).   Its growth occurs in four major steps:  
Firstly, around 5th and 6th week of development, the two compartments of the cell 
proliferation are formed, the Purkinje cells and the deep cerebellar nuclei and later the Golgi, 
arise from the ventricular zone of the metencephalic alar plates. Next, towards the end of the 
embryonic period, granule cell precursors are formed from the upper rhombic lip. Granule 
precursor cells form the external granule layer, from which the cells migrate inwards through 
the Purkinje cells and form the internal granular layer of the mature cerebellum (ten Donkelaar 
& Lammens, 2009). 
This complex and prolonged developmental process makes the cerebellum vulnerable to a 
broad spectrum of developmental disorders, such as spinocerebellar ataxia and Dandy-Walker 
malformation (Table 1.2) (Back & Plawner, 2012). Functional and anatomic abnormalities of 
the cerebellum have been linked to psychological disorders such as autism (Ito, 2008; Tsai et 
al., 2012).  
 
1.1.4. Neuronal formation 
The two main cell types that make up the nervous system are neuron and glia cells. The human 
brain contains billions of neurons, most of which are developed by mid-gestation (Bayer, 
Altman, Russo, & Zhang, 1993). Neurons, or nerve cells, are electrically excitable cells that 




Major proliferative events occur between second and fourth month of gestation, with peak cell 
proliferation around 8 to 16 weeks (Figure 1.2). 
 
Figure 1.2. Timeline of the major events occurring during brain development. This figure represents 
brain development beginning with neurulation, and proceeding with neural proliferation and neuronal 
migration, synaptogenesis and pruning, which represent the creation and elimination of synapses during 
growth, myelination, and neuronal apoptosis (figure adapted from (Tau & Peterson, 2010)).  
  
All neurons and glia are derived from ventricular and subventricular zones, present at every 
level of the developing nervous system (Joseph J. Volpe, 2008, pp. 55-118). With the closure of 
neural tube, at the end of gastrulation period, an area of neuroepithelial cells is formed. 
However, this group of neural stem cells is too small to sustain the whole creation of neurons, 
therefore the first step in production of neurons is to intensify and expand the populations of 
neural progenitor cells. Neural progenitor cells are mitotic cells, meaning they can divide and 
form new cells. The initial cycle of neural progenitor proliferation results from symmetrical 
expansion of the stem cell pool with each mitotic event creating two additional cells (Back & 
Plawner, 2012; Pasko Rakic, 1995). Over multiple rounds of cell division, the symmetrical 
expansion determines the total pool of stem cells from which cortical plate will form. Once the 
generation of stem cells pool is stable, the mode of cell division changes from symmetrical to 
asymmetrical (Figure 1.3). During this phase of clonal expansion, lasting from 5 months of 
gestation to 1 year after birth, two different cell types are produced, one neuronal progenitor 
cell and one neuron cell, that withdraws from the cell cycle (Caviness Jr & Takahashi, 1995).    
Neurons are post-mitotic cells, meaning they cannot divide and produce new cells (Stiles & 
Jernigan, 2010; Wodarz & Huttner, 2003). The postmitotic neurons then begin migrating from 




division is gradual and as it progresses, proportionately larger number of postmitotic neurons, 
which are all derived from the same proliferative pool, and fewer stem cells, are produced.  
 
Figure 1.3. The lineage trees showing the relationship between neuroepithelial cells (NE), radial glial 
cells (RG) and neurons (N) (adapted from(Gotz & Huttner, 2005)) 
 
Disorders related to impaired neural proliferation would be expected to have a major 
influence on the development of the CNS and they include undersized brain (micrencephaly) 
and oversized brain (macrencephaly)(Joseph J. Volpe, 2008). 
  
1.1.5. Neuronal migration 
Neural migration refers to process by which millions of nerve cells move from their origin site 
in the ventricular and subventricular zones to their terminal sites across the CNS. Two distinct 
modes of migration have been identified so far: radial and tangential migration.  Radial 
migration is the main mode of migration in the developing cerebral cortex. In tangential 
migration, neurons move parallel to the surface of the brain along axons or other neurons and 
often transgress regional boundaries. An example of this mode of migration is the movement 
of cortical interneurons from their origin in the ventral telencephalon to the developing 
cerebral cortex (Nadarajah & Parnavelas, 2002). In the early stages of brain development, 
neurons only travel very short distances, and the migration process is called somal 
translocation, which refers to a  displacement of the cell body rather than migration of the 
whole cell (Nadarajah & Parnavelas, 2002). In somal translocation, neuron whose basal process 
(extension of the cell’s body) is attached to the pial surface (the outer surface of the 
developing brain) and its cell body translocates as the process becomes shorter (Miyata, 
Kawaguchi, Okano, & Ogawa, 2001; Nadarajah, 2003). At the end of the somal translocation 




With the developmental progress, the brain grows and the primary mode of neural migration 
changes. Rakic first proposed that young neurons, that have to travel greater distances, 
require ‘radial glial guides’ to support their migration (Figure 1.4) (P. Rakic, 1972; Sidman & 
Rakic, 1973). The radial glia processes extend from the ventricular zone into the pial surface of 
the brain and provide scaffolding along which neurons can travel. The migrating nerve cells 
attach themselves to the radial glia guide and move along the cellular scaffold into the 
developing cortical plate (Nadarajah & Parnavelas, 2002). Each glial scaffold can support the 
migration of many neurons.   
 
Figure 1.4. A three dimensional figure a  migrating neuron (N) along the surface of a radial glial fiber 
(adapted from (P. Rakic, 1972)).  
 
As neural migration advances, the preplate is split by the arrival of subsequent population of 
neuronal stem cells that will form the cortical plate. This results in the formation of the 6-
layered cortical structure. The Cajal-Retzius cells of the marginal zone control the positioning 




the cortex, and later arriving neurons take superficial positions, forming an ‘inside-out’ (from 
layer 6 to layer 1) sequence.  
A wide spectrum of neural migration disorders can have a genetic background, such as 
schizencephaly, lissencephaly or pachygyria. Abnormalities of the LIS1 (Lissencephaly 1), DCX 
(doublecortin), ARX (Aristaless-related homeobox), TUBA1A (Alpha-1A tubulin) and RELN 
(reelin) genes have been associated with these malformations (Guerrini & Parrini, 2010). 
Additionally, abnormal neuronal migration causes abnormal cortical function, which frequently 
results in cognitive and motor impairment and epilepsy (Guerrini, Dobyns, & Barkovich, 2008). 
 
1.1.6. Neuronal differentiation and regionalisation.  
Neural regionalisation events occur from around the fifth month of gestation to several years 
after birth. It is not known what specifies the regional identity of the different areas of the CNS 
(McKay, 1997). There are versatile expression patterns of cell surface signals and 
transcriptional regulators in the developing neuroepithelium before neuronal differentiation 
occurs (J. L. Rubenstein & Puelles, 1994). One hypothesis of how regional identity occurs could 
be that different stem cells for different brain regions. During neurogenesis, neurons are 
produced from almost all regions of the neuroepithelium, however it is unlikely that 
neurogenesis represents the default pathway for differentiation (Kintner, 2002). In general, 
neurons are produced before glia and specific type of each cell has also a specific time of 
‘birth’.  Studies on Drosophila and grasshopper revealed that each stem-cell has its unique 
configuration based on its position within the neuroectoderm (Skeath, 1999). It has been 
suggested that stem cells fate can be at least partially due to intrinsic signalling (Shen et al., 
2006), however how particular changes in progenitor characteristics occur remains largely 
unknown (Stiles & Jernigan, 2010). It is believed that the main genetic programming involves 
basic helix-loop-helix (bHLH) transcription factors, which are required for the differentiation of 
neuroepithelial cells into neurons, regardless of where and when they form. It is becoming 
increasingly plausible that most proliferating cells in the developing nervous system have been 
encoded with positional and patterning information that limits their developmental repertoire 
and proliferative potential and it is a stage-dependant change (S. Temple, 2001). Therefore, 
many progenitor cells are specified long time before their terminal differentiation.  
Once they have reached their destination within a cortex, the neurons have to become a part 




develop neuronal process (axons and dendrites). Neurons share a common organisation, 
controlled by their function, which is to receive, process and transmit information. Neurons 
exist in a variety of shapes and forms, but generally consist of four basic regions: dendrites, a 
cell body, an axon and axon terminals (Figure  1.5). Based on shape, neurons are classified into 
3 major groups: unipolar, bipolar and multipolar (Figure 1.5). Unipolar neurons, are the most 
simple nerve cells, as they only have one primary process that can branch out. One branch 
serves as an axon, the other branches serve as dendrites. These type of neurons are present 
mainly in invertebrates; in vertebrates they are found in the autonomic nervous system. 
Bipolar neurons have a cell body that gives rise to two processes: one axon and a dendrite. 
Many sensory cells are bipolar cells, they are found in the retina and nose epithelium. 
Multipolar neurons are predominant in the vertebrate central nervous system. They have a 
single axon and typically number of dendrites that emerge from various points around the cell 
body. Multipolar cells vary greatly in their shape, especially in the axon length and the number 
of dendrites. Usually, the number of dendrites correlates with the number of synaptic 
connection the cell makes. Multipolar neurons predominate in the nervous system of 
vertebrates.  
 






Each part has distinct functions. Axons are the principal means of conveying the information 
over long distances and sending signals from the neuron to its terminals. Dendrites act as the 
receiver part of the neuron; their function is to process and transmit information to the cell 
body. This cell body, in which lies the nucleus, contains the genetic information that codes for 
production of cellular function elements. Each cell has multiple dendrites with a close 
proximity to the cell and a single axon that can extend for a long distance away from the cell. 
At the tip of each axon resides a growth cone, which is the site of axonal elongation and 




Once the axon has reached its designated position, synapses are formed, which are the 
connections between the axon and the target cell. The function of the synapse is to transfer 
electric activity (information) from one cell to another. The nerve cell transmitting the 
information is called the presynaptic cell and the cell receiving a signal is the postsynaptic cell. 
For synapses to perform their task chemical neurotransmitters are released from the 
presynaptic neuron that bind and activate neurotransmitter-gated ion channels on the 
postsynaptic cell (Waites, Craig, & Garner, 2005). Activity-dependent and -independent 
process stimulates the initial steps of synapse differentiation and formation (Jiang et al., 1996). 
It has been shown that synapse number can be greatly regulated by non-neuronal signals, 
showing that glia may actively participate in synaptic plasticity (Ullian, Sapperstein, 
Christopherson, & Barres, 2001). Synapses are held together by cell adhesion molecules 
(CAMs) which stabilise the initial contact between axons and dendrites (Craig, Graf, & Linhoff, 
2006). Research suggests that the actions of cell adhesion molecules is not only limited to 
providing adhesive support but they are also essential for subsequent multiple stages of 
synapse formation and maturation (Dalva, McClelland, & Kayser, 2007). A number of CAMs 
have been identified as mediating the assembly of the pre- and postsynaptic protein 
complexes. Neurexins and neuroligins were the first CAMs shown to be potent inducers for 
pre- and postsynaptic specialisation (Graf, Zhang, Jin, Linhoff, & Craig, 2004; Scheiffele, Fan, 
Choih, Fetter, & Serafini, 2000).  
There are many types of synapses in the brain, each identified by the neurotransmitter they 




dopamine and serotonin. They also include neurotransmitters that are cell-specific, 
determining the phenotype and function of a neuron. The specificity of released 
neurotransmitters is mostly regulated by transcription factors (Goridis & Brunet, 1999). For 
example, two members of the forkhead/winged helix transcription factor family, Foxa1 and 
Foxa2, were found to be necessary to regulate the maintenance of dopaminergic neurons 
(Stott et al., 2013). The final stage of synaptogenesis is referred to as synapse elimination 
where inappropriate synapses are pruned via activity-dependent competition.  The process is 
important for the formation of precise neural circuitry, which is necessary for proper brain 
functioning (Lichtman & Colman, 2000). During the early stages of development, synaptic 
contacts are generated in excess. During postnatal development the redundant synapses are 
eliminated while the proper ones are strengthened to construct specific neural connections 
(Kano & Hashimoto, 2009). 
 
1.1.6.2. Apoptosis 
Apoptosis, or programmed cell death is a genetically regulated and evolutionarily conserved 
process by which cells commit suicide. While most neurodevelopmental events involve 
differentiation and proliferation of the elements of central nervous system, cell death plays a 
critical role in the development of the nervous system. 
Apoptosis occurs throughout the nervous system in neuron, glial, and neural progenitor cells. 
It is estimated that between 20 and 80% original cell population is eliminated as a result of 
apoptosis in the developing nervous system (Oppenheim, 1991). During neural development 
the role of apoptosis include optimisation of synaptic connections, removal of unnecessary 
neurons, and pattern formation (Burek & Oppenheim, 1999). Factors activating the cell death 
system seem to directly depend on the extent of neuron connections to a postsynaptic target 
which suggests that neurons are initially overproduced and then compete for target-derived 
neurotrophic factors, thus matching the size of the target cell population with the number of 
innervating neurons (Cowan, Fawcett, Oleary, & Stanfield, 1984). Failure of programmed cell 
death or over-activation of this process can have major detrimental effects for brain 
development and subsequent function. It has been suggested that inappropriate activation of 
apoptosis is responsible for some neuronal loss during stroke and trauma (Barinaga, 1998), 
Alzheimer’s (Smale, Nichols, Brady, Finch, & Horton Jr, 1995), Huntington’s (Hickey & 





Though most of the production and differentiation of neurons occur prenatally, proliferation 
and migration of glial progenitor cells continues for extended period of time after birth (Stiles 
& Jernigan, 2010). Myelination refers to the process in which axons are wrapped with 
specialised myelin membrane that serves as an insulating layer and promotes a fast 
conduction of electrical impulses through the nerve cell. Myelin is synthesised by 
oligodendrocytes in the CNS, and it progresses most rapidly around and after birth (Umemori, 
Satot, Yagi, Aizawal, & Yamamoto, 1994). Initial proliferation and differentiation of 
oligodendrocytes is followed by expansion of the cell membrane to form the myelin sheath. 
Oligodendrocytes synthesise a number of trophic factors that play role in the axonal integrity 
and neuronal survival, therefore showing an oligodendrocyte influence on axonal diameter 
and neuronal size (McTigue & Tripathi, 2008). 
 
1.2. Transcription factors and brain development 
Important cell fate decisions during development of an organism are driven by gene 
expression changes, in which transcription factors play a pivotal role. Transcription factors 
(TFs) are proteins that control the expression of other genes. In general, they contain within 
their sequence variety of protein domains that bind to a specific consensus sequence of DNA 
and recruit additional cofactors to activate gene transcription (Nelson, 1995). Their activity is 
expected to play a crucial role in brain development and neural differentiation and functions, 
as these events depend on coordinated patterns of activation and inactivation of specific 
genes (He & Rosenfeld, 1991). Indeed, TFs play a key role in specifying cell identity during 
neuronal differentiation, and combination of transcription factors result in specific cell fates. 
These molecules perform their function alone or together with other proteins as part of 
complexes. To better understand different aspects of gene regulation, it is important to know 
the basic mechanisms behind this process.  
Transcription can be divided into two parts: basal transcription and regulatory transcription. 
Regulatory elements can be located within the gene promoter, directly adjacent to the 
promoter region or at a distance from transcription start site (TSS) of the gene. A cis- 
regulatory region of the gene required for the start of the transcription is the designated 




Makino, & Mikoshiba, 1996). A promoter is a target for basal transcription machineries. Trans- 
regulatory elements can lay millions of nucleotides away from the transcriptional start site and 
can interact with the cis- elements by directing transcription to specific cells or tissues. 
The sequence to which a transcription factor binds with the highest affinity is known as its 
consensus binding site, and typically consists of 5-15 base pairs (Remenyi, Scholer, & 
Wilmanns, 2004). The core promoter directs initiation of transcription and contains several 
regulatory elements, such as basal transcription factors and RNA polymerase II which produce 
all protein coding and most non coding RNAs.  
Because the primary function of transcriptional regulators is to govern the expression of target 
genes, the phenotypic abnormalities observed when TFs are misregulated are likely to be 
mediated by misexpression of target genes. Several neurodevelopmental disorders are caused 
by mutations of TFs (Hong, West, & Greenberg, 2005). For example, in the patients with 
schizophrenia, the expression of the transcription factor SRY-related HMG-box 10 (SOX10) was 
found to be decreased (Tkachev et al., 2003). Additionally, single nucleotide polymorphisms 
(SNPs) at the Neuronal PAS domain protein 3 (NPAS3) transcription factor gene locus was 
associated with increased risk of schizophrenia, bipolar disorder and major depression (J. 
Huang et al.; Sha et al.). Mutations within methyl CpG binding protein 2 (MECP2) gene are the 
cause of most cases of Rett syndrome (Shevell, 2009). disorders (Hong et al., 2005). Above 
examples illustrate the importance of transcription factors. However, how individual TFs 
contribute to brain development is largely unknown. 
  
1.2.1. Myelin transcription factor 1-like (MYT1L) 
One of the TFs that have been linked to brain development is the myelin transcription factor 1- 
like (MYT1L) gene product (J. G. Kim et al., 1997). MYT1L was first described recognised as a 
neural zinc finger transcription factor-1 (NZF-1) (Jiang et al., 1996). This gene is a member of 
the myelin transcription 1 gene family, which encodes neural specific, zinc-finger-containing 
DNA-binding proteins. In the human genome, there are three members of this family: myelin 
transcription factor 1 (MYT1), myelin transcription factor 1 like (MYT1L) and Myelin 
transcription factor 3 (MYT3), also known as Suppression of tumourigenicity 18 (ST18 (J. G. Kim 





The protein MYT1 is a representative of the Cys-Cys-His-Cys (CCHC) zinc-finger protein family, 
which has been highly conserved during evolution between both species and family members. 
MYT3 is the third member of this family (Yee & Yu, 1998). Romm et al. suggested that 
MYT1/MYT1L binding can result in the recruitment of histone deacetylases (HDACs) to target 
gene promoters, which results in transcriptional repression (Romm, Nielsen, Kim, & Hudson, 
2005). Jiang et al. first reported the presence of two separate zinc-finger DNA biding domains 
(Cys-Cys and His-Cys) in MYT1L, each of which could bind independently to similar DNA 
sequences (Jiang et al., 1996).  MYT1 gene maps to human chromosome 20, while MYT1L gene 
is located in chromosome 2 in humans (2p25.3). The gene spans >542kb and has 25 exons. 
Exon 1 to 5 and a distal part of exon 25 are untranslated regions while the other 19 exons and 
proximal parts of exon 25 are coding regions. The Myt1l gene is localised to mouse 
chromosome 12. This localisation is consistent with that reported for NZF-1 (Jiang et al., 1996), 
indicating that the rat NZF-1 and the mouse Myt1l represent the same gene (J. G. Kim et al., 
1997). Human MYT1L protein is similar to the Myt1l rodent protein, being 95% homologous to 
the mouse and 92% to the rat, showing its high conservation through evolution (S. J. C. Stevens 
et al., 2011).  
Both MYT1L and MYT1 zinc finger proteins are found in neurons at early stages of 
differentiation (J. G. Kim et al., 1997). MYT1 was found to be highly expressed in cells of the 
subventricular zone (Armstrong, Kim, & Hudson, 1995), a germinal area from which neurons, 
astrocytes, and oligodendrocytes arise, suggesting that this transcription factor may play a role 
in the differentiation of neural progenitor cells (J. G. Kim et al., 1997). MYT1L, unlike MYT1, 
was not found in glial cells, but MYT1L protein was expressed in neurons after terminal mitosis 
(J. G. Kim et al., 1997). It was also suggested that transcripts encoding for MYT1L were present 
in differentiating neurons but not in neuroblasts. This suggested that MYT1L might have a role 
in the development of the nervous system. MYT1L is specifically expressed in the CNS 
(Berkovits-Cymet, Amann, & Berg, 2004; J. G. Kim et al., 1997). Additionally, the microarray 
data obtained online from the quantitative atlas BioGPS (available at 
http://biogps.org/#goto=welcome) has helped to provide evidence of the restricted expression 
of MYT1L in human brain (Figure 1.6) which is further evidence that it may play a role in the 





Figure 1.6. Expression pattern of MYT1L across different tissues and organs. The expression levels 
correspond to the results obtained from microarray experiments conducted with Affymetrix chips (Wu 
et al., 2009). To analyse human mRNA levels, the probe 210016_at on the Human Genome U133 array 
was used (Su et al., 2004);  (source: http://biogps.org/#goto=welcome) 
 
Jiang et al. (1996) first analysed the expression of rat Myt1l (called NZF-1). They found that 
NZF-1 is expressed in the rat’s developing nervous system, primarily brain, spinal cord, sensory 
ganglia, retina, and nasal epithelia (Jiang et al., 1996). 
The other family members such as Myt1 have also been characterised as brain specific 
(Armstrong et al., 1995). Myt1 is a zinc-finger DNA binding protein that was named for its 
ability to recognise the promoter region of the proteolipid (PLP) gene, the most abundantly 
transcribed CNS myelin gene (J. G. Kim & Hudson, 1992). During development of the 
oligodendrocytes, Myt1 is localised within nuclei of immature cells and then downregulated 
after terminal differentiation and accumulation of myelin proteins in mature oligodendrocytes 
(Armstrong et al., 1995). Myt1 continues to be expressed in germinal zones of the adult CNS 
and is upregulated in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas as well 
as in a dysembryoplastic neuroepithelial tumor (Armstrong et al., 1997) and following spinal 
cord traumatic injury (Wrathall, Li, & Hudson, 1998). In vitro, expression of a dominant 
negative form of Myt1 showed that Myt1 can regulate a critical transition in oligodendrocyte 




terminal differentiation and upregulation of myelin gene transcription (Nielsen, Berndt, 
Hudson, & Armstrong, 2004). 
 
1.2.1.1. The importance of MYT1L during neuronal development 
Brain specific expression of MYT1L and the fact that its expression is higher before birth 
suggests its crucial role in neurodevelopment (J. G. Kim et al., 1997). Recent studies showed 
that Myt1l, along with Achaete-scute homolog 1 (Ascl1) and POU class 3 homeobox 2 (Brn2), is 
capable of transforming fibroblasts into functional neurons (T. Vierbuchen et al., 2010). It was 
demonstrated that expression of Ascl1 alone was sufficient to induce cells positive for markers 
of immature neurons (e.g., Tuj1, marker for neuronspecific β-tubulin). However, addition of 
Brn2 and Myt1l was sufficient to induce cells with complex neuronal morphologies and 
functional synapses, thus indicating conversion to mature neuronal cells (T. Vierbuchen et al., 
2010).  
Next, the same three factors were shown to bgenerate functional neurons from human 
pluripotent stem cells. When those factors were combined with Neuronal differentiation 1 
(NEUROD1) these factors could also convert fetal and postnatal human fibroblasts. These 
induced neuronal (iN) cells displayed typical neuronal morphologies and expressed  multiple 
neuronal markers (Z. P. Pang et al., 2011). The Ascl1/Brn2/Myt1l complex alone appeared to 
induce immature neurons but was insufficient to generate functional neurons from human 
foetal fibroblasts. NEUROD1 aided the generation of the most mature neuronal cells. These 
studies were further corroborated when those iN cells were able to generate action potentials 
and many matured to receive synaptic contacts when co-cultured with primary mouse cortical 
neurons (Zhiping P. Pang et al., 2011).  
It was also demonstrated that human fibroblasts could be reprogrammed to generate 
dopaminergic neurons. The factors Ascl1, Brn2, and Myt1l along with LIM homeobox 
transcription factor 1, alpha (LMX1A) and FOXA2, which are two transcription factors known to 
be involved in the developmental pathway for dopaminergic neurons, were necessary and 
sufficient for conversion. Induced cells were positive for tyrosine hydroxylase, an essential 
enzyme in the biosynthesis of dopamine and showed action potential activity when 




An alternative method was also proposed, in which gene silencing was used to directly trans-
differentiate fibroblasts into neurons. MicroRNAs, miR-9/9*, and miR-124 expression in human 
fibroblasts induced their conversion into neurons, however addition of the previously known 
neurogenic transcription factors NEUROD2, ASCL1, and MYT1L enhanced the rate of 
conversion and the maturation of the converted neurons. 
All of the aforementioned studies suggest a pivotal role of MYT1L in neuronal generation, 
differentiation and maturation.   
  
1.2.1.2. MYT1L and disease 
Considering the importance of MYT1L in neuronal development, it can be hypothesised that it 
may also play a role in the pathogenesis of certain neurodevelopmental disorders.  
Wang et al. (2010) reported that that MYT1L can be a potential risk gene for major depressive 
disorder (MDD) in the Chinese Han population (T. Wang et al., 2010). They recruited 1139 
patients and 1140 controls and used 8 SNPs as markers to investigate the role of MYT1L in 
MDD patients of Chinese origin. One SNP, rs3748989, located in exon 9, was found to be 
associated with MDD (T. Wang et al., 2010). This finding suggests that MYT1L may be a 
potential risk gene for MDD, although these results should be taken with caution as an obvious 
limitation to this study is the number of SNPs used; more markers should be utilised in 
subsequent studies for better mapping. 
In a recent copy number variation (CNV) study, MYT1L was found to be disrupted in 
schizophrenia patients (Vrijenhoek et al., 2008). In this study, in the initial cohort of 54 
schizophrenia patients, authors identified 13 rare CNVs. Each of the CNVs was detected in one 
patient only, illustrating the rare nature of these variants (Vrijenhoek et al., 2008). Among the 
genes disrupted by the rare CNVs was the MYT1L gene which has not been associated with 
schizophrenia before. Authors suggested that the (partial) duplications of MYT1L in patients 1 
and 5 might affect MYT1L regulatory function in the CNS by either disruption or dosage effects 
(Vrijenhoek et al., 2008). Additionally, two patients with childhood onset of schizophrenia 
were reported to carry a microduplication disrupting the PXDN and MYT1L genes (Addington & 
Rapoport, 2009). As a replication, a meta-analysis of four published studies provided additional 




overall rate of disruption in MYT1L found in this study was comparable to other CNVs that 
have been classified as high risk for schizophrenia (Yohan Lee et al., 2012) 
The association of a MYT1L polymorphism and schizophrenia was also explored in the Han 
Chinese population. The results showed that two out of six SNPs studied, rs17039584 and 
rs10190125, had a significant association with schizophrenic patients in comparison to the 
controls. After dividing by gender, the latter SNP was significantly associated with SZ in female 
patients. These results must be taken with caution because they were only found in Chinese 
Han population and were not replicated in any other ethnic group.  
A partial deletion within MYT1L has been associated with intellectual disability. In the case 
study of three siblings and three unrelated patients, a partial deletion of chromosome band 
2p25.3 (2pter), ranging 0.37–3.13 Mb in size, was reported. All patients had intellectual 
disability. The only gene which overlapped and which was disturbed in all cases was MYT1L. It 
was therefore suggested that the cause of intellectual disability was due to MYT1L 
haploinsufficiency (S. J. Stevens et al., 2011).  
Abberations in MYT1L have also been associated with autism. In this study, a de novo 
duplication in two male half-siblings with autism on chromosome 2p25.3, duplicating PXDN 
and partially duplicating MYT1L was reported. Their psychiatrically healthy mother was 
analysed and it was revealed that the transmission was due to germline mosaicism (Kacie J. 
Meyer, Michael S. Axelsen, Val C. Sheffield, Shivanand R. Patil, & Thomas H. Wassink, 2012). 
An important role for MYT1L in normal brain development is supported by the aforementioned 
studies. As described, first links between MYT1L and human neurodevelopmental disorders 
have been provided. However, the precise mechanisms through which MYT1L acts and its 





1.3. Aims and objectives 
The overall aim of the present project was to elucidate and characterise genetic functions of 
the transcription factor - MYT1L. Recent publications have identified a network consisting of 
Ascl1, Brn2 and Myt1l to be sufficient to convert human and mouse fibroblast into function 
neurons (Pfisterer et al., 2011; T. Vierbuchen et al., 2010). The literature available suggests it 
has role during neuronal cell differentiation, maturation and possible synapse development.  
Using expression quantitative trait loci (eQTL) mapping data, which offer a unique opportunity 
to evaluate the impact of genetic variation on gene expression, the supervisor’s laboratory 
have analysed gene expression profiles associated with and encoding for MYT1L (data 
unpublished). It has been found that single nucleotide polymorphisms (SNPs) in MYT1L are 
associated with expression of over 2000 transcripts, suggesting that these genes might be 
downstream targets for MYT1L. eQTL analysis provides a link between that particular SNP and 
those affected genes by measuring their expression levels. Pathway analysis suggested that 
MYT1L regulates a large number of genes involved in neural differentiation and neurite 
development. These findings imply that MYT1L may play a central role in brain development 
The aim of this study was sub-divided into following objectives:  
1. To elucidate the expression patterns of Myt1l during vertebrae embryonic 
development, with zebrafish and mouse used as model organisms.  
2. To understand the role of MYT1L in neuronal cell differentiation, the consequences of 
its overexpression and down-regulation were examined in vitro, using human neural 
stem/progenitor cell lines as a model for neural differentiation. 
3. Analysis of MYT1L co-expressed genes provided us with a potential candidate gene 
that can act as a regulator of MYT1L and its network – MEF2A. Therefore, the aim of 
the last part of this thesis was to further elucidate the link between MYT1L and 
MEF2A. To address this question, lentiviral mediated MEF2A silencing in neural stem 





2. Role of myt1l in vertebrate brain development 
2.1.  Introduction 
Animal models play a central role in the scientific investigation of normal and abnormal 
behaviours, and for the study of the (patho) physiological mechanisms underlying these 
behaviours (Fisch, 2007; Matthews, Christmas, Swan, & Sorrell, 2005; Petters & Sommer, 2000; 
Phillips et al., 2002). Understanding the functions of many genes that are necessary for 
development is one of the central goals in biology. Researchers have used genetic approaches 
in model organisms to dissect how neurodevelopmental processes work.  A number of studies 
have shown that developmentally important genes are conserved throughout species (Bier & 
McGinnis, 2004; McCarroll et al., 2004; Santini, Boore, & Meyer, 2003), suggesting that 
developmental processes in humans will be controlled by a similar sets of genes in vertebrates. 
However, there is a critical gap in our knowledge of how these genes act and what pathways 
and processes they regulate in the physiological setting, which can be filled through 
experimental and hypothesis-driven approaches in model organisms (Mouse Genome 
Sequencing et al., 2002).  
Several animal models can be used to study and analyse the function of a given gene. Here, I 
present data from two animal models that can be used to detangle genetic involvement during 
development. I used zebrafish and mouse as organisms of choice, due to features that are 
described below. Little is known about molecular and biological functions of MYT1L in human, 
thus choice of distant but related vertebrates to examine genetic properties of this 
transcription factor is plausible.   
 
2.1.1. Zebrafish as a model organism 
Zebrafish (Danio rerio) has been introduced as a model for development and genetic research 
by George Streisinger in 1981 (Streisinger, Walker, Dower, Knauber, & Singer, 1981; Walker & 
Streisinger, 1983). This animal has been widely studied as a model organism for vertebrate 
development because it appears to combine the best features of all the other models 
(Twyman, 2002). Though a vertebrate, it shares many strengths with invertebrate models, such 
as small size, easy maintenance and large number of progeny produced in a short time, 




2004). Zebrafish embryos develop externally from the mother’s body, therefore they can be 
viewed and manipulated at all stages. These are also transparent and show rapid 
development, taking only 5 days from fertilisation to fully swimming larva (Charles B. Kimmel, 
Ballard, Kimmel, Ullmann, & Schilling, 1995). Zebrafish are smaller than mice and they produce 
more offspring in a shorter time (Twyman, 2002). Considering all of the aforementioned 
aspects, the zebrafish is an ideal vertebrate model to study embryonic development (Figure 
2.1). The embryonic development is described in six broad periods of embryogenesis and each 
period is subdivided into stages, which are named according to their morphological features: 
the zygote (1-cell), cleavage (2-cells to 64-cells), blastula (128-cells to 30% epiboly), gastrula 
(50% epiboly to bud), segmentation (1-4 somites to 26+ somites) and pharyngula (prim-5 to 
long-pec) periods. During segmentation, somitogenesis occurs, which is the formation of 
somites from the presomitic mesoderm. The 16 somite stage marks the onset of ventral 
bending of the neural axis at the level of the cephalic flexure, a major morphogenetic process 
that generates the displacement of forebrain territories at distinct axial levels. The earliest 
dopaminergic (DA) neurons in zebrafish are detected at ≈24 h postfertilisation (hpf) in the 
basal forebrain (Guo et al., 1999). 
Zebrafish has been a subject to large-scale genetic screening, which identified thousands 
different mutations affecting development (Blader & Strähle, 2000). These huge screenings 
provided a further affirmation that zebrafish is a powerful genetic system and they allowed 
studying gene functions and complex developmental processes regulating embryogenesis in 








Figure 2.1. Embryonic development of the zebrafish. Pictures represent different stages of the 
developing embryo. Characteristic structures visible during embryogenesis are indicated. Stages are 
according to (Charles B. Kimmel et al., 1995).  Picture adapted from (Haffter et al., 1996; Nüsslein-
Volhard, 1995). 
 
With the development of more and more cutting edge technology to study molecular 
processes, researchers can benefit from a wide variety of tools and information on how to use 
zebrafish as a model organism. It has been established as an important vertebrate model to 
study human disease including heart disease (Chico, Ingham, & Crossman, 2008), cancer 
(Amatruda & Patton, 2008), motor neuron disease (Beattie, Carrel, & McWhorter, 2007) and 
Alzheimer's disease (Newman, Musgrave, & Lardelli, 2007). Furthermore, it is being used as a 




The zebrafish system has also been presented as a potential viable model for 
neurodevelopmental diseases, such as autism and autistic disorders (Tropepe & Sive, 2003) 
and schizophrenia (Morris, 2009). One avenue that can effectively model some of the 
abnormalities observed in individuals with neurodevelopmental disorders, is based on a 
candidate gene approach.  
There are established molecular genetic techniques to study the function of susceptibility 
genes in zebrafish.  
One of the methods to investigate loss of gene functions involves morpholino oligonucleotides 
(MOs) (Bill, Petzold, Clark, Schimmenti, & Ekker, 2009). MOs are chemically modified 
oligonucleotides that bind to the targeted transcript and interfere with RNA translation 
(Nasevicius & Ekker, 2000). To interfere with genetic function, MOs are injected in the early 
stages of embryonic development (for example 1/128 blastula stage) and consequences on 
fish development can be analysed by in situ hybridisations, immunocytochemistry or live 
imagining. As a consequence of embryo transparency, individual cells can be clearly visualised 
in vivo using microscopic techniques across a broad range of developmental stages. Whole 
mount in situ hybridisation (ISH) is a commonly used technique to determine gene expression 
patterns during early development. During the in situ hybridisation procedure, an antisense 
mRNA probe is designed to recognise and bind the endogenous transcript, which is later 
detected by the color-based or fluorescence-based assay.  
Sequencing of the zebrafish genome is close to completion with the latest release, Zv9 whole 
genome assembly (http://www.ensembl.org/Danio_rerio/Info/Index). Therefore, making it the 
largest gene set of any vertebrate sequenced so far (Howe et al., 2013). Zebrafish possess over 
26000 protein-coding genes (Collins, White, Searle, & Stemple, 2012), more than any 
previously sequenced vertebrate, and they have a higher number of species-specific genes in 
their genome than do human, mouse or chicken (Howe et al., 2013). Although, there is a large 
homology between zebrafish and human genes, there are numbers of genes that underwent 
duplication during evolution. As a result, zebrafish often have two co-orthologs in contrast to a 
single copy gene in humans and other mammals (Taylor, Braasch, Frickey, Meyer, & Van de 
Peer, 2003; Woods et al., 2005). These duplicates may have different expression patterns 
and/or novel or unrelated functions (Morris, 2009). As a consequence, the function of 
individual genes might be less complex in fish than in tetrapods, therefore easier to study in 
the former. myt1l is highly conserved throughout vertebrate development (S. Wang et al., 




controls a biological process that has been preserved during vertebrate evolution. In mammals 
there is only one MYT1L, while in zebrafish there are two paralogs of this gene – myt1la and 
myt1lb. According to zebrafish genome browser (zfin.org), myt1la (Gene ID: 559505) is the 
only form that has been characterised as protein coding and it is an ortholog of human, mouse 
and rat Myt1l. It maps to chromosome 20, where myt1lb (GI:23188298) has not got any 
genetic coordinates or any known biological function. It has only been identified by statistical 
methods as a part of large EST mapping project (Lo et al., 2003). Due to lack of information and 
possible nonfunctionalisation of myt1lb, this thesis concentrated only on characterisation of 
myt1la as an ortholog of mammalian Myt1l.   
 
With its many advantages as a vertebrate model to study development, combined with genetic 
screening and manipulations, zebrafish is becoming a very interesting and efficient model that 
can be used to search for genes involved in neurodevelopment (Fishman, 1999; Vascotto, 
Beckham, & Kelly, 1997).  
 
2.1.2. Mouse as a model organism 
Over the past years, the mouse has become one of the most used mammalian model system 
for genetic research. Scientists from a wide range of biomedical fields have been using mouse 
because of its close genetic and physiological similarities to humans, as well as the ease with 
which its genome can be manipulated and analysed. With both human and mouse genomes 
sequenced, it has been established that 99% of encoded genes are shared between the two 
(Mouse Genome Sequencing et al., 2002). Practically, mice are a cost-effective and efficient 
tool for development of new drug therapies.  
Mice are small, have a short generation time and an accelerated lifespan (one mouse year 
equals about 30 human years), keeping the costs, space, and time required to perform 
research manageable (Kile & Hilton, 2005). The sequencing of the mouse genome and the 
characterisation of a range of strain specific genetic markers allow mutations and genetic 
alterations to be readily mapped (Mouse Genome Sequencing et al., 2002).  
There is an obvious difficulty with obtaining early human embryonic and foetal material, 
making mouse models very useful for the study of mammalian development and also for the 




for 20 days, whereas human development lasts for 280 days, and the corresponding stages of 
development are not evenly distributed throughout the gestation period (Ko, 2001). For 
example, embryonic day 10.5 (E10.5) is the period of development characterised by closure of 
the caudal neuropore (Kaufman, 1992).  Stage E13.5-E14.5 is associated with neurogenesis and 
the beginning of cell migration to the primary neuropallial cortex. At E17.5 the brain displays 
an increased degree of differentiation (Schurov, Handford, Brandon, & Whiting, 2004). 
Altogether, their detailed characterisation, convenience of breeding and relatively close 
evolutionary relation to human has ascertained that mice are one of the best resources to 
model human development and disease (Hacking, 2008). For the purpose of our study, I 
interrogated the Allen Mouse brain atlas for expression details on Myt1l (Figure 2.2). These 
data shows that Myt1l is not expressed at E11.5 and its expression starts at E13.5 and 
continues postnatally until day P56. 
 
 
Figure 2.2. Summary of expression levels of Myt1l during mouse brain development. Dark colours 
represent higher expression and light colours represent no or little expression. Embryonic stage E11.5 
shows no expression with Myt1l detection being recorded beginning of stage E13.5 in all tested brain 
regions. RSP - Retrosplenial area. Tel – telecephalon, PedHy- peduncular (caudal) hypothalamus, p1-3 – 
prosomere 1-3, M- midbrain, PPH- prepontine hindbrain, PH- pontine hindbrain (pons proper), PMH- 
pontomedullary (retropontine) hindbrain, MH- medullary hindbrain (medulla) (from Allen Developing 





2.2.  Aims and hypothesis 
Myt1l is specifically expressed in the human brain, as mentioned already in Chapter 1. Since 
the fundamental steps in neural and brain development are highly conserved in vertebrates, 
we anticipate that Myt1l function and expression pattern will also be conserved. I propose to 
use zebrafish to examine myt1l expression patterns during embryonic development. The 
principal aim of this study was to map the distribution of myt1l mRNA and during embryonic 
and early larval stages of zebrafish development.  Specific techniques developed for zebrafish, 
such as in situ hybridasation  are proposed to investigate the role of myt1l during embryonic 
development. Using qPCR, changes of myt1l expression during fish maturation were assessed.  
Another aim was to validate zebrafish findings in a higher vertebrate group – mice, and to 
investigate Myt1l mRNA expression profiles, by qPCR during mouse brain development. To 
achieve this, several pre-natal (E10, E14, E18) and post-natal (P1week, P1month, P6months) 
stages of mouse brain development were analysed.  
 
2.3. Materials and methods.  
All zebrafish studies were performed with approval from the UK Home Office under a HO 
project license to Professor Corinne Houart (C.H.). Breeding, embryo maintenance and embryo 
preparation for experiments (such as fixation and dehydration) were performed by Victoria 
Snowden (V.S.) at the MRC Centre for Neurobiology, King’s College London. All embryos were 
provided by V.S. Visualisation and image capture was done by C.H. I have performed in situ 
hybridisation, RNA extractions, PCRs and qPCRs.   
Breeding fish were maintained at 28.5°C on a 14-hour light/10-hour dark cycle. Embryos were 
staged according to the protocol described previously by Kimmel et al. (Charles B. Kimmel et 
al., 1995). Collected embryos were cultured in fish water containing 0.003% 1-phenyl-2-
thiouera to prevent pigmentation. Embryos were allowed to develop in regular fish water until 
the end of gastrulation. For embryos older than 24 h, in order to prevent pigmentation, fish 
water was replaced, at the end of gastrulation by a solution of 0.0045% 1-phenyl-2-thiourea 





2.3.1. Zebrafish whole mount in situ hybridisation (ISH) 
To investigate expression patterns of myt1l during embryonic development we used in situ 
hybridisation. Whole mount in situ hybridisation (ISH) is commonly utilised to determine gene 
expression patterns during early development by detecting specific nucleic acid sequences 
with RNA probes. ISH consists of few steps, detailed below and previously described by [Thisse 
and Thisse. (C. Thisse & Thisse, 2008). Briefly, a full length clone of zebrafish MYT1L inserted in 
pCR-4-TOPO was used as a template for the synthesis of an antisense RNA probe, which was 
labelled with digoxigenin-linked (DIG) nucleotides. Following this, embryos collected at various 
stages of development, were fixed and permeabilised before being soaked in the digoxigenin-
labelled probe. Hybrids (embryos with DIG-labelled RNA probes) were detected by 
immunohistochemistry using an anti-DIG antibody.  
 
2.3.1.1. Preparation of antisense DIG labelled RNA Probes 
A zebrafish cDNA myt1l clone was purchased through Open Biosystems (clone ID: 9039342, 
accession: BC171626). The clone was obtained in pCR 4-TOPO (Figure 2.3) vector that already 
contains a T7/T3 priming site that is necessary for in situ hybridisation. The clone’s length is  
3872 bp and it represents a full length, open reading frame (ORF) clone. Manufacturer 
provided the clone in a bacterial stock.  To prepare the DNA plasmid the sterile tip was dipped 
into the vial containing stock, and the bacteria were allowed to  proliferate in a pre-culture of 5 
ml of LB Broth media (Invitrogen, UK) containing 100 µg/ml ampicillin (prepared as described 
in 3.3.1.4) at 37oC overnight and used for large-scale plasmid production. Plasmid DNA for was 
isolated by the Endofree Plasmid Maxiprep Kit (Qiagen, UK) (as described in 3.3.1.8). DNA 
concentration was determined using a NanoDrop ND-1000 spectrophotometer and plasmids 





Figure 2.3. pCR 4-TOPO vector map. The pCR4-TOPO vector contains both ampicillin and kanamycin 
resistance markers, T7 and T3 promoters are also present for in vitro transcription. Figure from pCR 
TA-TOPO protocol Version R, April 2004 (Invitrogen). 
 
2.3.1.1.1. Verification of the insert 
In order to verify the orientation of the insert, plasmid DNA generated by Maxi Prep was 
digested using a combination of restriction enzymes, such as  SalI and NotI, BglII and NotI (NEB, 
London, UK). These combinations were chosen as they cut once in the vector and once in the 
insert, providing distinctive different bands for either sense or antisense direction of a myt1l 
insert.   
The restriction reaction was performed as follows: 2 μl of plasmid DNA (200 ng) was digested 
with 5U of each enzyme (BglII+NotI or SalI+NotI)(NEB, UK) in the presence 1x NEB restriction 
enzyme buffer 3 (NEB, UK) and 1x Bovine Serum Albumin (BSA) topped up with dH20 to a final 
volume of 10 μl. The reaction was inclubated for 1h at 37 oC. The DNA digestions were 
separated by electrophoresis on a 1.5% w/v agarose gel (Sigma, UK) made up with 1X TBE 
buffer (0.0089 M Tris, 0.089 M Borate, 0.002 M EDTA; Merck, Germany) and supplemented 
with 2% of Ethidium Bromide (Electron, UK). 5 μl of the digested samples were mixed with 1 μl 
of 6X gel-loading buffer (Thermo Scientific, UK) and loaded into the gel wells. Additionally, one 




carried out at 120V for 1h. The DNA bands obtained from the gel were visualized using 
ultraviolet light. 
 
2.3.1.1.2. Antisense RNA Probe Synthesis 
After verification of the orientation of the insert, plasmid DNA was linearised with SalI 
restriction digest. The advised probe size was between 1 and 3 kb. Since the myt1l clone is 
~4kb long, the SalI enzyme was chosen to create a partial clone, as it only cuts once in the 
insert (creating fragment of 1kb and 2.9kb in size), and it does not cut the vector.  
The reaction was set as follows: 10 µg of plasmid vector was digested with 5U of SalI 
restriction enzyme(NEB, UK) in the presence 1x NEB restriction enzyme buffer 4 (NEB, UK) 
topped up with dH20 to a final volume of 50 μl. The mix was incubated for 2h at 37 oC and then 
separated on a 1.5% agarose gel (120V for 1h) to check that the plasmid was fully linearised.  
The linearised DNA was then precipitated using 5 μl of 3M sodium acetate (NaOAc) and 125 μl 
of 100% biology-grade ethanol (Sigma, UK) and incubated overnight at -20 °C. The following 
day, the mix was centrifuged at 13,000 rpm for 30 minutes. The ethanol was removed and 
300μl of ice cold 70% ethanol was added and then centrifuge at 13000 rpm for 15 minutes. 
The ethanol was removed and the DNA pellet was air dried. The DNA was then resuspended in 
50 μl of dH20, 1 μl of the reaction was checked on a 1.5% agarose gel (120V for 1h), and the 
DNA template was stored at -20°C. 1 μg of purified, linearised DNA template was transcribed 
and labelled with digoxigenin using 4 μl of 5 x transcription buffer (Promega, UK), 2 μl 10 x DIG 
RNA labelling mix (10mM each of ATP,CTP,GTP, 6.5mM UTP, 3.5mM DIG-11-UTP, pH 7.5 
(Roche) 1 μl of T3 RNA polymerase (Promega), 2µl of 0.1M DTT 1 μl of RNaseOUT Recombinant 
RNase Inhibitor (Invitrogen) and the volume was made up to 20 μl with nuclease-free water. 
The reaction mix was incubated at 37°C for 2 hours. DNA was digested by adding 1 μl of 
RNAse-free DNAseI (Roche) for 30 mins at 37°C. Synthesis was stopped by adding 1 μl of 0.5 M 
EDTA and the mix was purified using QIAquick PCR Purification columns. 1 μl was checked by 
electrophoresis on the 1.5% agarose gel (120V for 1h) for the probe quality.  A 120 μl of 





2.3.1.2. Whole Mount in situ Hybridisation Protocol 
The solutions used for in situ hybridisation are listed in Table 2.1. Embryos were fixed at the 
required stages (18somite stage, 24hpf, 48hpf, 72hpf and 120hpf) in 4% paraformaldehyde 
(PFA) overnight at 4°C. For longer term storage embryos were dehydrated in 100 % methanol. 
The PFA was washed out 3 times by soaking in PBS with 0.1% Tween20 (PBT) for 5 minutes 
before dechorionation. The embryos were manually dechorionated and dehydrated through a 
series of incubations in 25%, 50%, 75% and 100% methanol in PBST for 5 minutes in each step. 
100% methanol was added to cover the embryos. The embryos were then stored at -20°C for 
future use.  
Table 2.1. Solutions for in situ hybridisation.  
Solution Ingredients 
20x Saline Sodium Citrate (SSC) 3M NaCl, 0.3 M Citric acid trisodium salt, pH7  
Maleic acid buffer(MAB)  100 mM maleic acid, 150 mM NaCl, adjusted to pH 7.5 with NaOH 
Hybridisation Mix (HM) 50% formamide, 5 x SSC, 0.1% Tween20, 50µg/ml Heparin (Sigma), 500 µg/ml RNAse Free tRNA Torula (Sigma) 
Staining buffer (NTMT) 100 mM tris HCl pH 9.5, 50 mM MgCl, 100 mM NaCl, 1% Tween20 
PBT 1 x PBS (Dulbecco’s Phosphate Buffered Saline Modified, without CaCl2/MgCl2, Sigma), 0.1% Tween20 
 
Whole mount ISH was performed as previously published (C. Thisse & Thisse, 2008) with some 
modifications as described. All steps took place in 1.5ml tubes. Figure 2.4 outlines the stages 





Figure 2.4 Figure outlining the stages and timing involved in the in situ hybridasation (ISH) protocol. 
The different steps of the ISH are indicated in boxes linked by arrows and coloured: blue for steps 
corresponding to synthesis of the probe, dark green for preparation of embryos, light green for day 1 of 
in situ, yellow for day 2, orange for day 3 and pink for the final step. Time required for each step is 
indicated near the box (O/N: overnight). Pause points are indicated in the diagram by two red lines 
across arrows. (Picture from (C. Thisse & Thisse, 2008)) 
 
Day 1: Embryos were gradually rehydrated from methanol to 100% PBT by a series of 5 
minutes incubations in 75%, 50% and 25% methanol in PBT. Embryos were then washed once 
with 0.5ml of 100% PBT for 5 min. Proteinase K (0.3ml of 50µg/ml) treatment for embryos 
older than 18SS (somite stage) was performed to ensure permeabilisation of embryos and to 




developmental stage, was as follows: 1 min for 24hpf, 2 min for 32hpf, 5min for 36hpf, 8min 
for 48hpf, 10 min for 72hpf, 12 min for 96hpf and 14 min for 120hpf. Proteinase K treatment 
was stopped by replacing it with 0.5ml of HM. Embryos in HM were prehybridised for at least 
4h at 65°C horizontally on a heatblock. DIG-labelled probe was diluted 1:100 in HM and pre-
warmed for 5 minutes at 65°C. Pre-hybridisation solution was removed and embryos were 
incubated in 0.3ml of prewarmed diluted probe overnight at 65°C on a heatblock.  
Day 2: Hybridisation solution-containing probe was removed and embryos were washed with 
prewarmed 0.5ml HM solution for 30min. To remove non-specifically hybridised probes serial 
washes with SSC were carried out as follows: 1x 10min with 2XSSC (1ml) at 65°C, 2x 30 min 
with 0.2X SSC(1ml) at 65°C followed by 1x 5min in containing 0.1% Tween20 (1ml) (MABT). 
Embryos were then incubated in blocking buffer containing MAB supplemented with 1% 
Blocking reagent (Roche) for 3-4h at room temperature on the shaker. The blocking solution 
was replaced with 0.3ml of blocking buffer containing 1:5000 anti-DIG antibody and incubated 
at 4°C overnight while shaking.  
Day 3: Antibody solution was discarded and embryos were washed in 1ml MABT 0.1% at least 
8 times, 15-20 min each, equilibrated for at least 20min with NTMT staining buffer and 
transferred to 6 or 8-well plated. Colour development was performed in the dark at room 
temperature in 0.3ml of the staining solution (3.375 µl NBT (Sigma)(100mg/ml), 3.5 µl BCIP 
(Sigma)(50mg/ml) in 1ml NTMT). Embryos were observed every 10-15 min under the 
dissecting microscope to monitor colour development then theplate was placed in the dark to 
avoid overexposure to light. To stop the colour development, embryos were washed 3 times 
for 5 mins with PBT solution and incubated in 4% PFA for 20 minutes at room temperature. 
The PFA was removed by three 5 mins PBT washes. The embryos were stored in 
70%Glycerol/PBT at 4°C.  
 
2.3.2. Visualisation and Image Capture 
 Embryos were mounted on slides and cover slips in order to visualise the probe staining and 
record results, following the procedure below. To mount the embryos four cover slips of 
thickness 1.5mm were stacked together to form a bridge. Stained embryos were placed in a 
drop of glycerol in the middle of a microscope slide between bridges. The bridge and the 




viscosity of the glycerol, the embryo could be rolled and observed in different orientations by 
gently moving the 24 x 40 mm coverslip.  
 
2.3.3. RNA extraction from whole zebrafish embryos.  
RNA is relatively unstable and easily prone to cleavage by RNAses, therefore it is of utmost 
importance to clean the work area by spraying the work surfaces with a decontaminant 
reagent (RNaseZAP) before beginning the procedure.  To attain a sufficient amount of RNA, 
embryos of each stage were divided into groups of 50 or 20 (depending on the stage, 50 
embryos for 18SS, 25 embryos for 24hpf and 20 embryos per 48hpf and 72hpf) transferred to 
separate 1.5ml tubes and excess water was removed with a pipette. The embryos were then 
frozen by placing the tubes on dry ice and transferred to -80°C freezer until ready for 
extraction. Before starting the extraction PhaseLock heavy tubes (FisherScientific) were 
prespun at 1500 RPM for 30sec. 
One pool of samples was removed from -80°C, placed on ice and immediately 250 µl of Trizol 
reagent (Invitrogen) was added to the tube. Embryos were lysed and homogenised with a 
disposable tissue grinder (Sigma). When cells were sufficiently homogenised a further 250 µl of 
Trizol reagent was added. Samples were then transferred to prespun PhaseLock tubes 
(FisherScientific), mixed by inverting the tube and incubated at room temperature for 5 min. 
100 µl of chloroform was added to the samples and mixed vigorously for 20s before further 
incubation for 2min. Samples were then centrifuged at 13,000 x g for 15 minutes at 4°C. The 
colourless upper phase of the sample was transferred into an RNase free 1.5ml tube, using a 
1ml pipette and being careful not to transfer any of the interphase layer, and 250 µl of 
isopropanol was added to precipitate the RNA.  Samples were allowed to sit at room 
temperature for 10 min and then centrifuged at 13,000 x g for 10 min at 4°C. RNA formed a 
gel-like pellet on the bottom of the tube. Without disturbing the pellet, isopropanol was 
removed with a pipette and the pellet was washed with 0.5ml of 100% ethanol (for molecular 
biology use, Sigma). Without disturbing the pellet samples were mixed by gentle inversion 
followed by centrifugation at 13,000 x g for 5 min at 4°C. After centrifugation, the ethanol was 
removed, and the pellet was allowed to air dry while inverted for 10min. The pellet was 





2.3.4. RNA clean-up. 
Qiagen RNease Mini-Kit was used for total RNA clean-up and manual instructions were 
followed. Briefly, to each sample prepared as described in section 2.3.2, 350 µl of RLT buffer 
containing β-mercaptoethanol (β-ME) (10 µl of β-ME per 100ml of Buffer RLT) was added and 
samples were mixed well by pipetting then centrifuged for 3 minutes at 13,000 x g. 
Supernatant was carefully removed and transferred to a new 1.5ml tube and used in 
subsequent steps. 350 µl of 70% ethanol was added to the samples and mixed well by 
pipetting. The sample was then transferred to an RNeasy spin column placed in a 2 ml 
collection tube and centrifuged for 15 seconds at 8,000 x g and the flow through was 
discarded. 350 µl of Buffer RW1 was added to the RNeasy spin column and centrifuged for 15 
seconds at 8,000 x g. The flow-through was discarded and the RNeasy column was re-used. 
DNAse treatment with Qiagen RNAse-free DNAse kit was performed as follows. Per sample, 10 
µl of DNAse I stock solution (DNAse I powder dissolved using 550 µl of RNase-free water) was 
added to 70 µl of buffer RDD and the mix was added to each sample and incubated for 15 min 
at room temperature. Following DNAse treatment, 350 µl of buffer RW1 was added to the spin 
column and samples were centrifuged at 8000 x g for 1 min. 500 µl of Buffer RPE (containing 
70% ethanol) was added to the RNeasy column and centrifuged for 15 seconds at 8000 x g. The 
flow through was discarded and a second aliquot of 500 µl of Buffer RPE was added to the 
RNeasy spin column followed by centrifugation at 8000 x g for 2 minutes. The RNeasy spin 
column was then placed in a new collection tube and 30 µl of RNA-free water was added 
directly to the spin column membrane and centrifuged for 1 minute at 8000 x g to elute the 
RNA. RNA concentrations were determined using the Nanodrop-1000 spectrophotometer 
(Thermo Scientific, UK) and the quality checked by referencing the ratio of absorptions at 
260/280nm in order to detect protein contamination. Samples were then stored at -80°C 
freezer.  
 
2.3.5. Mouse RNA 
RNA samples extracted from CD1 mouse brains at embryonic day 10 (E10), E14, E18, and at 
postnatal (P) stages 1 week, 1 month, or 6 months were obtained from AMS Biotechnology, 
Abingdon, UK. RNA samples from the E10 and E14 stages were pooled from 5 and 3 brains, 




obtained from independent brains, and the P6month prefrontal cortex RNA sample was 
derived from a single mouse brain. 
 
2.3.6. cDNA Synthesis  
cDNA synthesis was performed by reverse transcription of RNA from both, zebrafish and 
mouse. First strand cDNA synthesis was carried out on total RNA using the Superscript™ III 
synthesis system (Invitrogen, Paisley, UK). 1 µg of total RNA was added to 1 µl of 10mM dNTP 
mix and 1 µl of Oligo(dT)18-20 (0.5 μg/μl) and the volume made up to 10 µl with RNAse-free 
water. Each sample was incubated for 65°C for 5 minutes and then placed directly on ice. Next, 
to each sample 2µl of 10x RT buffer, 4µl of 25mM MgCl2, 2µl of 0.1M DTT, 1μl of RNaseOUT™ 
Recombinant RNase Inhibitor and 1μl of Superscript™ III RT (2000U/µl) was added. The 
samples were incubated at 50°C for 50 minutes and the reaction was terminated by 5 minutes 
at 85°C. 1μl of RNase H was added to each sample and then samples were incubated at 37°C 
for 30 minutes followed by sample dilution with distilled water, making 100 µl of each sample 
at a concentration of 10ng/μl. 
 
2.3.7. Quantitative polymerase chain reaction (qPCR) 
Real-time quantitative PCR (polymerase chain reaction, q-rtPCR, qPCR) is a technique used for 
amplifying DNA and monitoring the progress of the reaction in the ‘real time’. To allow the 
progress of a PCR to be monitored a fluorescent marker (e.g. SYBR green) is used which binds 
to the DNA. Thus, as the number of gene copies increases during the reaction, the 
fluorescence increases as well. This is beneficial because the efficiency and rate of the reaction 
can be measured. 
cDNA samples were amplified using an ABI Prism 7900HT sequence detection system in a final 
volume of 20 μl. 10 µl of SYBR© Green PCR Master Mix (Applied Biosystems), 0.5μM  of primer 
F and 0.5μM of primer R were added to 4µl of cDNA template and topped up with RNase-free 
water. The qPCR reaction was performed in triplicates. The amplification procedure consisted 
of an initial enzyme activation step of 95°C for 15 min followed by 40 cycles of 30 sec at 95°C 
and 30 seconds at 59°C. Fluorogenic data was collected at the 59°C stage and the data were 




evaluated by a melting curve analysis. Sequences of the primers used can be found in Table 
2.2. Gapdh was used as an internal control for mouse RNA, and β-actin was used as a 
housekeeping gene for zebrafish samples.  
 
Table 2.2. Primer sequences used for establishing expression levels of myt1l by qPCR. 
Primer Sequence 
zf-βactin 
Forward 5’ – GCAGAAGGAGATCACATCCCTGGC – 3’ 
Reverse 5’ – CATTGCCGTCACCTTCACCGTTC – 3’ 
zf-myt1l 
Forward 5’ – TGATGAGCACGATGAAGAGG – 3’ 
Reverse 5’ – TTCGTGTTGTTGTTGTTGTTG – 3’ 
m-Gapdh 
Forward 5’ – TGTTCCTACCCCCAATGTGT – 3’ 
Reverse 5’ – CCTGCTTCACCACCTTCTTG – 3’ 
m-Myt1l 
Forward 5’ – TGGTGACGATGTAGAAGAGGA – 3’ 
Reverse 5’ – TCCTTGTCTGTGTCCTGCAT – 3’ 
 
Firstly, mRNA levels were first normalised to that of housekeeping gene to generate ∆Ct values 
(ΔCt = Cttarget – Cthousekeeping gene) at each developmental stage. Changes in expression at each 
stage were relative to E10 for which ∆∆Ct (∆Ct - ∆CtE10) were calculated. ∆∆Ct was then 
converted to relative fold expression using the formula 2-∆∆Ct. Data are presented as group 
means and error bars show the standard error. All RT-qPCR data were analysed by one-way 
ANOVA, followed by Tukey post-hoc analysis with p≤ 0.05. Statistical analysis was performed 




2.4.  Results 
2.4.1. myt1l tissue distribution during zebrafish development  
Our first action was to interrogate the Ensembl database to find MYT1L orthologs. We have 
found that myt1la is 68% homologous to human MYT1L and mouse myt1l. The myt1l gene is 
located on chromosome 20, with 4 known transcripts, the longest spanning 6347bp. So far no 
studies have examined the developmental distribution of myt1l during zebrafish development. 
Its expression patterns were investigated by whole-mount in situ hybridisation (ISH). ISH was 
performed on 18SS, 24hpf, 32hpf, 36hpf, 48hpf, 72hpf and 120hpf with a probe developed 
from PCR product as described in section 2.3.1. 
All the figures shown below represent only the developing nervous system region and the 
zebrafish head, as there was no visible staining anywhere else in the zebrafish body (data not 
shown).   
As shown in Figure 2.5A, myt1l mRNA expression was not found in the  18 somite-stage 
embryo.  At this stage we did not detect a presence of the labelled probe, suggesting that if 








































Figure 2.5. Whole mount in situ hybridisation of myt1l expression from 18ss-120hpf. Figures 
A,C,F,G,H,I, K are lateral views of zebrafish embryo head, D,E,J are frontal views of a zebrafish embryos 
displaying bilateral myt1l expression.Stages are indicated in the right bottom corner of each panel 
A- 18 somite stage showing no detectable expression. Figure C and E are 24hpf clear expression in the 
forebrain area as indicated by purple stain. E-G view of 32hpf zebrafish head displaying bilateral myt1l 
mRNA expression in the forebrain region, H show strong expression of myt1l in the 36hpf embryo, 
restricted to the forebrain. I-K represent views of widespread myt1l expression in the embryonic brains 
at 48hpf, 72hpf and 120hpf respectively. Figure B represents schematic of the brain segmentation at 
18SS, the telencephalon (T), diencephalon (D), mesencephalon (M), and about seven hindbrain 
rhombomeres (r1-r7). D schematic of brain development at 24hpf, the epiphysis (E) is present in the 
midline of diencephalic roof. The dorsal midbrain, or tectum (M), is partitioned from the ventral 
midbrain. The cerebellum (C) is at the hindbrain/midbrain boundary region. The floor plate (FP) extends 
in the ventral midline up to, but not including the forebrain (figure from(Charles B. Kimmel et al., 1995). 
Scale bars are 40 μm.  Arrowheads indicate telencephalon  
 
We detected the first expression at 24hpf (purple stain, Figure 2.5C), in the telencephalon, 
which is the anterior subdivision of the embryonic forebrain or the corresponding part of the 
adult forebrain that includes the cerebral hemispheres and associated structures. myt1l 
expression was not observed in any other part of the embryo, at any studied stage (data not 
shown), which confirms that the expression of myt1l is brain specific. Continuous expression of 
myt1l was clearly visible at 32hpf and 36hpf stages (Figure 2.5 F-G and H), its expression being 
still localised in the telencephalon with no staining observed in midbrain/hindbrain structures.  
By the second day of development (48hpf) myt1l expression became much more widespread 
throughout the CNS (Figure 2.5I). As expression domains were relatively large, it became 
difficult to precisely define myt1l expressing brain regions in whole mount preparations. The 
process of identifying specific brain regions in which myt1l was expressed became even more 
challenging for later stages of embryonic development, as the staining was very robust across 
the whole brain area. The pattern of expression at 72hpf and 120hpf was similar to that of 
48hpf, however during this additional 24hr period some brain regions exhibited progressively 
more intense and expanded expression (Figure 2.5 J-K). The staining at these stages was not 
improved by various experimental alterations, such as extended periods of Prokinase K 
treatment to allow the fluorescent probe better penetrate the embryo.  
These results show that myt1l mRNA transcripts are brain specific, and its presence was not 






2.4.2. qPCR analysis to measure myt1l mRNA levels in zebrafish embryos.  
As mentioned above, we have found brain specific myt1l expression during zebrafish 
embryonic development starting between 18SS and 24hpf. To examine the magnitude of 
change in expression, myt1l mRNA levels at various stages of zebrafish development were 
measured by qPCR. To accurately quantify gene expression, the expression levels of myt1l 
were normalised to the expression level of β-actin producing ∆Ct. Since it is the first insight 
into myt1l mRNA levels distribution in zebrafish, examining ∆Ct values provides more 
information about its expression in all samples, as it does require to relate changes in gene 
expression to a reference sample. We have found that myt1l is detected by qPCR at 18SS, 
however its levels at this stage are low (Figure 2.6). With each developmental stage expression 
gradually increased, which is consistent with ISH findings.  
 
Figure 2.6.  qPCR analysis of myt1l expression in zebrafish embryos. Highest expression (100-fold 
change) is reported from 3 day embryos. Results from 24hpf, 48hpf and 72hpf were calculated relative 
to the expression at 18SS stage. Data is presented as mean values of three independent experiments, 
error bars represent +/- 1SE of the mean. 
 
The results did not reach the significance level, when analysed by one-way ANOVA (F(3,8)= 3.04, 
p=0.093). It is interesting to note that although the samples used for qPCR were whole 
embryo-derived and overall brain-specific RNAs within these sample was diluted, we were still 




By examining the dissociation curves, the specificity of the qPCR products was assessed. 
Inspection of the dissociation curves for zebrafish myt1la expression in RT-qPCR experiments 




Figure 2.7. Confirmation of the specificity of myt1l RT-qPCR primers. Dissociation curves from qPCR 
analysis of myt1l (A) and β-actin (B) expression in zebrafish embryos indicate a single, specific amplicon 
(i.e. one PCR product per primer pair). The additional peaks visible on both figures were generated from 
negative controls only (i.e. water).  
 
To further validate our findings and to check for possible primer dimers, we run 5µl of each 
qPCR sample on 2% agarose gel with expected amplicons of around 200bp for myt1l and 






Figure 2.8. Agarose gel electrophoresis of qPCR samples.  Lanes 1-4 represent qPCR samples with actin 
(18SS, 24hpf, 48hpf and 72hpf respectively), lanes 6-9 correspond to myt1l amplified qPCR products 
(18SS, 24hpf, 48hpf and 72hpf respectively), lane 5 was left empty and lane L was the 1kb DNA ladder 
used as a marker.  
Gel electrophoresis of myt1l qPCR samples demonstrated a Myt1l transcript with band size of 
approximately 200bp, corresponding with the predicted size of 198bp (Figure 2.8). 
Furthermore, clear expression patterns were visualised on the gel. At 18SS stage the band is 
very faint and hardly visible, in the 24hpf embryos, myt1l is represented as a thin and grey 
band, demonstrating the higher levels of myt1l.  Presence of the qPCR product is evidently 
shown at 48hpf with a very strong and thick band on the gel. The expression is even higher at 
3dpf with an even more intense band being observed on the gel. These results confirm that 
myt1l mRNA level changes during embryonic development, with very little gene product 
present at 18SS stage and progressively increasing during development until 3dpf. We 
observed extra bands in the lanes containing myt1l samples which could suggest a slight gel 
contamination or possible a non-specific amplification. Small faint bands below the primary 
amplicons are likely to be primer-dimers or cDNA related amplicons and may be dismissed 
provided the dissociation curve displays only a single peak for each product.   
 
2.4.3. Myt1l expression in mouse brain samples. 
The validation of our findings and a further assessment of the changes of Myt1l transcript 
levels in the vertebrate brain were made by investigating changes in expression of this 




measure expression levels we performed qPCR analysis of Myt1l expression and the results 
were first normalised to that of Gapdh at each developmental stage. Inspection of the 
dissociation curves for Myt1l expression in RT-qPCR experiments revealed a single, specific 
amplicon for each measurement (Figure 2.9), which indicates that the primers only amplified 
the region for which they were designed.  
  
Figure 2.9. Confirmation of the specificity of Myt1l RT-qPCR primers. Dissociation curves from qPCR 
analysis of Myt1l (A) and Gapdh (B) mRNA expression in in mouse brains indicate a single, specific 
amplicon (i.e. one PCR product per primer pair). The additional peaks visible on both figures were 
generated from negative controls only (i.e. water).  
 
We observed an increase in Myt1l expression at each developmental stage. Highest expression 
of Myt1l is observed at E18 (Figure 2.10) which is just before the litter is born, and remained 
elevated at 1week and 1 month after birth, which corresponds to adolescence in mice . Myt1l 
expression gradually decreases at each postnatal stage. Results showed a 500-times increase 
in Myt1l expression at 6 months post-natally although lack of replicates prevented 
determination of statistical significance for this stage. A one-way ANOVA revealed a significant 
gene dosage effect in the mouse brain samples (F (3,8)= 13.175, p=0.002). Post-hoc analysis 
using Tukey  shown that the change was significant between E10 and E18 (p=0.003) and 







Figure 2.10. Graph representing stage specific expression of Myt1l during mouse brain development. 
The highest expression was recorded at E(embryonic day)18. Data from E14, E18, P1 week, P1 month 
and P6 months were calculated relative to the expression in the brain at E10. Statistical analysis 
(ANOVA) compared expression at E10, E18, 1 week and 1 month post natally. Tukey  post hoc analyses 
showed significant increase in expression at E18 (*-p=0.003) and at 1 week after birth compared to E10 
(*-p=0.035). Error bars represent +/- 1SE of the mean.  
 
2.5.  Discussion and study limitation 
This study aimed at characterising the developmental distribution of Myt1l in vertebrates, by 
two two model organisms – zebrafish and mouse. To visualise the localisation of zebrafish 
myt1l, in situ hybridisation experiments were performed. We found that myt1l is expressed 
specifically in the zebrafish brain, starting between 18SS and 24hpf, with expression remains 
high throughout the embryogenesis. At the end of the gastrulation period (10hpf), the first 
onset of neurogenesis in the neural plate becomes apparent.   At 24hpf this gene is clearly 
showing in the telencephalon, at the time when neuronal progenitor cells start proliferating in 
this brain region (Schmidt, Strahle, & Scholpp, 2013), suggesting involvement of myt1l in 
neurogenesis and its putative role as a developmental regulator. Our findings are consistent 
with recent genome-wide analysis study, by Armant et al.(Armant et al., 2013), where it was 
found that myt1la was one of 16 genes that were only expressed in the telencephalon at 






neurod6b. The authors of this study suggested that myt1l alongside other identified genes is a 
prime candidate for functional studies due to their single tissue specificity. Within the first 24h 
of fish embryogenesis, a precisely organised and simple network of neurons develops. These 
neurons form a foundation for central and peripheral axonal pathways (C. B. Kimmel, Hatta, & 
Eisen, 1991).  At 24h, neurogenesis has already started and continues; regionalisation starts in 
the pallium (septal formation) and subpallium (striatum). Some neurons begin to connect to 
their targets in the diencephalon. At this stage in the telencephalon, neurons of the dorso-
rostral cluster (drc) extend axons to form the supra-optic tract (SOT) and the anterior 
commissure (AC)(Hjorth & Key, 2002). The zebrafish telencephalon is composed of the pallium 
and the subpallium, which is the teleost analog of cortico-basal-ganglia circuits in mammals 
(Rink & Wullimann, 2002). In rodents and non-human primates, the formation of new neurons 
is particularly evident in two regions, the subventricular zone (SVZ) and the subgranular zone 
(SGZ) of the telencephalon (Schmidt et al., 2013). Exclusive presence of myt1l within this brain 
region from 24hpf till 36hpf supports the suggestion that this gene is involved in neurogenesis.   
As development proceeds, Myt1l transcript becomes detectable in many other areas of the 
brain and it becomes difficult to definitively define myt1l expressing brain regions in whole 
mount preparations. By 48 hpf and in the early larval period (from 72 hpf), expression of myt1l 
was observed throughout the head, but it was not detected anywhere else in the fish body. It 
is generally accepted that by 48-72h second neurogenesis occurs with the beginning of the 
hatching period (Charles B. Kimmel et al., 1995). This stage marks the origin and development 
of neurons building the main mass of the later brain. The 2-dpf zebrafish brain is unique in that 
the key markers of neurogenesis were found to be expressed in a pattern which is to be 
expected for the beginning of massive overall secondary neurogenesis and represents a first 
stage of zebrafish brain development comparable with what is described in the mouse brain 
(Mueller & Wullimann, 2003). 
To confirm the expression patterns of myt1l during zebrafish development, we performed 
qPCR across developmental stages. Similarly to ISH, we concluded that myt1l is highly 
expressed at 24hpf and its levels remain elevated until 3dpf. Our study is the first to provide an 
insight into myt1l expression across different embryonic stages during zebrafish development. 
Importantly, strong expression of myt1l was seen in the developing brain from 24 hpf to 3 dpf, 
suggesting its possible role in zebrafish neural development.  
To further elucidate the role of this gene and to examine if its expression followed similar 




points were analysed. Similarly to zebrafish, we found that Myt1l was not expressed early 
during the development (up to E13.5), and its levels were the highest just before birth (E18). 
We found that Myt1l mRNA levels remained elevated but gradually decreasing up to 6 months 
post-natally (last measured stage). This can suggest that although still highly expressed, Myt1l 
most robust role is before birth, when vertebrate neurogenesis is most active. Interestingly, 
we noted high levels (around 600-fold increase) of Myt1l at 6-month postnatally which 
corresponds to mature adult in human. These facts can imply that MYT1L might not only play a 
role during embryonic brain development but it can also have a functional part in adult 
neurogenesis, like maintaining synaptic functions and connections throughout the life. 
Discovering that Myt1l is highly expressed later in life can suggest its role as a possible 
neuroprotective agent or that it may be a factor required to maintain neuronal functions.        
Most interestingly we can conclude that Myt1l expression patterns are conserved throughout 
vertebrate development, and that its expression is restricted to brain. These suggest a pivotal 
role for this gene in vertebrate neurodevelopment.     
 
2.5.1. Limitations and future directions 
The first and foremost advantage of our study, which that is at the same time a limitation, is 
the choice of zebrafish as a model organism.  Though a vertebrate, the zebrafish is a non-
mammalian species, implying physiology and pathology to be more evolutionarily distant from 
human than mice, the most commonly utilised model organism.  
One limitation comes from in situ hybridasation staining. Using this method, we were only able 
to precisely visualise region-specific myt1l transcripts up to 48h of embryonic development. 
This could have been overcomed by performing tissue sections of fish brain. It would have 
given us more insight into the specific organisation of myt1l expression and its possible role in 
neurogenesis. Direct detection of myt1l protein can be achieved through 
immunohistochemical methods. Immunostaining is a powerful method for detecting the 
presence and the localisation of an endogenous protein. Analyses of the expression and the 
localisation of proteins are crucial to determine the function of genes at the tissue and organ 
levels mainly by immunohistochemical and live-imaging analyses. It is important to validate the 
expression and sub-cellular localisation of endogenous proteins. This is best analysed by 
immuno-histochemistry in sections or whole mount preparations. To determine which type of 




specific cellular markers (i.e. for GABA-ergic neurons, glutaminergic neurons, serotonergic 
neurons). Additionally, it would be interesting to investigate myt1l expression patterns and 
levels in later stages of fish development. It is known that during adulthood the brain remains 
plastic and behavioural changes like memory and learning can influence synaptic function and 
organisation (Spedding, Jay, e Silva, & Perret, 2005). Our mice data suggest that Myt1l might 
play a role during adulthood, thus it would be interesting to further examine the zebrafish 
model and potentially identify brain regions associated with myt1l expression. This information 
would provide us with valuable clues as to the function of this transcriptional factor. As for 
future directions, to further our knowledge and understanding of Myt1l role in vertebrate 
brain development, its down-regulation could be investigated. Interference with this gene 
function in vivo can produce invaluable data as to its role in fish brain development. There are 
several widely implemented techniques in both, zebrafish and mouse models that could 
potentially be implemented to study Myt1l function. For example, use of morpholino-modified 
oligonucleotides (morpholinos) is an effective knock-down technology widely used in the 
zebrafish. Morpholinos are synthetic complementary antisense oligonucleotides that can 
either block translation (ATG morpholinos) or modify pre-mRNA splicing ( splice morpholino) in 
order to knockdown a gene function (Nasevicius & Ekker, 2000). The ATG morpholinos act by 
blocking the initiation of a protein translation at the ribosomes, thereby rendering the 
embryos devoid of a particular protein (Bill et al., 2009).  Thus in order to investigate the 
function of myt1l on the development of the zebrafish, morpholino antisense oligonucleotides 
could be used to knockdown myt1l in vivo. Then, the outcome could be analysed by using in 







3. Identification of MYT1L target genes using a neuronal stem 
cell model  
 
3.1. Introduction 
Increasing amount of research has provided a better view on the possible function of MYT1L. 
We know, that in association with Ascl1, Brn2 and NeuroD1, it transforms mouse and human 
fibroblasts directly into functional neurons (Z. P. Pang et al., 2011; Pfisterer et al., 2011; T. 
Vierbuchen et al., 2010). Combining this knowledge with the fact that Myt1l mRNA transcripts 
in rats were most abundant during prenatal brain development when most neurons are 
formed (J. G. Kim et al., 1997), it is hypothesised that it has a role in brain development. The 
complexity of the human brain has made it difficult to study many developmental genes in 
model organisms, highlighting the need for an in vitro model of human brain growth. In the 
present study we utilised human neural stem cells as a model to study potential gene targets 
of MYT1L and the impact of this transcription factor on the expression of other genes. In order 
to identify downstream targets of transcription factors, one of the key analyses is to identify 
gene expression changes, which occur when the function of a transcription factor of interest is 
perturbed. Research with lentiviruses enabling overexpression and/or short hairpin (sh) RNA 
knock-down provide a mean for interfering with the function of genes of interest. A virus is 
nature’s own transport of genetic material, as it can incorporate into the cell without causing 
an immune response. Thus, viral infection is by far the most efficient transduction method (S. 
U. Kim, 2004). An important characteristic that distinguishes lentiviruses from the other viral 
vectors is their ability to transduce non-dividing cells, such as neurons, as well as dividing cells. 
Lentiviral vectors are able to stably integrate into the genome of host cells, without producing 
an immune response (Dissen et al., 2009). Further analyses to identify downstream target 
genes using a microarray gene expression analyses are described in this chapter. 
 
3.1.1. Stem cells as an in vitro model for neurodevelopment. 
Human embryonic stem cells have been widely used as model systems to inform scientists how 
typical developmental processes are implemented (Zeng et al., 2013).  Their use in research 




studying normal neural development and entangling involvement of particular genetic factors 
during neurogenesis. Stem cells are defined based on two criteria: their ability to self-renew 
and ability to differentiate into different cell types. Stem cells can be further divided into 
different categories, according to their differentiation potential: totipotent stem cells, 
pluripotent stem cells, and multipotent stem cells. Totipotent stem cells are cells derived from 
the fertilised egg or morula stage embryo, and these cells are capable of differentiating into 
any type of cell (Mitalipov & Wolf, 2009). Pluripotent stem cells originate from the isolated 
inner cell mass of the developing blastocyst embryos (Evans & Kaufman, 1981). Pluripotent 
stem cells are able to differentiate into all three germ layers of the human body including 
ectodermal, endodermal and mesodermal cell types. Multipotent stem cells are cells isolated 
from specific tissues, from foetuses or adults, and these cells are able to generate 
differentiated cells of the same tissue origin (Mitalipov & Wolf, 2009).  
Neural stem cells (NSCs) are self-renewing, multipotent cells that can give origin to neurons, 
astrocytes and oligodendrocytes and can be readily expanded in vitro (Mothe & Tator, 2012). 
During embryonic development, NSCs are found in several regions such as cerebellum, 
hippocampus, cerebral cortex, basal forebrain and spinal cord (Sally Temple, 2001). In the 
adult mammalian brain, it is generally accepted that NSCs are found in the dentate gyrus of the 
hippocampus and the subventricular zone (SVZ)(Doetsch, Caille, Lim, Garcia-Verdugo, & 
Alvarez-Buylla, 1999). This suggests the existence of a previously unrecognised neural plasticity 
in the mature CNS and the possibility of neural reconstruction in the adulthood. It has been 
suggested that the adult CNS retains the capacity for limited self-renewal in order to maintain 
its proper function, like learning and memory (Gage, 2000).  
In vitro, NSCs can be maintained at their proliferative state by combining basic fibroblast 
growth factor (bFGF) and epidermal growth factor (EGF) in the defined or supplemented 
medium (Conti et al., 2005; Gage, 2000). Adherent NSCs provide an excellent platform to study 
genetic factors of neural development, as they can be easily expanded and readily 
manipulated. A method that has been widely used to maintain stable cultures of neural 
stem/progenitor cells is immortalisation. Cells are immortalised by using viral oncogenes, such 
as SV40 largeT or v-myc (S. U. Kim, 2004). These cell lines were shown to retain a lot of the 
characteristics of the NSCs, with the capacity to differentiate into neurons and glial cells 
allowing for an extensive study in vitro and also after transplantation. Nonetheless, the 
presence of a genetic alteration makes immortalised cell lines a controversial model, because 




of tumorigenic cells. However, recent reports suggested another system that could lead to 
normally developing neural cells. It employs c-mycERTAM gene technology to immortalise 
embryonic stem cells (Littlewood, Hancock, Danielian, Parker, & Evan, 1995). The c-mycERTAM 
transgene is better suited as an immortalising agent for clinical applications because c-Myc 
protein function is conditional on the presence of the tamoxifen metabolite, 4-
hydroxytamoxifen (4-OHT) (Stevanato et al., 2009). To achieve conditional growth, a fusion 
protein is generated that consists of a growth promoting gene, c-myc, and a hormone receptor 
that is regulated by a synthetic drug, 4-hydroxy-tamoxifen (4-OHT). Pollock et al. (2006) have 
reported that in the absence of growth factors and 4-OHT, the cells differentiate into neurons 
and astrocytes. Recent findings suggest that c-mycER immortilised cells, derived from spinal 
cord, easily differentiate into V2 interneurons and motoneurons upon removal of growth 
factors and 4-OHT, thus inactivating the cMycER complex (Cocks et al., 2013). Those cells have 
been stably transplanted into rats without a tumorogenicity (Amemori et al., 2013; Cocks et 
al., 2013). Since the first stable hESC line was derived (Thomson et al., 1998), they have been 
considered as an excellent source of precursor cells to treat variety of conditions, such as 
motor neuron disease, spinal cord injuries, Alzheimer’s disease and many more. However, the 
great attention has been given to the possible therapeutic use of stem cells. However, hESCs 
are equally important as a research tool for human developmental processes, both normal and 
diseased. 
 
3.1.2. Use of lentiviruses to study gene function 
Viruses are natural gene delivery systems, as they can target specific cells while avoiding 
immuno surveillance. Particular viruses have been selected as gene delivery vehicles because 
of their capacities to carry foreign genes and their ability to efficiently deliver these genes 
associated with an efficient gene expression. Viral vectors derived from retroviruses (including 
lentiviruses), adenovirus, adeno-associated virus, herpesvirus and poxvirus are mostly 
employed in current clinical gene therapy trials worldwide (Walther & Stein, 2000). By 
eliminating pathogenicity of a specific virus while retaining efficiency of the gene transfer, the 
system may be well suited for a successful gene delivery for clinical and non-clinical research. 
Among these vector systems, retrovirus vectors represent the most prominent delivery 
system, since these vectors have a high gene transfer efficiency and mediate high expression 




Lentiviruses are members of the large retrovirus family (Goff, 2001). Lentiviral vectors gained 
interest in the molecular biology field dues to their ability to infect many cell types, including 
non-dividing cells such as stem cells and neurons. They are composed of two copies of a linear 
single stranded RNA molecule of 7-12 kb, which are protected by a protein core inside the 
enveloped virus particle (Barquinero, Eixarch, & Perez-Melgosa, 2004). Three open reading 
frames (ORFs) are common to all retroviruses: gag (group associated antigen) encodes for 
structural proteins and forms the core, pol encodes for the proteins needed in a viral 
replication and integration, and env encoding for the envelope glycoproteins that mediate 
virus entry. All retroviral genomes are flanked by two long terminal repeat (LTR) sequences 
and contain cis-acting packaging sequences (phi, Ψ) that are needed for the correct 
incorporation of unspliced genomic RNA molecules into the new virus particles (Goff, 2001). 
The life cycle of retroviruses commences by binding to a receptor on the host cell via 
glycoprotein ligands of the virus. This is followed by fusion of the virus envelope and the 
membrane of the host cell which allows an entry. Immediately after an entry, reverse 
transcription takes place and a pre-integration complex is formed (PIC). Lentiviruses are unique 
due to the fact that they can infect undividing cells by entering the nucleus of a cell through 
the nuclear envelope and PIC (A. Pfeifer & Hofmann, 2009). Once the provirus enters the 
nuclear envelope, it integrates itself with a host genome. The most widely used vector system 
is derived from human immunodeficiency virus -1 (HIV-1) and a 3rd generation of this 
lentivector system has been developed for an optimised performance (Alexander Pfeifer, Lim, 
& Zimmermann, 2010). The general strategy applied during the production of viral particles 
that are replication-defective has been to eliminate all non-essential genes from the HIV-1 
genome and separate cis- acting sequences from trans-acting particles (De Palma & Naldini, 
2002). It is achieved by dividing the coding regions for structural and enzymatically active 
proteins (gag and pol-genes), the envelope construct and the retroviral genome into individual 
expression plasmids. In such systems, the structural proteins and the envelope construct are 
expressed from helper plasmids, where a gene of interest is located within the vector 
construct containing the cis- acting sequences required for the vector packaging, reverse 
transcription and integration (Dull et al., 1998). The commonly used 3rd generation lentiviral 
vector consists of four plasmids: a packaging construct containing gag and pol genes which are 
essential for production of lentiviral particles; an env - an envelope protein; a plasmid 
expressing Rev protein - that is necessary to achieve sufficient expression of unspliced vector 
genomic RNA; a transgene plasmid (vector transfer construct) and the promoter, as well as cis-




in the vector, which is accomplished by a deletion of the promoter/enhancer sequences in the 
U3 region of the 3′LTR (generating self-inactivating (SIN) vectors). During reverse transcription 
the proviral 5’LTR is copied from the 3’LTR, therefore transferring the deletion to the 5’LTR, 
leading to transcriptional inactivation of the provirus (Dull et al., 1998). High-titer lentivector 
preparations are essential to achieve high transgenesis rates. Lentiviral vectors are commonly 
produced by co-transfecting adherent HEK 293T cells that act as a packaging cell lines, with 
calcium phosphate (Follenzi & Naldini, 2002). A large scale production of lentiviruses for 
clinical or molecular research requires a high titer vector production. Currently, the lentivarial 
systems generate 105 – 106 transducing units (TUs) per ml, which can be increased by 
centrifugation. Lentiviral transduction has been demonstrated to be the most effective 
method of a gene transfer (20-25%) with the >95% cell viability (Cao et al., 2010). 
Electroporation and lipofection demonstrated very low levels of transfection efficiency. 
Considering that human embryonic stem (hES) cells  are notoriously difficult to transfect, 
lentiviral- derived vectors are efficient tools for the delivery and stable expression of 
transgenes in hES cells.   
To summarise, use of lentiviral vectors is an appropriate choice to study gene function due to 
their unique ability to transduce dividing and non-dividing cells, such as stem cells, and to 
stably integrate into the host cell genome and achieve a long term transgene expression in 
vitro and in vivo (Cockrell & Kafri, 2007). 
 
3.1.3. Molecular characterisation of MYT1L and its role in neurodevelopment 
Information about the role of MYT1L in neurodevelopment comes from clinical studies, where 
aberrations of this transcription factor were found to be associated with several 
neurodevelopmental disorders, such as schizophrenia (Y. Lee et al., 2012; Van Den Bossche et 
al., 2013; Vrijenhoek et al., 2008), intellectual disability (Rio et al., 2013; S. J. Stevens et al., 
2011), major depressive disorder (T. Wang et al., 2010) and autism (Matsunami et al., 2013; K. 
J. Meyer, M. S. Axelsen, V. C. Sheffield, S. R. Patil, & T. H. Wassink, 2012).  
So far, our knowledge about MYT1L is limited. We know, that the MYT1L gene (also known as 
NZF1) maps to chromosome 2 in humans (2p25.3), it spans >542kb and has 25 exons. It has 13 
known transcripts in humans (http://www.ensembl.org/Homo_sapiens/Gene/), 4 of which are 
protein coding variants, the longest consisting of 1186 amino acids. MYT1L is a member of the 




is highly homologous to MYT1. MYT1 is a representative of the Cys-Cys-His-Cys (CCHC) zinc-
finger protein family, which has been highly conserved during evolution between both species 
and family members. It has been suggested that MYT1/MYT1L binding can result in the 
recruitment of histone deacetylases (HDACs) to target gene promoters, which results in a 
transcriptional repression (Romm et al., 2005). These studies suggest that MYT1L may have a 
regulatory role in the developing nervous system. The role of MYT1L in regulating neuronal 
differentiation is further highlighted by breakthrough studies showing that this protein in 
combination with other factors, such as ascl1 and brn2 (also known as pou3f2) could directly 
convert mouse fibroblasts into neurons (T. Vierbuchen et al., 2010) Another study, found that 
addition of POU3F2 to MYT1L and ASCL1 can generate functional neurons from human 
pluripotent stem cells as early as 6 days after the transgene activation (Z. P. Pang et al., 2011). 
When combined with NeuroD1, these factors could also convert foetal and postnatal human 
fibroblasts into induced neuronal cells showing typical neuronal morphologies and expressing 
multiple neuronal markers. These induced neuronal cells express multiple neuron-specific 
proteins, generate action potentials, and form functional synapses (Z. P. Pang et al., 2011; T. 
Vierbuchen et al., 2010). It was reported that miR-9* and miR-124 were found to induce the 
conversion of human fibroblasts into neurons with NeuroD2 (Yoo et al., 2011). Addition of 
MYT1L and ASCL1 further enhanced the rate of conversion and the maturation of the 
converted neurons. All of the aforementioned studies have provided evidence to suggest the 
importance of MYT1L in neural development.  
Another important finding comes from a collaboration between Dr Sylvane Desrivières 
(supervisor) and Professor Jack Price’s laboratory, where they have tested, using quantitative 
real-time PCR (qPCR), the expression patterns of MYT1L in differentiated and undifferentiated 





Figure 3.1. MYT1L expression in various human stem/progenitor cell lines. The y-axis shows the fold 
MYT1L mRNA induction in differentiated cells compared undifferentiated cells; the x-axis represents 
different types of human stem/progenitor cells. SPC stands for spinal cord embryonic stem cells, CTX 
stands for embryonic cortical stem cells, and STR stands for cells derived from human foetal striatum. 
Numbers in each cell line represent different clones. 
These experiments indicated that MYT1L has very low or no expression in undifferentiated 
stem cells and is strongly induced during the differentiation, in most cell lines tested. This 
suggests that MYT1L may play a role in the differentiation process. As the SPC-04 cell line 
showed the highest induction of MYT1L upon differentiation (>200 fold), we planned to use 
this cell line for subsequent neural differentiation studies (described below).  
 
3.2. Aims. 
Despite its apparent involvement in neurogenesis, the cellular and molecular functions of 
MYT1 remain largely unknown. The role of MYT1L on the expression of other genes during 
neural development is yet to be determined. The search for interacting partners of MYT1L will 
help us to understand the biological role of MYT1L and mechanisms by which its gene product 
regulates neural differentiation. The general aim of this chapter is to functionally characterise 
MYT1L and investigate its direct gene targets using different approaches to achieve two main 
points:  
1. Generate a MYT1L over-expressing lentiviral construct for infection into 
undifferentiated SPC-04 cell line to enable co-immunoprecipitation of exogenous 






2. Use a MYT1L knock-down lentiviral construct to infect pre-differentiated neuronal 
stem cells to enable: 
a.  Identification of downstream transcriptional targets of MYT1L by comparing 
global gene expression levels between MYT1L knock-down cells and control 
cells differentiated for 7 and 14 days using microarray technology. 
b. Characterisation of differentially expressed genes by performing a gene 
ontology term enrichment analyses and Ingenuity Pathway Analysis to identify 
possible biological processes and molecular mechanisms by which MYT1L 
might influence brain development.  
 
3.3. Materials and methods. 
3.3.1. Construction of lentiviral vectors for overexpression of MYT1L 
This section describes the constructs used to develop overexpression plasmids. Several 
commercially available systems were used in this attempt; however none of them produced 
satisfactory results meaning we were unable to successfully express exogenous MYT1L. Results 
and possible implications will be discussed later in the chapter.  
Two lentiviral vectors were constructed, one to express MYT1L in its native form and  a second 
one as a recombinant protein with a C-terminal V5 epitope, allowing recognition of the 
recombinant protein by an anti-V5 antibody. pLenti7.3/V5-TOPO® vector (Life Technologies, 
UK) was used for cloning MYT1L to produce a recombinant fusion protein. pLenti7.3/V5-TOPO 
vector is a lentiviral expression vector that has been adapted for use with TOPO TA Cloning 
technology. TOPO cloning is a method for cloning PCR products into a plasmid vector. The key 
to TOPO cloning is the enzyme DNA topoisomerase I, which functions both as a restriction 
enzyme and as a ligase.  The plasmid (pLenti7.3/V5-TOPO) is provided as linearised vector with 
a single 3 ́ thymidine (T) overhangs for the TOPO Cloning and the topoisomerase I covalently 
bound to each 3´ phosphate. The 3'A overhangs of the PCR product complement the 3'T 
overhangs of the vector and allow for fast ligation with the topoisomerase I. Using the TOPO 
cloning technology, the pLenti-TOPO vectors are a highly efficient cloning strategy for the 
direct insertion of amplified PCR products into a plasmid vector. Once cloned, the plasmid can 
then be transformed into competent bacterial cells. After analysis of the plasmid, and 




shown on Figure 3.2, illustrating the main features of the vector including the human 
cytomegalovirus (CMV) immediate early promoter to control high-level expression of the gene 
of interest, the WPRE (Woodchuck Posttranscriptional Regulatory Element) from the 
woodchuck hepatitis virus, which permits increased transgene expression, the Emerald Green 
Fluorescent Protein (EmGFP) to monitor transduced cells and the V5 epitope which allows 
detection of the recombinant fusion protein by anti-V5 antibodies.  
 
Figure 3.2. Schematic representation of pLenti7.3/V5-TOPO® vector. This lentiviral expression plasmid 
contains a CMV promoter, an EmGFP reporter gene, an ampicillin resistance gene. A V5 epitope is 
present in the multiple cloning site which can result in a tagged protein of interest if cloned in frame 
with the V5 sequence. 
 
3.3.1.1.  Primer design for MYT1L amplification 
Primers were designed to amplify MYT1L ORF (open reading frame) by PCR using the Phusion® 
High-Fidelity DNA Polymerase (Thermo Scientific).  The forward primer incorporated the 
KOZAK consensus ([G/A]NNATGG) sequence – the optimal sequence required for translation 
initiation. Two reverse primers were designed to obtain either the MYT1L protein sequence in 
frame with the V5 epitope tag resulting in a fusion protein (MYT1L +V5) or the native MYT1L 
protein. Table 3.1 shows primer sequences used for the amplification. To obtain the native 
form of MYT1L, a stop codon (TGA) was included in the reverse primer. Whereas to obtain a 
V5-tagged MYT1L protein, a stop codon was removed and additional (underlined) nucleotides 






Table 3.1. Primers used to amplify MYT1L ORF for cloning into pLenti7.3/V5 TOPO® TA vector. In order 
to generate V5-tagged and native form of the protein, two different reverse primers were used. Both 
primers have a similar sequence except that the primer resulting in the fusion protein has no stop codon 
(highlighted in red in the native primer) and has two additional base pairs (guanine and cytosine – 
underlined) to keep the MYT1L sequence in frame with the V5 sequence. Kozak consensus sequence is 
underlined in the forward primer. 
Primer Sequence 
Forward 5’ – AAGATGGAGGTGGACACCGAGGA – 3’ 
Reverse with V5 tag (MYT1L+V5) 5’ – GCGACCTGAATTCCTCTCACAGC – 3’ 
Reverse native 5’ – TCAGACCTGAATTCCTCTCACAGC – 3’ 
 
3.3.1.2. PCR amplification of MYT1L 
The PCR reaction to amplify MYT1L ORF was performed using the Phusion® High-Fidelity DNA 
Polymerase (Thermo Scientific, UK), in a total volume of 50μl containing 5x Phusion high 
fidelity (HF) buffer (Thermo Scientific, UK), 10mM dNTP mix, 0.5μM forward and reverse 
primer (either native or V5), 1U Phusion DNA Polymerase, 10ng DNA template and dH20 to a 
final volume of 50μl.  The thermal cycler conditions are presented in Table 3.2:  
 
Table 3.2: PCR thermal cycling conditions to amplify MYT1L ORF. 
Step Time Temperature (°C) 
1 - Initial denaturation 10s 98 
2 - denaturation 10s 98 
3 - annealing 30s 68 
4 - extension 2mins 72 
5 - number of cycles Go to step 2 - 35 times 





3.3.1.3. DNA gel electrophoresis 
PCR products were electrophoresed, in order to evaluate the success and specificity of the 
amplification; i.e., to confirm the presence of a single, clear DNA band representing the MYT1L 
ORF (~3.55kb in length). DNA gel electrophoresis was performed using a 0.8% agarose gel, 
which consisted of 0.8g agarose and 1x Tris/Borate/EDTA (TBE) buffer to a total volume of 
100ml in a conical flask. The mixture was swirled gently by hand and heated in the microwave 
(on the high setting) until the agarose dissolved completely. The solution was then placed 
under a cold tap for ~1min. Once cooled, 2μl ethidium bromide was added and the solution 
was mixed thoroughly by gentle swirling. Ethidium bromide is a fluorescent intercalating dye 
that can be seen under UV light and is used to visualise DNA on agarose gels. The solution was 
then poured into a sealed (with an autoclave tape) gel casting tray containing a comb to form 
appropriately sized wells and left to set for ~20mins.  Wells were loaded with samples 
consisting of 5μl DNA and 1μl 6x gel loading buffer (GLB) (Thermo Scientific, UK), with one or 
two wells reserved for 5μl of 1kb DNA ladder (Invitrogen). Gels were electrophoresed at 110V 
for ~1hr or until the ladder had undergone sufficient separation. Gels were then visualised 
using a UV transilluminator. 
 
3.3.1.4. Preparation of lysogeny broth (LB) and LB agar 
LB was prepared by dissolving 20g Lennox L Broth Base (Invitrogen) in dH2O to a total volume 
of 1 litre, whereas LB agar was prepared using 32g Lennox L Agar (Invitrogen) with dH2O to a 
total volume of 1 litre. Both solutions were autoclaved. The pLenti 7.3/V5 vector expresses 
resistance to the antibiotic ampicillin (Figure 3.2), therefore 100μg/ml ampicillin was added to 
cooled, autoclaved LB agar and LB broth. This procedure ensures that only bacteria containing 
successfully ligated plasmids would be present, as open plasmids are unable to express 
ampicillin resistance.  Directly after the addition of ampicillin, the LB agar solution was 
distributed evenly into numerous Petri dishes (around 10ml per dish) and plates were left to 






3.3.1.5. Ligation of MYT1L into pLenti 7.3/V5 TOPO expression vector 
TOPO Cloning technology allows a quick production of PCR product, by ligating it into the 
pLenti-TOPO vector, and followed by a transformation of the recombinant vector into stable, 
component cells. pLenti 7.3/V5 TOPO® TA cloning kit (Life Technologies, UK) was used to ligate 
a fresh PCR product with the expression vector. 
The TOPO® cloning reaction consisted of: 4μl of the PCR product, 1μl salt solution, 1μl pLenti-
TOPO® vector in a final volume of 6μl. In parallel, a control reaction was set up with no insert 
DNA to assess the re-ligation efficiency of the linearised vector. This mixture was incubated at 
RT for 20 minutes and then placed on ice. 5μl of this reaction was then transformed into MAX 
Efficiency Stbl2™ Competent E.coli, according to manufacturer’s instructions. 
 
3.3.1.6. Transformation of bacteria with plasmid DNA 
5 μl of ligated products (V5-MYT1L, Native MYT1L and empty vector) were added to 50μl 
chemically competent MAX Efficiency Stbl2 cells (Invitrogen, UK) and incubated on ice for 30 
mins. Bacteria were then inactivated by heat-shock at 42°C for 25s and returned to ice for 2 s. 
Next, 450 μl of S.O.C medium was added to each transformation and the bacteria were 
incubated at 30o, shaking at 225rpm for 1.5 hours. The cells were then gently mixed by 
pipetting and 100μl of the cell suspension from each construct was streaked onto LB agar 
plates (containing 100μg/ml ampicillin), which were then incubated overnight at at 30°C to 
isolate individual colonies. 
 
3.3.1.7. Screening bacterial colonies for positive clones 
Individual colonies were aseptically picked in order to screen for positive clones (vector with 
insert) and were pre-cultured in 5 ml of LB Broth media (Invitrogen, UK) containing 100μg/ml 
ampicillin at 30o C overnight and used for small- or large-scale plasmid production.  
 
3.3.1.8. Plasmid purification 
For small-scale plasmid isolation minipreps were used (NucleoSpin Plasmid Kit, Macherey-




1500 RPM for 5 minutes at room temperature. Approximately, 4 ml of the supernatant was 
discarded using sterile tips, and bacteria were resuspended in the remaining 1ml and 
transferred to a microcentrifuge tube for further centrifugation at 11000 x g for 1 minute. The 
supernatant was discarded and the bacterial pellet was resuspended in 250 μl of buffer A1 
(containing RNase A at concentration of 100 μg/ml). This was followed by the addition of 250 
μl of lysis buffer A2, the suspension was mixed by inversion (6 to 8 times), incubated at room 
temperature for 5 minutes and the lysis was neutralised by the addition of 300 μl of buffer A3. 
The mixture was centrifuged at 11000 x g for 5 minutes to pellet bacterial debris and the 
plasmid-containing supernatant was carefully removed and transferred into a NucleoSpin 
Plasmid column provided with the kit. Plasmid DNA was bound to the column by brief 
centrifugation (1 min) at 11000 x g. Column-bound DNA was washed with 600 μl of buffer A4 
(containing 80% ethanol), flow-through discarded and the membrane was dried by 
centrifugation for 2 mins at 11000 x g. Plasmid DNAs were eluted with 30 μl of buffer AE (5 
mM TrisHCl,pH 8.5).  
For a large-scale plasmid preparation, 1 ml of the pre-culture bacteria was added to 400 ml of 
LB Broth media (supplemented with 100 μg/ml ampicillin) and incubated at 30o C overnight 
while shaking at 50RPM. The bacteria were then harvested by centrifugation at room 
temperature for 20 mins at 1500 RPM. Supernatants were discarded and the bacterial pellets 
used for maxi-prep DNA isolation using the Endofree Plasmid Maxiprep Kit (Qiagen, UK), 
according to the manufacturer’s instructions. Briefly, bacteria were resuspended in 10 ml 
buffer P1 [50 mM TrisHCl (pH 8.0) and 10 mM EDTA] supplemented with RNase A (100 μg/ml). 
The mix was lysed by adding 10 ml of buffer P2 (200 mM NaOH and 1% SDS) and incubating for 
5 mins at room-temperature. Next, lysates were neutralised by the addition of 5 ml of chilled 
buffer P3 (3.0 M potassium acetate,pH 5.5) and mixed by a vigorous tube inversion (6-8 times). 
Then, the lysates were filtered through the QIAfilter cartridge, 2.5 ml of buffer ER was added 
for endotoxin removal and lysates were incubated on ice for 30 mins. The supernatant was 
then applied into an equilibrated QIAGEN-tip 500 column and allowed to flow-through by 
gravity flow. The column was then washed twice with 30 ml of buffer QC (1 M NaCl, 50 mM 
MOPS (pH 7.0) and 15% isopropanol). The plasmid DNAs were eluted in 15 ml of buffer QN (1.6 
M NaCl, 50 mM MOPS, pH 7.0 and 15% isopropanol), precipitated by adding 10.5 ml of 
isopropanol (Sigma, USA), which was followed by centrifugation at 20000 x g for 30 min at 4oC. 
The supernatants were carefully decanted and DNA pellets were washed with 5 ml endotoxin-
free 70% ethanol and centrifuged further for 10 min at 20000 x g at 4oC; Again, supernatants 




dried for 5 minutes and resuspended in 150 μl of TE buffer (10 mM Tris-HCl,pH 8.0 and 1 mM 
EDTA). DNA concentrations were measured by UV spectrophotometry using a 
nanospectrophotometer (NanoDrop 1000, Thermo Scientific) and plasmids were stored at -20o 
C till required.  
 
3.3.1.9. Verification of correct DNA inserts 
Following transformation, colony isolation and plasmid purification by minipreps, samples 
were screened for positive clones by restriction digest using the HindIII restriction enzyme. 
This enzyme was chosen for verification, as it cuts 6 times in the pLenti vector (Figure 3.3) and 
it cuts the MYT1L ORF once creating two fragments: 3118bp and 437bp. HindIII cuts are not 
within the multiple cloning site of the vector, they are placed before the CMV promoter site 
and GFP site, making it a good candidate for testing the orientation of the insert. The TOPO 
cloning site is located at 2558 – 2567bp, and the V5 epitope site is located at 2630-2671bp on 
the vector. If the vector had no insert present, the expected sizes after cutting with HindIII 
would be as follows: 312 bp, 481bp, 556bp, 584 bp, 2658bp and 3344bp. If MYT1L was 
inserted in a correct (sense) orientation (5’ towards 3’) instead of a 2658bp band we expected 
two bands sized: 2353bp and 3747bp representing the MYT1L insert. The restriction reaction 
was performed as follows: 10 μl of plasmid DNA from the mini-prep was digested with 5U of 
HindIII enzyme (NEB, UK) in the presence 1x NEB restriction enzyme buffer 2 (NEB, UK) and 
topped up with dH20 to a final volume of 20 μl. The reaction was inclubated for 1.5h at 37 oC. 
The DNA digestions were separated by electrophoresis on a 1.5% agarose gel (Sigma, UK) 
made up with 1X TBE buffer (0.0089 M Tris, 0.089 M Borate, 0.002 M EDTA; Merck, Germany) 
and supplemented with 2% of Ethidium Bromide (Electron, UK). 10 μl of the digested samples 
were mixed with 2 μl of 6X gel-loading buffer (Thermo Scientific, UK) and loaded into the gel 
wells. Additionally, two wells (first and last well on the gel) were used for loading the 1 kb DNA 
ladder (250-10,000 bp Sigma, UK). Electrophoresis was at 100 V for 1.5h. The DNA bands 
obtained from the gel were visualised using ultraviolet light. In addition, DNA plasmids were 
sent for sequencing (Bioscience, UK) to check the correct MYT1L ORF and to verify that no 






Figure 3.3. Figure represents restriction sites for pLenti 7.3/V5-TOPO vector. TOPO cloning site within 
pLenti vector is located at 2558-2567bp HindIII enzyme cuts vector six times and was used to determine 
orientation of the inserted MYT1L sequence.  
 
3.3.1.10. Transfection and virus production 
To produce a lentiviral stock, 293FT cells (Invitrogen, UK) were used. Cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM), containing 10% heat-inactivated Foetal Bovine 
Serum (FBS), 4mM L-Glutamine, 1mM MEM Sodium Pyruvate, 0.1 mM MEM Non-Essential 
Amino Acids and 1% penicillin/streptomycin and 500 μg/ml geneticin (Sigma, UK).  Cells were 
transfected using ViraPower™ HiPerform™ Lentiviral TOPO Expression Kits (Invitrogen, UK) and 
Lipofectamine™ 2000 (Life Technologies, UK) according to the manufacturer’s instruction.  
Briefly, the day prior transfection, 293FT cells were seeded at a density of 5.5 x 106 cells/ml in 
10cm sterile dishes in 10ml of culture medium without antibiotics. On the day of transfection, 
the culture medium was replaced with 5ml Opti-MEM I medium containing 5% FBS. Three 
separate reactions were prepared: empty pLenti vector, pLenti + MYT1L native and pLenti + 
V5-tagged MYT1L. For each transfection sample, 9μg of the ViraPower™ Packaging Mix (Life 
Technologies, UK) and 3μg of appropriate pLenti expression plasmid DNA (empty vector, 
MYT1L native and MYT1L-V5) was added to 1.5ml Opti-MEM I Medium without serum and 
mixed gently. Separately, for each transfection reaction, 36μl of Lipofectamine™ 2000 was 
diluted in 1.5ml Opti-MEM without serum, mixed gently and incubated at RT for 5 minutes. 
The diluted Lipofectamine™ 2000 was subsequently added to the diluted plasmid DNA mix. 
This combination was then incubated for 20 minutes at RT. Following incubation, all the DNA-




gently and incubated at 37°C with 5% CO2. The following day, the medium containing the DNA-
Lipofectamine™ 2000 complexes was removed and replaced with 10ml culture medium 
without antibiotics and placed back in an incubator at 37°C with 5% CO2 for a further 24-48h.  
The plates were microscopically examined for the presence of GFP (fluorescent reporter), an 
indicator of transfection efficiency. Supernatants containing virus were collected 24 and 48h 
post transfection. These were centrifuged at 3000RPM for 15 minutes at RT to pellet the cell 
debris. Following centrifugation, the supernatants were filtered through 0.22μm pore 
nitrocellulose filter (Millipore, UK), aliquoted and stored at - 80°C until use.  
 
3.3.1.11. Viral transduction  
293T and 293 FT cells were infected with viruses overexpressing MYT1L as well as the empty 
vector as a control. The day before transduction, 5 x 105 293T cells were plated in each well of 
a 6-well plate and incubated overnight at 37°C with 5% CO2. On the following day, the media 
was removed and changed to 1 ml of serum free and antibiotic free cell media and 2 ml of 
lentiviral supernatant with a final concentration of 0.4mg/ml Polybrene (Sigma, USA) to 
increase transduction efficiency. The plates were centrifuged for 90 mins at 2500 RPM and 
incubated for 2.5h at 37o C in 5% CO2. The media was then changed to 3 ml of complete media 
and the incubation continued for a further 72 hours. Cells were observed daily under a 
fluorescent microscope for the presence of GFP and estimation of transduction efficiency. 
Additionally, to accurately assess transduction efficiency, cells were lysed and RNA was 
extracted to perform qPCR.  
 
3.3.1.12. Total RNA extraction. 
All RNA extractions were performed using the RNeasy Mini Kit (Qiagen, UK), according to the 
manufacturer’s instructions. Briefly, the culture medium was aspirated and cells were washed 
twice with cold 1x PBS, then 600μl of RLT buffer containing 1% β-mercaptoethanol (Sigma, UK) 
was added to each plate. Cells were then collected using a sterile cell scraper and transferred 
to a 1.5ml tube. The mixture was vortexed briefly to ensure thorough lysis. All cell lysates were 
then homogenised using the QIAshredder columns (Qiagen, UK), and centrifuged at 21000 x g 
for 2 minutes. One volume of 70% molecular biology-grade ethanol (Sigma, UK) was added to 




column and centrifuged for 15s at 21000 x g. The flow-through was discarded and 350μl of 
RW1 buffer was added to each column followed by centrifugation for 15s at 21000 x g. Again, 
the flow was discarded and 80μl of DNase I incubation mix, (1:7 ratio of DNase I stock solution 
and Buffer RDD; Qiagen, UK) was added to each column. The reaction was incubated for 15 
mins at room temperature, followed by addition of 350μl of RW1 buffer. The columns were 
then centrifuged for 15s at 21000 x g. The flow was discarded and each column was washed 
with 500μl of RPE buffer followed by centrifugation for 15s at 21000 x g, discarding the flow at 
the end. A second wash with 500 μl of the RPE buffer was applied and the column was 
centrifuged for 2mins at 21000 x g. Next, the column was transferred into a clean RNase-free 
collection tube and RNA was eluted by adding 30μl of RNase-free water directly to the 
membrane of the column and centrifuging it for 1 minute at 21000 x g. RNA samples were 
quantified using a nanospectrophotometer (NanoDrop 1000).  
 
3.3.1.13. Reverse transcription and complementary DNA (cDNA) synthesis 
Reverse transcription was performed using the Invitrogen SuperScript™ III first-strand cDNA 
synthesis kit (Invitrogen, UK). 1µg of total RNA was added to 1 µl of 10mM dNTP mix and 1µl of 
Oligo(dT)18-20 (0.5μg/μl) and the volume made up to 10µl with RNAse-free water. Each sample 
was incubated at 65°C for 5 minutes and then placed directly on ice. Next, to each sample 2µl 
of 10x RT buffer (200 mM Tris-HCl,pH 8.4, 500 mM KCl), 4µl of 25mM MgCl2, 2µl of 0.1M DTT, 
1μl of RNaseOUT™ Recombinant RNase Inhibitor and 1μl of Superscript™ III RT (2000U/µl) was 
added. The samples were incubated at 50°C for 50 minutes and the reaction was terminated 
by incubation for 5 minutes at 85°C. 1μl of RNase H was added to each sample and then 
samples were incubated at 37°C for 30 minutes. cDNA was then diluted with distilled water, 
making 100µl of each sample at a concentration of 10ng/μl.  
 
3.3.1.14. Real Time quantitative PCR. 
cDNA samples were amplified using an ABI Prism 7900HT sequence detection system in a final 
volume of 10μl containing 2x power SYBR green master mix (Applied Biosystems, UK), 4μl of 
cDNA (10ng/μl) and 0.07μM of forward and reverse primer (Table 3.3). PCR reactions were 
performed in triplicate under the following thermal cycler conditions: 95°C for 15 minutes 




by dissociation curve analysis to ensure that the PCR product generated were specific. β-ACTIN 
was used as the housekeeping gene against which expression values for MYT1L were 
normalised to produce ΔCt values (ΔCt = Ctmyt1l – Ctactin).   
Table 3.3. Primer sequences used for qPCR amplification of MYT1L and the control gene β-ACTIN in 
293T and 293FT cells. 
Primer Sequence 
h β-ACTIN Forward 5’ – GCTCGTCGTCGACAACGGCTC – 3’ 
h β-ACTIN Reverse 5’ – CTCTGGCACGCTCGAACT – 3’ 
hMYT1L Forward 5’ – TGGAGAGCAACCTGAAGACC – 3’ 
hMYT1L Reverse 5’ – CAAACATGATCTGGGTCATCTTCTC – 3’ 
 
 
3.3.2. Lentiviral-mediated gene silencing of MYT1L 
3.3.2.1.  Lentiviral constructs for MYT1L silencing 
Concentrated lentiviral stocks carrying either non-silencing shRNA or MYT1L silencing shRNA 
were kindly provided by Lourdes Martinez-Medina (LMM) (SGDP, King’s College London). The 
MYT1L shRNA was cloned into a lentiviral vector that belonged to the Thermo Scientific Open 
Biosystems pGIPZ shRNAmir library developed by Dr Greg Hannon and Dr Steve Elledge (Figure 
3.4). This particular gene silencing system combines the advantages of micro-RNA adapted 
shRNA with the pGIPZ lentiviral vector to create a highly active RNAi pathway with its unique 
short hairpin design. The short hairpin is expressed as human microRNA-30 (miR30) primary 
transcript. The hairpin stem includes 22 nucleotides of dsRNA and the miR30 loop composed 
of 19 nucleotides. Additionally, the miR30 design allows the use of rule based design such as 
destabilising the 5’ end of the antisense strand to incorporate strand specific microRNAs into 





Figure 3.4. A schematic representation of pGIPZ vector (bottom) and a schematic shRNA design (top) 
that is cloned inside of the vector. The pGIPZ lenti-vector contains various features to allow effective 
expression and tracking of shRNAs, such as bacterial selection (ampicillin (Ampr), zeocin (Zeo) or 
puromacin (Puror resistance); CMV promoter, tGFP  marker to track shRNA expression and the 
shRNAmir. The short hairpin RNA constructs are composed of 22 nucleotides (red) with a 
complementary strand (black) that forms a dsRNA and a miR-30 loop (green). It was designed to have a 
Drosha and a Dice processing site to achieve greater siRNA production (figures from Thermo Scientific 
Open Biosystems pGIPZ shRNAmir library, UK) 
 
The sense sequences for the shRNAs used are provided below: 
1) pGIPZ + non-silencing shRNA; sense sequence: 5’ – ATCTCGCTTGGGCGAGAGTAAG – 3’ 
2) pGIPZ + shRNA MYT1L 1; MYT1L target sequence: 5’ – CCGTGACTACTTTGACGGAAAT – 3’  
 
Open Biosystems TransLenti Viral Packaging System (Thermo Scientific, UK) was used for 
transfection and production of lentiviral particles according to the manufacturer’s instructions. 
The lentiviral supernatants were filtered through a sterile 0.22μm pore filter (Sartorius Stedim, 
UK) and concentrated by ultracentrifugation at 75000 x g (Beckman Coulter, UK; SW27 Rotor) 
at 4°C for 1.5 hours. The supernatant was carefully removed without disturbing the viral pellet, 
and then cold PBS (30µl) was added to the vial and stored overnight at 4°C. The following day a 





3.3.2.2. SPC-04 culture and maintenance  
SPC-04 cells were maintained in reduced modified media (RMM-) with growth factors and 4-
hydroxy-tamoxifen (4-OHT) denoted (RMM+) at 37°C in a humidified chamber at 5% CO2.  
Components and final concentrations required for RMM- and RMM+ preparation are detailed 
in Table 3.4:  
Table 3.4. RMM media preparation for SPC-04 cell line. RMM+ includes all the components with groth 
factors (highlighted in grey), where RMM- includes only non-highlighted components  
Components for RMM Final concentration Stock preparation 
DMEM:F12 (Ham) 
(Life Technologies, UK) 
- no preparation required 
Albumin serum, Human (HAS) 
(Baxter Healthcare Ltd., UK) 
0.03% stock: 20% (w/v), no preparation required 
Human Apo-Transferrin  
(Sigma, UK) 
100μg/ml  50mg/ml diluted in DMEM:F12with 1mM 
HEPES pH 7.4 
Insulin, Human recombinant 
(Sigma, UK) 
5μg/ml  stock: 10mg/ml, no preparation required 
L-Glutamine  (Sigma, UK) 2mM stock: 200mM, no preparation required 
Progesterone  
(Sigma, UK) 
60ng/ml  1st step: 1mg (stock) dissolved in 100μl 
molecular biology grade ethanol 
2nd step: dilute the mix in DMEM:F12 to final 
concentration 20mg/ml 
Putrescine Dihydrochloride, 
Human  (Sigma, UK) 
16.2μg/ml stock: 8.1mg/ml dissolved in tissue culture 
grade water 
Sodium Selenite  
(Sigma, UK) 
 40ng/ml stock: 20μg/ml dissolved in DMEM:F12 
4-hydroxy-tamoxifen   
(Sigma, UK) 
100nM stock: 1mM dissolved in molecular biology 
grade ethanol 
Human EGF  
(PeproTech EC Ltd, Germany) 
20ng/ml  stock: 10μg/ml dissolved in DMEM:F12 with 
1mM HEPES and 
0.03% human albumin serum 
Human bFGF   
(PeproTech EC Ltd, Germany) 
10ng/ml stock: 10μg/ml dissolved in DMEM:F12 with 
1mM HEPES and 
0.03% human albumin serum 
 
Reduced modified media plus (RMM+) was composed of DMEM:F12 (Gibco, UK) supplemented 
with 4-OHT (100nM; Sigma, UK) and all the components written in Table 3.4. The media was 




weeks. Differentiation media RMM- was prepared in the same manner but this media was 
depleted of the growth factors and 4-OHT.  
 
3.3.2.2.1. Preparation of differentiation inducing agents 
Two reagents were used in combination with RMM- medium to induce differentiation:  
1) DAPT (LY-374973 N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) at 
stock concentration 10mM in DMSO. 
2) ATRA (All trans retinoic acid) stock concentration 10mM in DMSO.  
Both reagents were aliquoted and stored at -80°C. 
DAPT is an inhibitor of the γ-secretase complex (Dovey et al., 2001). ITacts as an inhibitor of 
Notch (Sastre et al., 2001), a γ-secretase substrate. it has been found to promote neuronal 
differentiation from human pluripotent stem cells (Androutsellis-Theotokis et al., 2006; 
Chambers et al., 2012; Dimos et al., 2008). Another study demonstrated that DAPT-mediated 
inhibition of the Notch response resulted in an enhanced neuronal differentiation (Crawford & 
Roelink, 2007). ATRA is the oxidised form of Vitamin A and is a signalling molecule involved in 
pathways that control differentiation and proliferation (Duester, 2008; Ertesvag, Naderi, & 
Blomhoff, 2009). ATRA has been widely used for various differentiation protocols including 
neural differentiation from human embryonic stem cells (Dhara & Stice, 2008; Sasai, 2002; 
Takahashi, Palmer, & Gage, 1999; Wichterle, Lieberam, Porter, & Jessell, 2002).  
 
3.3.2.2.2. Maintenance and passaging of SPC-04 cells 
All flasks and plates used for SPC-04 cell culture and experiments were Nunclon™ Δ Delta 
(Nunc) surface treated to ensure optimal conditions for cell attachment and growth. Cells were 
grown until 80% confluency. All reagents were pre-warmed to 37 °C.  
Firstly, tissue culture flasks were coated with DMEM containing 20µg/ml mouse laminin, for at 
least 3h.  Just prior to plating cells, the excess laminin was removed and the flask was washed 
twice with DMEM:F12 to remove residual laminin. DMEM:F12 was replaced with RMM+ and 
the flask was returned to the incubator. Next, culture flask to be passaged was first rinsed with 




immediate addition of TrypZean (Lonza, UK) and returned to the incubator for approximately 2 
minutes till the cells started detaching. Then Trit (1% Human Albumin Serum, 0.55% soyabean 
trypsin inhibitor, and 0.025U/ml bensonase solution (Merck, UK) in DMEM:F12) was added to 
the flask to inactive the enzyme. The cell suspension was transferred using a sterile pipette to 
a 15ml Falcon tube, followed by centrifugation at 900RPM for 5 minutes. The pellet was then 
resuspended in 1-2ml of RMM+ medium, the number of cells counted and the cell suspension 
was used for further plating or freezing. For freezing, a 20% DMSO solution (diluted in RMM+) 
was prepared and 0.5ml of it was added to 0.5ml of cell suspension to give a final 
concentration of 10% DMSO. Cells at a final concentration of at least 2 x 106 cells/ml were 
frozen at 1°C/min in a freezing container (Nalgene) filled with isopropanol and stored at -80°C 
overnight and transferred to a liquid nitrogen the day after. Cells for further propagation were 
plated in freshly coated and prepared flasks at a density of 20000cells/cm2.  
 
3.3.2.2.3. Cell counting 
After trypsinisation, cells were counted and their viability was assessed using NucleoCounter 
NC-100 (Chemometec, Denmark). For total cell number, an equal amount of cell suspension, 
Reagent A – lysis buffer (Chemometec, Denmark) and Reagent B - stabilising buffer 
(Chemometec, Denmark) were mixed together in a final volume of at least 120µl. The mixture 
was loaded into a NucleoCassette and placed into the NucleoCounter to obtain the cell 
concentration. NucleoCassette contains propidium iodine (PI), an integrated fluorescent dye, 
which binds to the DNA released from the trypsinised cells. The fluorescence is then detected 
by the camera in the NucleoCounter and correlated into a cell count. Presented concentration 
(cells/ml) was multiplied by the dilution factor to obtain total number of cells.   
 
3.3.2.2.4. Differentiation of SPC-04 cells 
To induce differentiation, cells were seeded in a 6-well laminin- coated Nunc 
(ThermoScientific, UK) plate at a density of 12000cells/cm2 and incubated for 2 days. After 
reaching around 80% confluence, RMM+ medium was removed, cells were washed twice with 
pre-warmed RMM- to remove any residual growth factors, and replaced with RMM- containing 
10μM DAPT and 100nM ATRA. Cells were incubated for 48h. This stage is referred to as 




cells were observed daily, with medium change every 2 days till the end of the experiment. 
Cells were differentiated for 7 and 14 days, which refers to 7 days or 14 days after the pre-
differentiation stage (after DAPT/ATRA were removed and replaced with RMM- medium).  
 
3.3.2.3. Lentiviral infection of SPC-04 cells 
One day before transduction, SPC-04 cells were seeded in 6-well laminin-coated Nunc plates at 
a density of 20000 cells/cm2. The following day, growth media was removed and replaced with 
RMM- containing 10μM DAPT and 100nM ATRA and a concentration of 3.5x105 TU/ml of 
lentivirus per well. The pre-differentiation stage was chosen for lentiviral infection based on 
previous observations showing higher cell survival compared to viral transduction at 
undifferentiated stage. Cells containing lentiviral particles were incubated for 48h at 37°C, 5% 
CO2. Transduction efficiency was assessed using a fluorescent microsope (Leica DMIL) equipped 
by a Leica camera DFC420C (x10 objective). The cells were lysed for RNA extractions using the 
QIAgen RNeasy Mini Kit (QIAGEN, UK), followed by cDNA synthesis (as described in 3.3.1.12 
and 3.3.1.13 respectively). 
 
3.3.2.4. Quantification of MYT1L levels in SPC-04 cells 
qPCR reaction was performed as described in section 3.3.1.14. RPL18 (60S Ribosomal Protein 
L18) was used as a housekeeping gene for normalisation of SPC-04 cDNA and ΔCt values (ΔCt = 
CtTARGET – CtRPL18) were produced for analysis. RPL18 expression was found to be relatively 
stable across different stages of neural stem cell differentiation. Sequences of the primers 
used can be found in Table 3.5. 
 
Table 3.5. Primer sequences used for qPCR amplification of MYT1L and the control gene RPL18 in SPC-
04 cells. 
Primer Sequence 
hRPL18 Forward  5’ – GAGAGGTGTACCGGCATTTC – 3’ 
hRPL18 Reverse 5’ – CTCTGGCACGCTCGAACT – 3’ 
hMYT1L Forward 5’ – TGGAGAGCAACCTGAAGACC – 3’ 





ΔCt values for each were calculated using Ct values from one independent experiment. ΔCt 
value for each condition was subtracted from the ΔCt of the control condition (i.e. cells 
transduced with non-silencing shRNA) producing ∆∆Ct. The changes in mRNA expression 
relative to control were then presented as a relative fold expression, using the formula 2-∆∆Ct.  
All qPCR data were analysed by a one-way ANOVA with MYT1L dosage and differentiation 
stage as factors. All statistical analyses were performed using IBM SPSS Statistics 20 software 
(IBM Corp., USA). A p-value < 0.05 was considered statistically significant. The data was 
expressed as mean ± Standard Error of the Mean (S.E.M.). 
3.3.3. RNA labelling and microarray hybridisation 
The RNA labelling, hybridisation, washing and scanning steps were outsourced and carried out 
by High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics, 
Oxford. RNA integrity was analysed using Agilent RNA 6000 Nano Kit (Agilent Technologies, Inc; 
Germany) on an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc). Total RNA was amplified 
and labeled (biotinylation) using the TargetAmp™-Nano Labeling Kit for Illumina Expression 
BeadChip (Cambio, UK) according to the manufacturer’s instruction. A whole genome gene 
expression profiling was run on Illumina’s HumanHT-12 v4.0 Expression BeadChip, which 
contains over 47000 probes. Samples were randomly allocated across the chip. The hybridised 
and washed chips were scanned using an Illumina iScan Scanner. 
 
3.3.4. Statistical and bioinformatic analyses of microarray data 
Experiments were performed in triplicates for cells differentiated for 14 days, and quadruplets 
for cells differentiated for 7 days. RNA from each condition was included in the microarray. 
However, post microarray analyses revealed, that one sample from 14days of differentiation 
infected with shRNA MYT1L, did not meet the required criteria due to low RNA quality, and 
was excluded from further analysis. Thus, results of differential gene expression at 14 days of 
differentiation could not be analysed separately (experimental group consisted only of 2 
independent samples) and they were combined with results from day 7 of differentiation. Raw 
data was extracted using GenomeStudio Data Analysis Software, and was further processed by 
Dr. Sylvane Desrivières in R statistical environment (http://www.r-project.org) using a Lumi 




normalisation. Probes with the unreliable expression measurements were flagged and 
removed from the analysis. Next, based on the coefficient of variation, genes whose 
expression was constant across all the experiments (i.e., was invariant) were removed from 
the dataset. Of the 47,230 probes that feature on the Illumina platform, data from 9,673 
probes were retained for the further analysis. Using the Benjamini and Hochberg FDR method, 
the p-values were corrected for multiple testing, by generating q-values (Benjamini & Yekutieli, 
2001). All differentially expressed transcripts between Myt1l knock-down and non-silencing 
controls with a false discovery rate (FDR) q-values <0.05 were selected for bioinformatic 
analyses. Transcripts from a total of 170 distinct genes were selected based on the above 
criteria.  
The functional annotation clustering tool, part of the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov/), was used to identify 
enriched biological themes and functional-related gene groups in gene lists generated from 
microarray data. DAVID systematically maps a large number of genes in a given list to the 
associated biological annotation terms (i.e. GO terms). Probe IDs from the Illumina HumanHT-
12 v4.0 Expression BeadChip array corresponding to each differentially expressed gene were 
submitted to DAVID, whilst all known transcripts probed by the closest array to this one 
(HumanHT-12_V3_0_R2_11283641_A) were used as background for analyses. The DAVID 
defined default annotation databases (i.e., GO terms) were interrogated using the default 
medium stringency setting and the threshold for the significant enrichment was represented 
by an enrichment score (es) ≥1.3 (p<0.05) (D. W. Huang, Sherman, & Lempicki, 2008). 
Additional analyses were performed using Ingenuity® systems software 
(http://www.ingenuity.com/) to  identify relationships, mechanisms, functions, and pathways 
significantly enriched (p<0.05) in the dataset. To test if our set of differentially expressed (DE) 
genes was  enriched for any known susceptibility genes for autism or schizophrenia, the 
Simons Foundation Autism Research Initiative (SFARI) (https://sfari.org)  and the Schizophrenia 
Gene Resource (SZ, http://www.szgene.org) gene lists were downloaded and interrogated 
using the phyper function in R. SFARI is a comprehensive, up-to-date database for all known 
human genes associated with autism, which currently contains 528 genes. The SZgene 
database contained 287 genes implicated in schizophrenia by association studies. For both 
enrichment analyses, the number of overlapping genes was calculated between DE genes and 
each disease related gene list. These values were then put into the phyper function in R, along 
with the number of DE genes, number of disease related genes, and number of probe sets 





3.4.1. Generation of lentiviruses enabling MYT1L overexpression 
Attempts were made to try to identify potential interacting partners for Myt1l by 
overexpressing this gene, therefore allowing us to look at protein-protein interactions and help 
to determine Myt1l functionality. The human MYT1L ORF was initially cloned into the 
pLenti7.3/V5-TOPO® vector (Life Technologies, UK) to enable exogenous expression in cultured 
cell lines. Firstly, the MYT1L ORF was successfully amplified by high-fidelity PCR, which 
revealed a specific band of the expected size (~3.55kb) (Figure 3.5). Reactions were carried out 
in two independent experiments and results were visualised on the gel. Samples with the 
clearest band (second and third sample on the gel corresponding to V5-MYT1L and Native 
MYT1L respectively) were chosen for ligation into the expression vector, as they showed only 
single and specific band.   
 
Figure 3.5. Agarose gel electrophoresis to determine amplification of MYT1L ORF containing both 
native and V5-tagged primers. PCR reaction was carried out in duplicates. The first lane, labelled L is 
the 1kb DNA ladder used as a marker, samples 1 and 2 belong to V5-MYT1L and sample 3 and 4 
corresponds to Native-MYT1L. Samples 2 and 3  showed no unspecific binding or primer dimers, and 
were chosen for ligation into expression vector.    
 
The amplified MYT1L insert was successfully ligated into the expression vector in the correct 
orientation, which was confirmed by HindIII enzyme digest (Figure 3.6). As mentioned in 
section 3.3.1.9, for sense insertion we expected the following bands sizes: 312bp, 481 bp, 556 
bp, 584bp, 2353bp, 2658bp and 3747bp. The bands for V5 (lanes 6 nad 7) and Native (lanes 4 
and 5) MYT1L amplicons are of correct sizes for the sense insertion, therefore confirming that 
the insert was successfully ligated into the expression vector in the correct orientation.  








Figure 3.6. Agarose gel electrophoresis of pLenti vector ligated with MYT1L. Lane 2 and 3 represent 
empty vector, lanes 4 and 5 correspond to pLenti ligated with Native MYT1L, lanes 6 and 7 exemplify 
vector ligated with V5-MYT1L and lanes 1 and 7 are the 1kb DNA ladder used as a marker.The four 
smallest bands were common for all samples and pertained to sizes: 312bp, 481bp, 556bp and 584bp. 
The top bands were specific for either empty vector (2658 bp and 3344bp) or vector with MYT1L insert 
(2353bp, 2658bp and 2747bp).    
 
The MYT1L insert contained within the pLenti vector was then sequenced (data not shown); 
thereby confirming the absence of any de novo mutations that might disrupt MYT1L protein 
sequence; and verifying that both the V5-tagged and the MYT1L native inserts were in the 
correct frame.  
The next step involved production of viruses containing MYT1L in either native or V5-tagged 
form or empty pLenti vector to enable subsequent confirmation of exogenous MYT1L protein 
expression. For this purpose 293FT cells (supplied with pLenti7.3/V5-TOPO® kit) were 
transfected with either V5-MYT1L or Native-MYT1L containing pLenti or empty pLenti vector. 
The transfection efficiencies of these cell lines were checked indirectly using a GFP tag 
embedded in the vector, which after numerous experiments indicated an estimated efficiency 





Figure 3.7. The fluorescent microscope images illustrating the GFP expression in 293FT cells obtained 
after transfection with pLenti empty vector (A), pLenti + Native-MYT1L (B), pLenti plus V5-MYT1L (C), 
positive control (d) and non infected cells.  All photographs were taken using objective X10. 
 
We have transfected a vector supplied with the kit (pLenti7.3/V5-GW/lacZ) expressing β-
galactosidase to use as a positive control. The positive control yielded a very similar amount of 
green fluorescent cells, as all the other samples, suggesting there were no problems with the 









single green cells. Having optimised the protocol several times, by increasing viral particles, 
longer incubation times with particles, there was no improvement in infection efficiency. As 
we did not measure viral titers for those cells, one possibility is that the titer was inefficient. 
Other possible explanations will be mentioned in the discussion.   
Since, there was a possibility that virus was successfully transduced but GFP-tag was not 
visualised, cells were lysed and total RNA extracted and used for qPCR to check mRNA levels of 
MYT1L. Firstly, we checked for genomic plasmid contaminations of our samples, which could 
mean that any apparent induction of MYT1L mRNA expression observed may have been 
caused by amplification of plasmid DNA contaminants in total RNA samples, as opposed to the 
corresponding cDNA. To achieve this, a reverse transcription reaction was set-up, where the 
reverse transcriptase enzyme (Super Script III,Invotrogen, UK)  was not included, preventing 
cDNA synthesis. Thus, any signal obtained from the amplification reaction would reflect only 
plasmid DNA contamination. Initial data obtained from reaction with reverse transcriptase 
indicate induction of MYT1L (Table 3.6). Considering that lower ΔCt values indicate higher 
levels of expression, these data indicated a 317-fold change for Native and 595-fold induction 
for V5 MYT1L. However, when control reaction (no reverse transcriptase) was performed we 
also observed low ΔCt values, indicating that some contaminating plasmid was present in the 
cDNA samples. When we accounted for the plasmid contamination, we still observed an 
increase in MYT1L expression (last column of Table 3.6). However, the induction observed was 
very modest, with only 10-fold change for Native MYT1L and 2.5-fold change for V5. Also, the 
changes could be at least partially attributed to the endogenous expression of MYT1L.    
Table 3.6. ∆ Ct values from reactions with and without reverse transcriptase to determine 
amplification of plasmid DNA contaminants in total RNA samples. By excluding reverse transcriptase 
(SuperScript III) cDNA synthesis is prevented, and all amplification would be due to plasmid 
contamination with genomic DNA. Data generated this way shows very similar Ct values to ones 
obtained from cDNA synthesis.  






Empty vector pLenti 7.12 -4.19 11.31 
V5  -1.19 -11.20 10.01 
Native -2.10 -10.06 7.96 
 
Although, 293T cells are widely used for transduction experiments, we wanted to verify their 




different construct and obtained high levels of exogenous expression, therefore eliminating 
the possibility of a ‘faulty’ cell line.  
 This again suggests that only endogenous MYT1L was present in all conditions and we failed to 
overexpress this gene. Despite several protocol optimisation techniques, such as changing 
plasmid DNA:Lipofectamine 2000 ratios or increasing the total amount of the 
DNA:Lipofectamine 2000 complex or leaving viral supernatants with the cells for an additional 
24h, the above results persisted, indicating the lack of lentiviral stock containing MYT1L-ORF. 
Considering the lack of success with pLenti and the ViraPower Expression System, we decided 
to use another commercially available method to assess if the construct itself was problematic.  
We cloned the MYT1L ORF into the pFLAG-CMV™-4 vector (Sigma, UK) expressing a FLAG tag, 
which acted in a similar way to the V5-tag, by enabling immunoprecipitation of MYT1L protein 
using an anti-FLAG antibody, however, similarly to pLenti vector, we were not successful at 
producing transduced cells, i.e. we observed no green cells present under microscope, and 
qPCR failed to reveal any changes on mRNA level. As a last resort, we tried In-Fusion® HD 
Cloning Plus Kit (Clonetech, UK), which allows cloning of any PCR fragment into any linearised 
vector. We designed primers as per the manufacurer’s manual and the expression vector of 
choice was Lego- iG2 (Lentiviral Gene Ontology (LeGO) vector). This vector was previously used 
and tested, producing satisfactory results by another laboratory member. After numerous 
experiments, MYT1L ORF, containing primers for V5 or native form and appropriate restriction 
site (BamHI in our case), was successfully ligated with Lego-iG2 using the In-Fusion Kit. 
Unfortunately, subsequent bacterial transformations did not produce any colonies, thus 
prohibiting cell transfection. The above experiments indicate that although the transfection of 
MYT1L ORF-containing pLenti vectors into 293FT cells was successful, we were unable to 
detect GFP-positive cells after transduction and mRNA analysis showed plasmid contamination 
and very modest induction of MYT1L. 
 
3.4.2. Use of SPC-04 cells to validate MYT1L knock-down  
The virus containing shRNA against MYT1L was kindly provided by Lourdes Martinez-Medina 
(L.M.M). A 3.50 x105TU/ml concentrated stock of lentiviruses containing MYT1L or non-
silencing shRNA was used by L.M.M, which resulted in a 60% reduction of MYT1L in SPC-04 
cells. Our experiments were designed to test possible gene expression changes in 




The human neural stem cell line SPC-04 was used as a neural development in vitro model. The 
cells were transduced with viruses at the pre-differentiation stage (viruses added together 
with ATRA and DAPT). This allowed us to examine any potential effects of MYT1L knock-down 
on stem cells differentiation patterns. We infected SPC-04 cells with virus expressing either 
non-silencing shRNA or shRNA targeting MYT1L.  Firstly, we observed non-infected SPC-04 cell 
morphology to see if visible phenotypic changes are present upon introduction of MYT1L 
silencing virus. We know that SPC-04 cells can readily differentiate into neurons (Cocks et al., 
2013), so any changes in the morphology would have been attributed to the effects of 
silencing MYT1L. Cells showed signs of axonal growth 7 days after differentiation, with more 
elongated and pronounced morphology being observed 14 days after differentiation. As a 
control, cells infected with non-silencing shRNA were used, as well as non-infected cells. Cells 
were collected at 7 days and 14 days of differentiation (after removal of the virus and 
DAPT/ATRA from medium). Prior to lysate collection for RNA extraction, pictures were taken to 
assess morphological features of cells infected with the lentiviruses (Figure 3.8). The results 
show that the morphology of the cells in all experimental conditions changed with 
differentiation, with cell bodies presenting more elongated forms at day seven (Figure 3.8B) 
and axonal growth is even more prolonged at day 14 (Figure 3.8E), however there was no 
visible effects of lentiviral infection on the cells (Figure 3.8C-D and Figure 3.8F-G) confirming 
previous results from the lab, that MYT1L has no evident effect on phenotypic changes of 





Figure 3.8. Figure representing the human neural stem/progenitor cell line SPC-04 morphology and 
viral infection efficiency during differentiation and transduction with lentiviral pGIPZ shRNA MYT1L 
and non-silencing. The figures represent cells without the infection (Figure 3.8 A, B and E), cells 
transduced with non-silencing shRNA (Figure 3.4 C and F) and infection with MYT1L shRNA (Figure 3.8 D 
and G) at two different time points (7 and 14 days. First column shows phase contrast pictures of 
uninfected cells, second column represents fluorescent images of GFP-expressing cells treated with non-
silencing shRNA and last column represents fluorescent images of GFP-expressing cells with shRNA 
targeting MYT1L. Bar represents 200 µm. 
 
One-way ANOVA indicated that MYT1L was significantly reduced by 90% at day 7 of 
differentiation (F1,6=420.32, p=8.76E-07) and by 75% in SPC-04 differentiated for 14 days (F1,4= 
55.69, p=0.002) (Figure 3.9). On the other hand, we observed no significant difference in 
MYT1L expression between day 7 and day 14 of differentiation (F1,8 = 0.018, p = 0.895). 
Inspection of the dissociation curves for MYT1L expression and RPL18 as a housekeeping gene 
in qPCR experiments revealed a single amplicon for each measurement, confirming primers 







































Figure 3.9. Figure showing reduced MYT1L mRNA levels in SPC-04 cells infected with MYT1L silencing 
shRNA compared to cells infected with non-silencing shRNA. Quantification of mRNA levels was 
performed by real-time qPCR, of at least 3 independent experiments, error bars represent +/- 1SD from 
the mean. MYT1L was significantly knocked down in cells at either 7 days or 14 days post differentiation, 
* - p=0.002, ** - p=8.76E-07 
 
  
Figure 3.10. Confirmation of RPL18 (A) and MYT1L (B) qPCR primer specificity. Dissociation curve from 
qPCR analysis of RPL18 and MYT1L indicated a single, distinctive peak (i.e. one PCR product), indicating 
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3.4.3. MYT1L knock-down alters expression of other genes during SPC-04 
differentiation. 
After verifying MYT1L knock-down efficiency during stem cells differentiation, microarray 
analyses were performed in order to identify potential downstream transcriptional targets of 
MYT1L. This allowed us to compare gene expression profiles obtained from SPC-04 cells 
infected with MYT1L shRNA differentiated for 7 and 14 days to those of non-silencing shRNA, 
which acted as controls.  
A total of 170 illumina probes were differentially expressed (FDR < 0.05) between MYT1L 
silencing and non-silencing cells, which corresponded to transcripts from 141 distinct genes 
(105 downregulated in MYT1L knock-down cells, 36 up-regulated). These finding can suggest 
that MYT1L can regulate the expression of those genes. The list of the top 30 differentially 
expressed (DE) genes is presented below (Table 3.7), and a full list of DE genes is attached as 
an appendix (Table A1). Unfortunately, the expression of MYT1L did not reach the detection 
threshold at any differentiation time point or condition; hence its downregulation could not be 
corroborated by microarray. This could be due to the fact that MYT1L expression, although 
detectable by qPCR, in differentiating stem cells, is generally low, and therefore could have 





Table 3.7. List of top 30 differentially expressed (FDR < 0.05) genes between MYT1L knock-down and 
non-silencing shRNA controls in SPC-04 cells. Relevant illumina probe, gene symbol and a name, log 
fold change (FC) for cells differentiated for 7 and 14 days, as well as uncorrected and FDR-corrected p-
values are listed for each gene. Genes are sorted according to p- value; lowest to highest. 
 
 





520474 ODZ4  odz, odd Oz/ten-m homolog 4 (Drosophila) (ODZ4), 
mRNA.
-1.65 -1.97 8.27E-07 0.003904
3450138 CTSC  cathepsin C (CTSC), transcript variant 1, mRNA. 1.66 0.80 8.90E-07 0.003904
5490019 GPX3  glutathione peroxidase 3 (plasma) (GPX3), mRNA. -0.75 -1.07 1.38E-06 0.003904
5270367 CTSC  cathepsin C (CTSC), transcript variant 1, mRNA. 1.48 0.49 2.01E-06 0.003904
4220068 CD70  CD70 molecule (CD70), mRNA. 1.36 1.11 2.33E-06 0.003904
4890181 RAP1GAP  RAP1 GTPase activating protein (RAP1GAP), 
mRNA.
-1.40 -2.24 2.42E-06 0.003904
4290403 CMTM7
 CKLF-like MARVEL transmembrane domain 
containing 7 (CMTM7), transcript variant 2, mRNA. 0.86 0.80 4.63E-06 0.006394
4050025 0  mRNA; cDNA DKFZp686J23256 (from clone 
DKFZp686J23256)
-2.03 -1.67 7.58E-06 0.008798
6620008 KAL1  Kallmann syndrome 1 sequence (KAL1), mRNA. -2.17 -1.94 8.19E-06 0.008798
3930026 RASL10A  RAS-like, family 10, member A (RASL10A), 
transcript variant 2, mRNA.
-1.02 -2.04 9.52E-06 0.00921
6250019 SHC1
 SHC (Src homology 2 domain containing) 
transforming protein 1 (SHC1), transcript variant 2, 
mRNA.
1.11 1.25 1.35E-05 0.01186
670386 ID1
 inhibitor of DNA binding 1, dominant negative 
helix-loop-helix protein (ID1), transcript variant 2, 
mRNA.
1.27 1.67 1.82E-05 0.012904
2100446 BCAN  brevican (BCAN), transcript variant 1, mRNA. -3.19 -2.53 1.83E-05 0.012904
3370162 SPON1  spondin 1, extracellular matrix protein (SPON1), 
mRNA.
-0.39 -1.43 1.96E-05 0.012904
7050575 PPAP2B  phosphatidic acid phosphatase type 2B (PPAP2B), 
transcript variant 1, mRNA.
-1.52 -1.07 2.00E-05 0.012904
2570564 HLA-DRA  major histocompatibility complex, class II, DR 
alpha (HLA-DRA), mRNA.
-0.58 -1.82 2.37E-05 0.014347
6110152 C21orf62  chromosome 21 open reading frame 62 (C21orf62), 
mRNA.
-1.07 -1.51 2.52E-05 0.014357
110333 LOC440585 PREDICTED:  hypothetical LOC440585, transcript 
variant 3 (LOC440585), mRNA.
-1.76 -1.67 2.93E-05 0.015223
4060433 MAOB  monoamine oxidase B (MAOB), nuclear gene 
encoding mitochondrial protein, mRNA.
-1.74 -2.05 3.17E-05 0.015223
3310307 C21orf63  chromosome 21 open reading frame 63 (C21orf63), 
mRNA.
-1.45 -1.71 3.27E-05 0.015223
3780092 TNFRSF21  tumor necrosis factor receptor superfamily, 
member 21 (TNFRSF21), mRNA.
-1.33 -0.70 3.30E-05 0.015223
1410403 LRRN2  leucine rich repeat neuronal 2 (LRRN2), transcript 
variant 2, mRNA.
-0.41 -0.92 4.35E-05 0.019105
4890021 36403  septin 3 (SEPT3), transcript variant B, mRNA. -1.72 -1.51 5.23E-05 0.019215
7050333 HEPACAM  hepatocyte cell adhesion molecule (HEPACAM), 
mRNA.
-0.68 -1.56 5.28E-05 0.019215
2600465 SH3GL2  SH3-domain GRB2-like 2 (SH3GL2), mRNA. -0.97 -1.08 5.38E-05 0.019215
7000577 GYPC  glycophorin C (Gerbich blood group) (GYPC), 
transcript variant 2, mRNA.
0.78 1.39 5.60E-05 0.019215
1690403 PMP2  peripheral myelin protein 2 (PMP2), mRNA. -0.36 -1.40 5.93E-05 0.019215
6620538 UBL3  ubiquitin-like 3 (UBL3), mRNA. -0.96 -1.07 6.04E-05 0.019215
2760239 RASGRP1  RAS guanyl releasing protein 1 (calcium and DAG-
regulated) (RASGRP1), mRNA.
-0.95 -1.10 6.05E-05 0.019215
6040451 SLC47A2  solute carrier family 47, member 2 (SLC47A2), 
transcript variant 1, mRNA.




3.4.3.1.  Functional annotation clustering DAVID of differentially expressed genes 
To determine whether this set of differentially expressed genes was enriched for any 
functional terms, the functional annotation-clustering tool, part of the DAVID (v6.7) 
bioinformatic resource (D. W. Huang et al., 2008) was employed. DAVID is a web-based 
bioinformatics application that identifies enriched biology associated with large gene lists 
derived from high-throughput genomic experiments, such as microarray. Upregulated and 
down-regulated genes were analysed separately, as this provides an insight into a more 
specific functional clustering based on the similarity of gene expression pattern. Of the 170 
Illumina probes submitted to DAVID, 142 (36 up-regulated and 105 down-regulated) were 
recognised as probing distinct genes in the human genome. A total of 42 functional gene 
clusters (16 for up-regulated genes, and 26 for down-regulated genes) were generated from 
these sets of DE genes. One cluster from up-regulated gene list achieved an enrichment score 
(es) ≥ 1.3 (p < 0.05). The enrichment score provides an indication of the biological significance 
of the gene groups being analysed. Briefly, the top scoring cluster (ES= 2.04) consisted of genes 
enriched for vesicle-mediated transport, membrane organisation and homeostasis (Figure 
3.11). 
DAVID functional-annotation clustering analysis of 105 down-regulated genes produced 2 
significantly enriched (es > 1.3) functional clusters. To better understand the details of 
enriched annotation terms associated with this gene list, the functional annotation chart 
option was invoked. The enriched term and its associated statistical values is listed below 
(Table 3.8). Briefly, the only significant GO-term (GO:0007155; Bonferroni corrected p= 0.0453) 





Figure 3.11. 2-D view modules from DAVID illustrating functional gene cluster significantly enriched 
(es=1.97) within the list of up-regulated genes differentially expressed between SPC04 cells infected 
with silencing MYT1L and non-silencing controls. The cluster pertain to transport, membrane 
organisation, endocytosis homeostasis.  
 
Table 3.8. The most enriched annotation term from DAVID chart performed on genes that were 
downregulated in MYT1L knock-down SPC-04 cells. The enrichment p-value and gene count and 
percentages of total number of genes submitted for analysis are listed along the gene names.  
GO-Term Name Count 




value Genes Bonferroni 
GO:0007155 cell adhesion 14 13.33 
4.9E-
05 
LRRN2, NELL2, ASTN1, CD99, 
BCAN, NLGN3, MEGF10, 
VCAM1, HEPACAM, HEPN1, 





3.4.4. Ingenuity pathway analysis (IPA).  
Further analyses were then performed to determine whether the set of DE expressed genes 
obtained from microarray data was enriched in any biological pathways or diseases as defined 
by IPA (Ingenuity System Inc, USA). The 'Core Analysis' function included in IPA was used to 
interpret the data in the context of biological processes, pathways and diseases. The genes 
that showed significant DE at FDR corrected p-value <0.05 were used for this analysis. IPA 




loci were mapped. Here, for the downregulated set of DE genes, the top associated biological 
function highlighted by IPA was nervous system development and function, as 9 molecules in 
this network had an altered expression in MYT1L knock-down stem cells (Table 3.9). The top 
associated diseases and disorders were hereditary disorders and neurological diseases (Rett 
syndrome, p=5.36E-06). The most common network for downregulated genes was cellular 
movement, cardiovascular system development and function, cell to cell signalling and 
interaction (Figure 3.12). These results are in line with what we found using DAVID, and they 
provided additional information about specific diseases and pathways that were associated 
with DE expressed genes from MYT1L knock-down dataset. For the upregulated set of genes, 
the most common network highlighted by IPA was cell signalling, small molecule biochemistry 
and cellular movement (Figure 3.13).  
 
Figure 3.12. Top network in the downregualted set of DE genes in MYT1L knock-down stem cells. 
Cellular movement, cardiovascular system development and function, cell to cell signalling and 
interaction. Green indicated genes which were significantly down-regulated in the MYT1L knock-down 





Figure 3.13. Top network in the upregulated set of DE genes in MYT1L knock-down stem cells. Cellular 
signalling, small biochemistry and cellular movement. Red indicated genes which were significantly up-






Table 3.9. Ingenuity analyses showing top 20 diseases, disorders, and molecular and cellular functions 
with significant (p < 0.05) enrichment of genes downgulated in MYT1L knock-down SPC-04 cells. The 
corresponding p-value and relevant gene symbols are also included. 
 
 
3.4.5. Enrichment for SFARI and SZ genes 
To further elucidate the potential relevance of deregulated genes for neurodevelopmental 
disorders, DE genes were analysed for enrichment of genes that have previously been 
associated with ASD or schizophrenia (Table 3.10). We have found a small number of 
overlapping genes for both disorders; however, we did not see significant enrichment for 
either set of disease related genes.  
  
Category Function Function Annotation p-value Molecules
Nervous System Development and 
Function
development development of central 
nervous system
9.50E-04 GPR56, PHGDH, PROX1, 
PTPRZ1, SH3GL2
Hereditary Disorder Rett syndrome Rett Syndrome 5.36E-03 ATP1B1, BEX4, GPR56, 
NELL2
Neurological Disease Rett syndrome Rett Syndrome 5.36E-03 ATP1B1, BEX4, GPR56, 
NELL2
Nervous System Development and 
Function
development development of dorsal 
spinal cord
6.56E-03 PROX1
Nervous System Development and 
Function
maturation maturation of neuronal 
progenitor cells
6.56E-03 WNT7A
Nervous System Development and 
Function
quantity quantity of neurosphere 
cells
6.56E-03 WNT7A
Amino Acid Metabolism transport transport of glycine 6.56E-03 SLC6A9
Cardiovascular System Development 
and Function
chemotaxis chemotaxis of lymphatic 
endothelial cells
6.56E-03 PROX1
Cardiovascular System Development 
and Function
vasodilation vasodilation of kidney 6.56E-03 AGT
Cell Cycle cell  cycle progression cell  cycle progression of 
adipoblasts
6.56E-03 AGT
Cell-To-Cell  Signaling and Interaction immune response immune response of 
tumor cell  l ines
6.56E-03 AQP4
Cell-To-Cell  Signaling and Interaction interaction interaction of dendritic 
cells
6.56E-03 VCAM1
Cell-To-Cell  Signaling and Interaction response response of brain 
cancer cell  l ines
6.56E-03 AQP4
Cellular Development maturation maturation of neuronal 
progenitor cells
6.56E-03 WNT7A
Cellular Development quantity quantity of neurosphere 
cells
6.56E-03 WNT7A




chemotaxis of lymphatic 
endothelial cells 6.56E-03 PROX1
Connective Tissue Development and 
Function
cell  cycle progression cell  cycle progression of 
adipoblasts
6.56E-03 AGT
Embryonic Development formation formation of lens 
placode
6.56E-03 PROX1






Table 3.10. Enrichment of known ASD and SZ genes in the DE data set. The number of overlapping 
genes between the SFARI or SZ datasets and the DE genes lists, and the p values.   
SFARI (no. of overlapping genes) SFARI p-
value 
SZ (no. of overlapping genes) SZ p-
value 
6 (ASS1, NFIA, SH3KPB1, NLGN3, 
PLCD1, HEPACAM) 




3.5. Discussion, study limitations and future direction 
The use of human neural progenitors is an important asset for uncovering the genomic 
patterns of expression in the normal neuronal differentiation and for the study of 
neurodevelopmental or neuropsychiatric disorders. 
Previous studies suggested that MYT1L plays a key role in neuronal development (Jiang et al., 
1996; J. G. Kim et al., 1997; Weiner & Chun, 1997). To explore the molecular effect that MYT1L 
silencing may have at the level of the transcriptome in differentiating neuronal progenitor 
cells, a gene expression project was carried out to look at genome-wide expression profiles in 
the SPC-04 cells infected with shRNA against MYT1L.   
We identified 170 differentially expressed transcripts, suggesting that signalling via MYT1L 
protein is involved in the regulation of their transcription rates. The majority of the DE genes 
were downregulated in the knock-down sample compared to control, suggesting that their 
expression is regulated by MYT1L under vehicle conditions and they can be potential 
downstream targets of MYT1L. The 3 most significant hits were: ODZ4, RAP1GAP and GPX3. 
ODZ4 encodes a human homolog of the Drosophila pair-rule gene ten-m (odz) and it is highly 
expressed in CNS. This gene has been associated with bipolar disorder (Psychiatric, 2011). It 
has been suggested that it plays a critical role in the myelination of small-diameter axons in the 
CNS and acts as a regulator of oligodendrocyte differentiation (Suzuki et al., 2012). RAP1GAP is 
a Ras-like guanine-nucleotide-binding protein (GNBP) that is involved in a variety of signal-
transduction processes, it regulates integrin-mediated cell adhesion and might activate 
extracellular signal-regulated kinase (Daumke, Weyand, Chakrabarti, Vetter, & Wittinghofer, 
2004). It has not been associated with neurodevelopment or neurodevelopmental disorders, 
however its downregulation been associated with human tumours and tumour progression 
(Tsygankova et al., 2010).  Nevertheless, the microarray data should be always interpreted 
with caution and effects of selected genes from this type of analysis should be further 




Gene set enrichment analyses performed on the DE genes revealed nervous system 
development as the most common pathway and biological process and the top diseases are 
neurological or heredity (Rett syndrome). As the MYT1L gene has previously been associated 
with neurodevelopmental disorders, the results from the enrichment analysis are very 
interesting. They suggest a gene expression effect that includes genes associated with 
neurological diseases and nervous system development.. Our findings demonstrate that MYT1L 
is necessary for neurodevelopmental process process, inducing the expression of gene 
networks involved in neurite outgrowth, axonal development, synaptic transmission and cell 
adhesion. Since, MYT1L has been implicated in neurodevelopmental disease such as 
schizophrenia and ASD (Y. Lee et al., 2012; K. J. Meyer et al., 2012; S. J. Stevens et al., 2011), 
we sought to determine whether there may be shared biological processes or pathways 
between distinct ASD or SZ risk genes in our dataset. We found several overlapping genes for 
both ASD and SZ, however their correlation was not significant. This could be simply due to the 
fact that we lacked power to detect significant results in our dataset. The analysis are based on 
the number of probes submitted for analysis, thus the higher the number of probes the higher 
the probability of obtaining significant result.  
We have also performed microscopic examination of stem cells, which showed no distinctive 
morphological differences between cells infected with lentiviruses compared to non-infected 
cells. Interestingly, loss of Myt1 function (close Myt1l paralog) can be, at least partially, 
compensated by Myt1l activity (S. Wang et al., 2007). Therefore, it is possible that 
consequences of MYT1L inactivation in the differentiating neuronal stem cells could be masked 
by the activation of its paralogs (such as MYT1 and MYT3). It is also plausible to suggest that 
MYT1L might not have a detrimental or very obvious effect on stem cells differentiation, but 
instead it has a more subtle influence on changes within individual genes or pathways. The 
presence of genes involved in synaptic transmission and axonogenesis can suggest 
involvement of MYT1L in those processes. Interestingly, two genes: WNT7A and NLGN3 were 
repeatedly present with aforementioned GO terms. WNT7A is a member of the Wnt family of 
signaling molecules which are involved in axon and dendrite development, and synaptogenesis 
(Salinas & Zou, 2008). Wnt7a signalling specifically regulates the formation and function of 
excitatory synapses (L. Ciani et al., 2011) and it has been shown to stimulate the proliferation 
of neural progenitors derived from embryonic mouse brains (Viti, Gulacsi, & Lillien, 2003). It 
has been suggested that Wnt7a regulates genes involved in neuronal differentiation (Qu et al., 
2013). Additionally, gene encoding a member of the neurolignin family of neuronal cell surface 




NLGN3 (R451C) was first reported in two affected brothers, one with autism and the other 
with Asperger syndrome (Jamain et al., 2003). It has been found that NLGN3 can promote the 
formation of presynaptic elements in cultured hippocampal neurons and that autism-
associated mutation lead to a loss of this activity (Chih, Afridi, Clark, & Scheiffele, 2004). It has 
been shown that NLGN3 mutation does not alter neuron morphology but it impairs synaptic 
transmission (Földy, Malenka, & Südhof, 2013). Taken together this may suggest that MYT1L 
contribute to shaping synapses and their properties without altering cell morphology.  
 
Part of this project was devoted to functionally characterise human MYT1L protein, by 
generating an overexpression model that would have likely proved useful for this work. The 
aim was to identify other transcription factors or other proteins with which MYT1L interacts, 
thereby providing clues as to the biological context and function of MYT1L. To achieve this 
goal, the human MYT1L open-reading frame (ORF) was cloned into an expression vector 
(pLenti7.3/V5-TOPO). Unfortunately, even though cloning was successful we failed to detect 
high levels of exogenous MYT1L. Although GFP-expressing cells were transfected with over 
expressiong MYT1L, we failed to produce infected cells. One possible explanation for this is the 
problem with the purchased plasmids. All kits came with pre-mixed packaging system which 
could be the source of our problem. Since the virus packaging mix is pre-made, we were 
unable to separate and verify each of the plasmids.   The lack of success with all the system is 
baffling as the sequencing confirmed absence of frame shifts, de novo mutations, or any 
sequence aberrations that would explain lack of progress. Alternatively, some not yet defined 
factors that are cell specific could have prevented exogenous MYT1L expression. Genomic DNA 
plasmid contamination was detected in our samples, even after DNase I treatment and PCR 
purification. The possible solution would be to use different a method of RNA extraction (i.e. 
using Trizol) or to use a different DNase I. Also, it would have been beneficial to perform 
antibiotic selection (i.e. puromycin selection) on positive clones, to obtain stably transduced 
cells that were only expressing MYT1L gene and GFP. 
Therefore, at this point, it is difficult to draw any conclusions concerning the MYT1L protein 
and potential targets of MYT1L upon its upregulation compared to controls. It would be 
interesting to see the effects of exonegously expressed MYT1L on undifferentiated stem cells, 
in which this gene is present at very low levels.  Further research should concentrate on trying 




potential interacting partners, which in turn can lead to unraveling the specific molecular 
mechanisms driving the apparent association between MYT1L and neural development.  
 
There are a number of limitations that are associated with this study. One limitation comes 
from microarray analysis, in which we observed no significant evidence (FDR < 0.05) of 
reduced MYT1L mRNA expression in MYT1L silenced SPC-04 cells compared to cells infected 
with non-silencing shRNA, although qPCR analyses demonstrated a significant reduction of this 
gene in a silencing samples. As mentioned before, one possible explanation for the 
discordance of results lay within microarray sensitivity. Microarray is a powerful tool for 
studying the molecular basis of interactions on a scale that is impossible using conventional 
analysis, but it not without limitations. The sensitivity threshold of microarray measurements 
defines the concentration range in which accurate measurements can be made. Although 
microarray sensitivity is impressive, it might still be insufficient to detect relevant changes in 
low abundance genes, such as transcription factors (Czechowski, Bari, Stitt, Scheible, & 
Udvardi, 2004; Draghici, Khatri, Eklund, & Szallasi, 2006). Therefore, the ability to detect 
changes in the expression of specific individual genes might be affected. Thus, we found that 
MYT1L probes were present on the array but they produced low signal from each condition, 
suggesting that this gene can be below the microarray sensitivity threshold. Another limitation 
comes from pooling data from day 7 and day 14 of differentiation. We have analysed the 
combined dataset which could lead to potential errors. Due to pooling we could have missed 
genes that were differentially expressed at one time point but not the other compared to 
controls. We were also unable to distinguish or measure the magnitude of difference of DE 
genes between both time points. Despite the aforementioned issues, at the time of writing this 
thesis, this is the first study showing effects of MYT1L knock-down in SPC-04 stem cells and 
investigating its role and potential putative targets by microarrays. 
Additionally, there is an issue of validation of our findings by an independent method. It would 
have been beneficial to test the top hits from microarray study by qPCR to confirm and 
validate our findings. However, due to time constraints within this thesis this was not 
performed.  
It is also noteworthy that SPC-04 cells are derived from a 12-week old foetus and it is possible 
that the genes expressed by this line differ from the primary cultures or cells in vivo. Despite 




possibility to manipulate gene expression at various stages of differentiation in order to 
investigate gene function.  
In terms of future studies, further research is required to determine the role of MYT1L in 
neurodevelopment. Since we did not observe any obvious phenotypic changes associated with 
MYT1L down-regulation, it would be interesting to characterise neuronal properties of the 
cells with deregulated MYT1L, by for example by staining cells with different cell markers, such 
as a presynaptic marker (synaptophysin), a postsynaptic marker (PSD-95) and a neurite marker 
(MAP2). The stained neurons can be analysed by fluorescence microscopy and compared to 
non-infected cells. It would also be beneficial to perform immunostaining in undifferentiated 
cells using markers such as Sox1 and Nestin as well as differentiation markers such Tuj1 
(neurons) and GFAP (glia) to investigate the differentiation potential in this cell line upon 
Myt1l knock-down and to determine the time period required for producing mature neurons 
and/or glia. 
Additionally, it would have been advantageous to test MYT1L downregulation effects in vivo. In 
fact, behavioural tests on mice injected with Myt1l silencing virus were performed by another 
PhD student in our laboratory.  Animal experiments can provide a real life functional 
characterisation of the effects which Myt1l downregulation can have on the whole organ or 
body. 
 
In conclusion, this project has explored the gene expression alterations in differentiating stem 
cells upon MYT1L reduction. The results from this study have supplemented the knowledge of 
the possible downstream targets of MYT1L during brain development.  They have indicated the 
importance of MYT1L for neuronal development, and suggest that this transcription factor is 





4. Investigating the putative relationship between MYT1L and 
MEF2A. 
4.1. Introduction 
4.1.1. MEF2 transcription factors  
Myocyte enhancer factor 2 (MEF2) is a member of the MCM1-agamous-deficiens-serum 
response factor (MADS) family of transcription factors, identified initially in muscle cells (Yu et 
al., 1992). Since then, MEF2s have been identified in cells of the immune system where they 
mediate cell fate decisions (Youn, Sun, Prywes, & Liu, 1999). Also, they are highly expressed in 
neurons of the central nervous system where they show distinct patterns of expression in 
different regions of the brain with highest levels in the cerebellum, cerebral cortex and 
hippocampus (Heidenreich & Linseman, 2004; Lyons, Micales, Schwarz, Martin, & Olson, 1995; 
She & Mao, 2011).  
Through evolution, C. elegans and D. melanogaster only contain one isoform of MEF2, whereas 
vertebrates express four different MEF2 isoforms – MEF2A-D. The N-terminus of MEF2 
contains a MADS box, which is conserved between species, and it is located adjacent to the 
MEF2 domain, which is important for dimerisation, DNA binding and co-factor interactions 
(McKinsey, Zhang, & Olson, 2002). The C-terminal region of MEF2 is the transcription 
activation domain that can undergo extensive alternate splicing to create complex pattern of 
gene transcription (McKinsey et al., 2002). MEF2 family members have distinct but overlapping 
expression patterns in the brain during embryogenesis (Lyons et al., 1995), following that of 
neuron maturation, which suggests that onset of MEF2 expression coincides with neuronal 
differentiation.  
Recent studies identified the involvement of MEF2 in a number of neurodevelopmental 
processes, including synapse formation (S. W. Flavell et al., 2006; Pulipparacharuvil et al., 
2008). Furthermore, the alterations of downstream target genes of MEF2 have been 
implicated in a variety of neurological disorders (Greer et al., 2010; Lanz et al., 2013), 
suggesting that MEF2 is an important transcription factor involved in neurodevelopment.  
The transcriptional activity of MEF2 is activity-regulated, in which membrane depolarisation, 




transcriptional activity through calcium influx via L-type voltage-gated calcium channels (Mao, 
Bonni, Xia, Nadal-Vicens, & Greenberg, 1999) and calcineurin activation (Mao & Wiedmann, 
1999). During mammalian development, electrical activity promotes the calcium-dependent 
survival of neurons that have made appropriate synaptic connections. It has been shown that 
calcium influx into cerebellar neurons triggers the activation of the MKK6-p38 MAP kinase 
cascade and that the p38 MAP kinase then phosphorylates and activates MEF2s (Mao et al., 
1999). Once activated by this calcium-dependent p38 MAP kinase signalling pathway, MEF2 
can regulate the expression of genes that are critical for survival of newly differentiated 
neurons. These findings demonstrate that MEF2 is a calcium-regulated transcription factor 
that has a well-characterised, defined function during nervous system development that is 
distinct from previously identified functions of MEF2 during muscle differentiation.  Inhibition 
of MEF2 function in cortical neurons has been shown to cause apoptotic death, implying that 
MEF2-dependent regulation of transcription is necessary for survival (Mao et al., 1999).  
Understanding how MEF2–cofactor interactions are influenced by diverse signalling pathways, 
both calcium-dependent and independent, represents a major challenge for the future. The 
fact that MEF2 acts as a transcriptional switch for cellular processes that are disrupted in 
numerous diseases also makes it an attractive target for pharmacological and genetic 
modification. For example, the loss of MEF2D-mediated neuronal survival has been shown to 
underlie the process of the survival of DA neurons in models of Parkinson’s disease (Yin et al., 
2012) and rare variants in the MEF2C gene have been associated with autism, mental 
retardation and developmental delay (Neale et al., 2012; Novara et al., 2010).  
MEF2 proteins also regulate dendrite morphogenesis, differentiation of post-synaptic 
structures and excitatory synapse number (S. W. Flavell et al., 2006; Shalizi et al., 2006). 
Promotion of the post-synaptic differentiation of granule neurons can be achieved through 
sumoylation, by repressing the expression of the Nur77 transcription factor - a negative 
regulator of dendritic differentiation (Shalizi et al., 2006). Sumoylation is a post-translational 
modification that involves the attachment of one or more SUMO groups to a protein and is 
catalysed by an enzymatic cascade termed the ‘sumoylation pathway’ (Scheschonka, Tang, & 
Betz, 2007). A recent study investigated the role of MEF2A in pre-synaptic development in the 
mammalian brain. Knockdown of MEF2A increased the density of orphan pre-synaptic sites in 
primary neurons and in the cerebellar cortex of rats in vivo, while a sumoylated transcriptional 
repressor form of MEF2A mediated the suppression of orphan pre-synaptic sites (Yamada et 




activity-regulated cytoskeletal-associated protein (Arc) and synaptic RAS GTPase-activating 
protein (synGAP or Syngap1). Both, ARC and synGAP play important roles in synaptic 
disassembly by promoting the internalisation of glutamate receptors and by inhibiting Ras-
MAP signalling pathway (S. W. Flavell et al., 2006). MEF2A and MEF2D have been reported to 
negatively regulate synaptic development based on RNAi experiments in vitro (S. W. Flavell et 
al., 2006). However, a more recent study suggested only a subtle role of MEF2A/D in regulating 
synaptic function (Akhtar et al., 2012). Mef2a and Mef2d brain-specific double knock-out mice 
showed only deficits in motor coordination and short-term synaptic plasticity, but did not 
exhibit any other behavioural changes and had no impact on learning and memory, long-term 
potentiation or number of synapses (Akhtar et al., 2012).  MEF2A and MEF2D have been 
shown to control expression of genes associated with autism spectrum disorder (ASD) (Ube3A, 
Slc9A6, Pcdh10, C3orf58) (Steven W. Flavell et al., 2008; Lanz et al., 2013; Eric M. Morrow et 
al., 2008), which led to the proposition that autistic phenotypes can be generated by abnormal 
regulation of synaptic development and altered MEF2 signalling as a possible cause (Dietrich, 
2013).  
An understanding of the ways in which signalling pathways are connected to MEF2 targets in 
the brain remains an interesting and exciting research possibility. Analysis of alterations of 
expression of such targets in neurodevelopment and neurological diseases might reveal 
additional information on causation of many disorders in which MEF2 has been implicated.  
 
4.1.2. MEF2 interaction with MYT1L: a preliminary analysis 
MEF2 factors activate transcription via binding to A/T rich DNA consensus sequence 
CTA(A/T)4TAG/A as homo- or heterodimers (Black & Olson, 1998; Cserjesi & Olson, 1991). The 
ability of MEF2 to regulate neuronal-specific transcriptional programs may occur through DNA-
binding site selection. The expression of MEF2 in neurons shows optimal DNA-binding 
constraints for specific nucleotide sequences that flank the MEF2 site, and this is not observed 
with MEF2 factors from other cell types (Andrés, Cervera, & Mahdavi, 1995). The additional, 
brain-specific sequence (5’-TGTTACT(A/T)(A/T)AAATAGA(A/T)-3’) was not observed in the 
skeletal or cardiac muscle extracts.  
The analyses of gene expression patterns during stem cells differentiation, performed in our 
laboratory, have revealed the aforementioned brain-specific MEF2 binding site as present in 




stages of differentiation was performed in experiments consisting of three independent 
replicates of undifferentiated cells, pre-differentiated cells and cells that had been 
differentiated for 7 days (Desrivieres et al., 2014). Data analysis was performed by Dr Sylvane 
Desrivières and Dr Anbarasu Lourdusamy.  
Normalised and FDR-corrected results showed 270 genes that were co-expressed with MYT1L 
at day 7 of differentiation. Many of those genes have been linked to neurogenesis or 
differentiation. This set of co-expressed genes was significantly enriched for the presence of 
MEF2 transcription factor binding site (n = 114 genes, fold enrichment = 1.69; FDR-adjusted p-
value = 1.40E-09; see Table 4.1). These results showed us that the MEF2 biding site is present 
somewhere within each of those genes. Being interested in the potential link between MYT1L 
and MEF2 and wanting to see if the putative MEF2 binding site is present within the promoter 
portion of the genes of interest, we examined the data further by interrogating sequences 
10kb downstream and 2kb upstream of the transcription start site of each of those genes in 
search of MEF2-binding site. To perform this task, we have used TFBS Conserved table, part of 
UCSC genome browser, by coping all of the genomic coordinates and customised it to display 
only MEF2A sites (restricting the list to display only V$MEF2).This way, we have found that 190 





Table 4.1. Top 20 transcripts which correlated with the expression of MYT1L during differentiation of 
SPC-04 cells. Highlighted in yellow are genes that contain MEF2 brain-specific binding sites in the 
proximity of their TSS.  
Symbol Definition Correlation co-efficient R 
Correlation P-
value 
MYT1L Homo sapiens myelin transcription factor 1-like (MYT1L), mRNA. 1 2.68E-07 
JPH3 Homo sapiens junctophilin 3 (JPH3), mRNA. 0.9552052 1.32E-06 
SEZ6L2 Homo sapiens seizure related 6 homolog (mouse)-like 2 (SEZ6L2), transcript variant 2, mRNA. 0.9525285 1.75E-06 
CDK5R1 Homo sapiens cyclin-dependent kinase 5, regulatory subunit 1 (p35) (CDK5R1), mRNA. 0.95077276 2.10E-06 
LRRC24 Homo sapiens leucine rich repeat containing 24 (LRRC24), mRNA. 0.94956756 2.36E-06 
ARHGEF7 Homo sapiens Rho guanine nucleotide exchange factor (GEF) 7 (ARHGEF7), transcript variant 2, mRNA. 0.9484351 2.63E-06 
KCNQ2 Homo sapiens potassium voltage-gated channel, KQT-like subfamily, member 2 (KCNQ2), transcript variant 3, mRNA. 0.9483695 2.65E-06 
MAP4 Homo sapiens microtubule-associated protein 4 (MAP4), transcript variant 3, mRNA. 0.94808483 2.72E-06 
ZNF423 Homo sapiens zinc finger protein 423 (ZNF423), mRNA. 0.9458477 3.35E-06 
RTN1 Homo sapiens reticulon 1 (RTN1), transcript variant 1, mRNA. 0.94325316 4.21E-06 
PTPRO Homo sapiens protein tyrosine phosphatase, receptor type, O (PTPRO), transcript variant 5, mRNA. 0.9416315 4.84E-06 
SNAP91 Homo sapiens synaptosomal-associated protein, 91kDa homolog (mouse) (SNAP91), mRNA. 0.940563 5.28E-06 
PKIA Homo sapiens protein kinase (cAMP-dependent, catalytic) inhibitor alpha (PKIA), transcript variant 7, mRNA. 0.93742937 6.80E-06 
PPP2R2C 
Homo sapiens protein phosphatase 2 (formerly 2A), 
regulatory subunit B, gamma isoform (PPP2R2C), transcript 
variant 2, mRNA. 
0.9357074 7.76E-06 
BCL11B Homo sapiens B-cell CLL/lymphoma 11B (zinc finger protein) (BCL11B), transcript variant 1, mRNA. 0.93507975 8.14E-06 
GRIA2 Homo sapiens glutamate receptor, ionotropic, AMPA 2 (GRIA2), mRNA. 0.9347996 8.31E-06 
ELMO1 Homo sapiens engulfment and cell motility 1 (ELMO1), transcript variant 1, mRNA. 0.93372506 9.00E-06 
SLC17A6 
Homo sapiens solute carrier family 17 (sodium-dependent 




Homo sapiens protein phosphatase 2 (formerly 2A), 
regulatory subunit B, gamma isoform (PPP2R2C), transcript 
variant 2, mRNA. 
0.9319617 1.02E-05 
PKIA Homo sapiens protein kinase (cAMP-dependent, catalytic) inhibitor alpha (PKIA), transcript variant 6, mRNA. 0.9312388 1.08E-05 
 
These analyses provided an interesting opportunity and suggested a link between MYT1L and 
MEF2. As the primary function of transcription factors it so either activate or repress the 
expression of target genes by interacting with sequence specific DNA motifs and since most of 
MYT1L co-expressed genes in this data set contain MEF2 binding site, we hypothesised that 




4.2.  Aims  
Given the above analyses indicating that MYT1L and MEF2 co-expressed genes contain a MEF2 
binding site in their promoter region, we hypothesised that MYT1L is a target gene of MEF2A. 
The present study aimed at investigating the link between MYT1L and MEF2A. To achieve this, 
we first tested if Mef2a expression is conserved in vertebrates using zebrafish embryos and 
mouse brains as a model for brain development. To address the question of whether MEF2A is 
involved in stem cell differentiation and whether it regulates expression and function of MYT1L 
in this process, a gene knockdown approach was utilised in neural stem cells during the 
differentiation, followed by microarray gene expression analysis.  
 
4.3.  Materials and methods 
4.3.1. RNA extraction and cDNA synthesis of mouse and zebrafish samples.  
RNA from zebrafish embryos at stages: 18SS, 24hpf, 48hpf and 72hps were extracted according 
to the protocol described in chapter 2.3.3. Briefly, whole embryo RNA was extracted from 
pooled (25 embryos) embryos at each developmental stage. Whole brain mouse RNAs were 
extracted from pools of 5 (for the E10 stage) and 3 (for the E14 stage) embryos. RNA extracted 
from the frontal cortex was used from later developmental stages (E18, P1week, P1month, 
P6months). In this case, triplicates from independent brains were analysed for each stage up 
to 6 months, for which data was obtained from a single brain. Mouse RNA samples extracted 
from CD1 mouse brains at embryonic day 10 (E10), E14, E18, and at postnatal (P) stages 1 
week, 1 month, or 6 months were purchased from AMS Biotechnology (Abingdon, UK). cDNA 
synthesis was carried out according to the protocol described in 2.3.6.  
 
4.3.2. qPCR analysis of mouse and zebrafish extracts.  
Quantitative RT-PCR (qPCR) was performed as described in section 2.3.7. Briefly, cDNA samples 
were amplified using ABI Prism 7900HT sequence detection system installed with ABI Prism ® 
SDS 2.1 software (Applied Biosystems) in a final volume of 20 μl containing 2x power SYBR 
green master mix (Applied Biosystems), 4μl diluted cDNA and 0.07μM of forward and reverse 




the following thermal cycler conditions: initial enzyme activation step of 95°C for 15mins 
followed by 40 cycles of 95ºC for 30secs and 59ºC for 30secs. Fluorogenic data was collected at 
the 59ºC stage. The qPCR reaction was evaluated by dissociation curve analysis to ensure that 
the amplicons generated were specific. Zebrafish β-actin was used as the housekeeping gene 
for qPCR analysis of cDNA produced from zebrafish RNA extracts while the control gene used 
for analysis of mouse cDNA was Gapdh. Zebrafish primers were designed to target mef2aa 
gene, as this form has been identified as the protein coding gene and it is an orthologs of 
human MEF2A.  
 
Table 4.2. Table showing the oligonucleotide sequences of Mef2a primers for qPCR analysis of 




Forward 5’ – GCAGAAGGAGATCACATCCCTGGC – 3’ 
Reverse 5’ – CATTGCCGTCACCTTCACCGTTC – 3’ 
zf-mef2a 
Forward 5’ – GGCTCTCCAGGGCTCTCTAT – 3’ 
Reverse 5’ – AAACCAGATGGGGTTACACG – 3’ 
m-Gapdh 
Forward 5’ – TGTTCCTACCCCCAATGTGT – 3’ 
Reverse 5’ – CCTGCTTCACCACCTTCTTG – 3’ 
m-Mef2a 
Forward 5’ – TTACTTCCCCTGGAATGCTG – 3’ 
Reverse 5’ – GGAGGTGAAATTGGCTCTGA – 3’ 
The qPCR data was analysed by taking the mean of the Ct values for each of the 3 technical 
replicates for the housekeeping gene (zf-actin or m-Gapdh) and for mef2aa and Mef2a 
expression respectively. In order to generate ΔCt values, the mean Ct for mef2aa/Mef2a 
expression was subtracted from the mean Ct for zf-actin/m-Gapdh (ΔCt = Cttarget – Cthousekeeping 
gene) at each stage. ΔΔCt values were then obtained in order to calculate relative expression. 
Changes in expression at each stage were relative to E10 for mouse and 18SS stage for 
zebrafish and were calculated as ∆∆Ct (∆Ct - ∆CtE10 or 18SS).  ∆∆Ct was then converted to relative 
fold expression using the formula 2-∆∆Ct. Data are presented as group means and error bars 
show the standard error (+/-1.0 SE) from the means. The expression data was analysed by a 




4.4. Construction of shRNA targeting human MEF2A 
A MEF2A targeting shRNA was cloned into a lentiviral gene ontology (LeGO) vector (K. Weber, 
Mock, Petrowitz, Bartsch, & Fehse, 2010) to generate a MEF2A silencing plasmid for in vitro 
studies as follows:  
4.4.1.1. Vector preparation  
LeGO vectors are third-generation lentiviral plasmids, meaning they do not encode any viral 
proteins but contain cis-active elements for packaging, reverse transcription, and integration 
(Kristoffer Weber, Bartsch, Stocking, & Fehse, 2008). These lentiviral expression vectors 
efficiently transduce slowly dividing cells, including hematopoietic stem-progenitor cells 
(HSCs), resulting in stable gene transfer and expression. Additionally, LeGO vectors allow 
incorporating up to 9kb of foreign sequences. LeGO-G expresses enhanced green fluorescent 
protein (eGFP), as a marker gene to ensure efficient detection (Figure 4.1). 
 
 
Figure 4.1. The lentiviral gene ontology (LeGO-G) vector principle. LeGO-G vector was used for gene 
silencing. LeGO-G also contains a retroviral enhancer/promoter of spleen focus-forming virus (SFFV), 
which allows a broad and high expression pattern for expression of the reporter gene eGFP (enhamnced 
Green Flouresecent Protein) while the U6 promoter drives the expression of the shRNA cloned into the 
Multiple cloning site (MCS) using the HpaI and XhoI restriction sites. Other features include rev-
responsive element (RRE); selfinactivating- long-terminal repeat (SIN-LTR); Woodchuck hepatitis virus 
post-transcriptional regulatory element (wPRE) and central polypurine tract (cPPT). Picture adapted 
from (Kristoffer Weber et al., 2008). 
 
To linearise the vector, LeGO-G was digested by using the HpaI and XhoI restriction enzymes. 
Enzymes and buffers were purchased from NEB, UK. A typical reaction contained 2U of each 
enzyme, 1μg DNA (vector), 1x Buffer EcoRI, 1x BSA made up to a final volume of 20μl with 
dH20. The reaction mix was incubated at 37°C for 1 hour to allow complete digestion, followed 
by 20 minutes at 65°C to inactivate the restriction enzymes. To prevent re-circularisation, the 
vector was dephosphorylised with 5 units of Antarctic phosphatise, 1μg of digested vector and 
1x Antarctic phosphatase buffer and incubated at 37°C for 30 minutes followed by enzyme 




kit (QIAGEN, Crawley, UK), according to the manufacturer’s instructions and 200ng of the 
purified, digested and dephosphorylated vector was electrophorised on the gel, to check for 
complete digestion. 
 
4.4.1.2. MEF2A shRNA oligos 
The shRNA against human MEF2A was designed based on previously described shRNA 
targeting rat Mef2a. We adapted the sequence to target only the human isoform of MEF2A. 
Target sense sequence is presented in Table 4.3.  
To design a hairpin we followed a protocol previously described by Dr Tyler Jacks at MIT 
(http://www.addgene.org/static/data/94/67/16242780-af64-11e0-90fe-003048dd6500.pdf). 
Briefly, an HpaI site in Lego-G vector leaves a blunt end prior to the –1 position in the 
promoter. The oligo design incorporated a 5’ T in order to reconstitute the –1 nucleotide of the 
U6 promoter. Therefore the oligo format is as follows:  
Sense oligo: 5’T-N19-loop sequence (TTCAAGAGA)-corresponding antisense sequence (91NC)-
termination sequence (TTTTTTC)  
Anti-sense oligo: complement of sense with additional nucleotides at 5’ end to generate XhoI 
Overhang.  
To properly assess knockdown, the gene expression level from the scramble control vector was 
used in comparison with the target-specific shRNA transfected samples. We used another gene 
from the MEF2 family to produce a non-silencing scrambled shRNA (Table 4.3). The sequence 
of the MEF2D shRNA was altered in a way that it did not recognise any known human gene, 
therefore should not lead to any alterations on a molecular or cellular level. We have also used 
empty, ligated LeGO-G vector as another control. 
Table 4.3. Sense sequence of shRNA targetting MEF2A and a scrambled MEF2 as a negative control. 
Gene Sense target sequence 
MEF2A 5’ – GTTATCTCAGGGTTCCAAT – 3’ 





The oligos were ordered from Integrated DNA Technologies (Coralville, IA, United States of 
America), with 5’ phosphates and PAGE purified. 60pmoles of sense and antisense oligos were 
annealed in a buffer containing 100mM K-acetate, 30mM HEPES-KOH pH 7.4, 2mM Mg-acetate 
by incubating at 95°C 4min, 70°C for 10 mins, followed by a slow temperature decrease 
(0.1°C/min) to 4°C.  
 
4.4.1.3. Ligation of annealed shRNA into the LeGO-G plasmid vector 
DNA ligation reactions were carried out in the molar ratio 1:1 of annealed oligos and 
linearised, dephosphorylated LeGO-G vector. 30fmol of each component was mixed with 1x T4 
DNA ligase buffer and 1U T4 DNA ligase (NEB, UK) in a total reaction volume of 10μl. Control 
reaction was set up, to contain only digested vector with no shRNA plus ligase and used to 
check for successful ligations. The ligations were incubated overnight at 16°C. The following 
day, 5μl of each ligation reaction was transformed into a 50μl aliquot of MAX EFFICIENCY Stbl2 
bacteria (Life Technologies, UK), as described in section 3.3.1.6. Individual colonies were 
picked and grown for precultures and subsequently minipreps and maxi preps were carried out 
for plasmid DNA extraction, as described in 3.3.1.8.  
 
4.4.1.4. Screening for positive clones 
Following transformation, colony isolation and plasmid purification by minipreps, samples 
were screened for the presence of an insert by restriction digest using the XhoI and XbaI 
restriction enzymes. The reaction consisted of 1x Buffer 4, 1x BSA, 1 unit of each enzyme and 
18μl of miniprep DNA. Both enzyme restriction sites were present in the multiple cloning site 
of the vector and positives were analysed in comparison to empty vector. The expected sizes 
were as follows: For an empty vector: 334bp + 7.1kb; for vector + insert: 448bp + 7.1kb. Due to 
this very small difference, the digests were run on a 2% gel (w/v) for 2 hours at 80V. In 
addition, plasmids were sent for sequencing (Bioscience, UK) to verify each construct, using 
the primer that recognises the U6 promoter sequence in the vector:   





4.4.2. Virus production 
Lentiviruses were created using co-transfection (calcium phosphate co-precipitation) of shRNA 
MEF2A, shRNA scrambled and empty vector with the packaging plasmids into HEK 293T cells. 
HEK 293T cells are derived from human embryonic kidney cells (ATCC, USA) and are highly 
transfectable, because they express the SV-40 large T antigen, which allows for very high levels 
of plasmid replication. They were routinely grown in Falcon T75 flasks a complete media 
consisting of: DMEM containing 4.5g/L glucose and 2mM L-Glutamine supplemented with 10% 
heat inactivated FBS, 100U/ml Penicillin and 100μg/ml Streptomycin (Sigma, UK).  
The day before transfection, 5x106 cells were plated in 10ml of complete medium in 10cm 
dishes to reach 70-80% confluency. The following day, three hours prior to transfection, the 
medium was replaced with 5ml fresh culture medium. For each dish to be transfected, a 
separate reaction mix was prepared in a sterile 15ml Falcon tube, consisting of 10μg gene 
transfer plasmid, 5μg pRSV-Rev, 10μg pMDLG/pRRE and 3.5μg pMD2.G (packaging plasmids 
from Open Biosystems, Thermo Scientific, UK) topped up to 500 µl with sterile dH2O. The 
above DNA assemble was mixed with 50μl 2.5mM CaCl2 (Open Biosystems, UK). Whilst 
bubbling with a sterile, serological pipette, 500μl of 2x Hepes Buffer Saline (HBS) pH7.12 was 
added dropwise to the DNA/CaCl2 mix. This was incubated at RT for 30 minutes. Shortly before 
transfection, 1μl of 100mM chloroquine was added to each culture dish that was to be 
transfected, followed by dropwise addition of 1ml of the DNA/CaCl2/HBS complex and the cells 
were incubated overnight at 37°C, 5% CO2. The following day, the medium was replaced with 
10ml of fresh, complete medium and the plates were microscopically examined for the 
presence of GFP, an indicator of transfection efficiency. Supernatants containing lentiviral 
particles were collected 48 and 72 hours after transfection, pooled together, filtered through 
0.22μm pore nitrocellulose filter and stored at -80°C. To concentrate the virus, the supernatant 
with lentiviral particles was transferred to ultracentrifugation tubes (Beckman Coulter) and 
spun down at 25000 RPM for 1.5h at 4oC. The supernatant was carefully removed from the 
tubes without disturbing the lentiviral pellet. 30 μl of PBS was added to each tube and left 





4.4.3. Transduction of 293T cells and SPC-04 cells with lentiviruses silencing 
MEF2A.  
To assess the effectiveness, specificity and knock-down efficiency of the shRNA constructs 
293T cells were transduced with the lentivirus. The day prior infection, 293T cells were seeded 
in a 6-well plate at a concentration of 1 x 105 cells/well and incubated overnight. The following 
day, the media was changed to contain 2ml of lentiviral stock and 1ml of standard medium. To 
increase transduction efficiency, 3 µl of 8mg/ml polybrene (Sigma, USA) was added to each 
well. The plates were centrifuged for 90 minutes at 2500 RPM followed by 2.5h incubation at 
37o C, 5% CO2, after which media was changed to 3ml of complete media and plates were 
returned to the incubator for a further 72h. Cells were then lysed for RNA extractions using the 
QIAGEN RNeasy Mini Kit (QIAGEN, UK), followed by cDNA synthesis (as described in 3.3.1.12 
and 3.3.1.13). 
Once transduction of 293T cells was confirmed and knock-down efficiency established, SPC-04 
cells were infected with the concentrated virus, as described in 3.3.2.3. Briefly, the day before 
transduction, SPC-04 cells were seeded in 6-well laminin-coated Nunc plates at a density of 
20000cells/cm2. The following day, growth media was removed and replaced with RMM- 
containing 10μM DAPT and 100nM ATRA (pre-differentation stage) and a 1 μl of concentrated 
lentivirus per well. Cells containing lentiviral particles were incubated for 48h at 37°C, 5% CO2, 
after which media was replaced with RMM- and the media was changed every 2 days until the 
end of the experiment. Differentiation day 1 was counted as the day after pre-differentiation 
had finished. Transduction efficiency was assessed using a fluorescent microscope (Leica DMIL) 
supplied with a Leica camera DFC420C (x10 objective). 
RNA extracts were taken at the following time points: undifferentiated cells, pre-differentaited 
DAPT/ATRA stage, 7 days differentiation and 14 days differentiation. The cells were lysed for 
RNA extractions using the QIAgen RNeasy Mini Kit (QIAGEN, UK), followed by cDNA synthesis 
(as described in 3.3.1.12 and 3.3.1.13) 
 
4.4.4. Quantification of MEF2A levels in 293T and SPC-04 cells. 
cDNA samples were amplified by qPCR as described in 3.3.1.14. GAPDH was used as a house-
keeping gene for extracts from 293T cells, and RPL18 was used as a control for SPC-04 extracts. 




Table 4.4. Primer sequences used for qPCR amplification of MEF2A and the control gene GAPDH (for 
293T cells) and RPL18 for SPC-04 cells. 
Primer Sequence 
GAPDH 
Forward 5’-CATGAGAAGTATGACAACAGCCT -3’ 
Reverse 5’-AGTCCTTCCACGATACCAAAGT-3’ 
RPL18 
Forward 5’ – GAGAGGTGTACCGGCATTTC – 3’ 
Reverse 5’ – CTCTGGCACGCTCGAACT – 3’ 
hMEF2A  
Forward 5’ – AGCCCTTCAAGGCTTCAACT – 3’ 
Reverse 5’ – GGTTCGGACTTGATGCTGAT – 3’ 
 
All qPCR data were analysed by a one-way ANOVA with MEF2A dosage and differentiation 
stage as factors and were followed post hoc analyses using Tukey’s test. All statistical analyses 
were performed using IBM SPSS Statistics 20 software (IBM Corp., USA). A p-value <0.05 was 
considered statistically significant. The data was expressed as mean ± Standard Error of the 
Mean (SE). 
 
4.4.5. RNA labelling and microarray hybridisation 
The RNA, labelling, hybridisation, washing and scanning steps were outsourced and carried out 
by High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics, 
Oxford. RNA integrity was analysed using Agilent RNA 6000 Nano Kit (Agilent Technologies, Inc; 
Germany) on an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc). Total RNA was amplified 
and labelled (biotinylation) using the TargetAmp™-Nano Labeling Kit for Illumina Expression 
BeadChip (Cambio, UK) according to the manufacturer’s instruction. Whole genome gene 
expression profiling was run on Illumina’s HumanHT-12 v4.0 Expression BeadChip, which 
contains over 47000 probes. Samples were randomly allocated across the chip. The hybridised 
and washed chips were scanned using Illumina iScan Scanner. 
 
4.4.6. Statistical and bioinformatic analyses of microarray data 
Raw data was extracted using GenomeStudio Data Analysis Software, and was further 




using Lumi package. The variance stabilising transformation method was used, followed by 
quantile normalisation. Probes with unreliable expression measurements were flagged and 
removed from the analysis. Next, based on the coefficient of variation, genes which expression 
is constant across all the experiments (i.e., are invariant) were removed from the dataset. Of 
the 47,230 probes that feature on the Illumina platform, data from 10,069 probes were 
retained for further analysis. Using the Benjamini and Hochberg FDR method, q-values were 
generated in an attempt to correct for the effects of multiple testing, whereby expression 
differences producing q-values of q < 0.05 were considered true effects (Benjamini & Yekutieli, 
2001). Transcripts from a total of 13 probes, representing 11 distinct genes were selected 
based on the above criteria.  
Due to absence of a strong DE signal in this experiment, with only 11 genes meeting the 
criteria for q < 0.05, the uncorrected p-value threshold of p < 0.005 was chosen for subsequent 
functional analyses. This p-value is less stringent than FDR corrected q < 0.05 cutoffs and it has 
previously been used to identify differentially expressed genes in microarray studies (Miller, 
Woltjer, Goodenbour, Horvath, & Geschwind, 2013). Using this method, we generated a 
dataset containing 148 transcripts (representing 128 distinct genes) that were differentially 
expressed between MEF2A knock-down and non-silencing controls, which were subject to 
further functional analyses.  
The functional annotation clustering tool, part of the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov/), was used to identify 
enriched biological themes and functional-related gene groups in gene lists generated from 
microarray data (as described in 3.3.4). Additional analyses were performed using Ingenuity® 
systems software (http://www.ingenuity.com/) to  identify relationships, mechanisms, 
functions, and pathways significantly enriched (p<0.05) in the dataset (as in 3.3.4). To identify 
if our set of differentially expressed (DE) genes were enriched for known susceptibility genes 
for autism or schizophrenia, the Simons Foundation Autism Research Initiative (SFARI) 
(https://sfari.org)  and the Schizophrenia Gene Resource gene list were downloaded (SZ, 







4.5.1. Mef2a expression in zebrafish and mouse follows similar pattern to 
Myt1l. 
MEF2A-MYT1L interaction during brain development in vertebrates was determined by 
performing qPCR analysis for Mef2a and compared its expression patterns to that of Myt1l in 
zebrafish and mouse.  
Firstly, developing zebrafish embryos were screened for expression pattern of mef2aa gene. 
Mef2aa was chosen based on the literature as an ortholog of human MEF2A protein. Mef2ab 
was also identified bioinformatically in zebrafish, however it has no known biological function. 
Mef2a is located on chromosome 18 in the fish; it has 4 known transcripts, the longest 
spanning 2113bp. 
qPCR time course analysis of the zebrafish mef2a expression pattern was performed with 
cDNA from 18SS, 24, 48 and 72h hpf-stage embryos. A high throughput analyses performed by 
Thisse et al. (B. Thisse, Thisse, C., 2004) showed that mef2aa starts being expressed between 
20 somite stage (19hpf) and 5-Prim (24hpf), in various parts of the fish body, including the 
telencephalon. In agreement with this, we found that mef2aa expression was lowest at 18SS, 
increasing up to 2-fold at 24hpf and 48hpf and 6-fold at 72hpf (Figure 4.2). The results did not 
reach the significance level, when analysed by one-way ANOVA (F(3,8)= 2.375, p=0.146). This 
could be due to only small changes in expression observed in these experiments. Nonetheless, 
the results confirm that mef2a is conserved throughout the fish development and its mRNA 
levels increase slightly with the embryo development. It is noteworthy that we only analysed 
extracts from the whole embryos, thus the observed changes in mRNA levels should not be 
merely attributed to differences observed within the brain, but the entire body.  
From previous studies, we know that mef2a is highly expressed in the heart and somites 
during zebrafish embryogenesis (Y.-X. Wang et al., 2005), therefore increase in expression 
observed in our study could be partially attributed to that. However, it has also been shown 
that mef2a is expressed in brain during embryo development (Hammond & Udvadia, 2010). 
Looking at the ISH for mef2a as shown by Hammond et al. (Hammond & Udvadia, 2010) and 
comparing them to our myt1l ISH (see Chapter 2.4.1), we can observe similarities in brain 
expression patterns between myt1l and mef2a. Overlapping expression of Myt1l and Mef2a is 
most prominent in the telencephalon (Figure 4.3). Due to the widespread expression of myt1l 




cerebellum, hindbrain and midbrain (Figure 4.3). The expression pattern of mef2a and myt1l 
the overlap in specific regions of CNS representing areas where mef2a could potentially 
regulate Myt1l activity in the developing brain.  
 
Figure 4.2. qPCR analysis of mef2a expression in zebrafish embryos. Highest expression (6-fold change) 
is reported from 3 day embryos. Results from 24hpf, 48hpf and 72hpf were calculated relative to the 
expression at 18SS stage. Data is presented as mean values of three independent experiments, error 
bars represent +/- 1SE of the mean. 
 
 
Figure 4.3. Mef2a and Myt1l expression overlaps in the central nervous system. At 48hpf, the overlap 
is most prominent in telencephalon (t), midbrain (m) and hindbrain (hb). A and B – lateral views of the 
head at 48hpf after whole mount ISH for Mef2a (taken from (Hammond & Udvadia, 2010)) (A) and myt1l 
(B). t-telenecephalon, di- diencephalon, m-midbrain, c-cerebellum, hb- hindbrain, pa- pharyngeal 










To validate these findings and to further assess changes of Mef2a transcript levels in the 
vertebrate brain, we investigated changes in expression of this transcription factor in the 
mouse brain during embryonic and postnatal development. The analysis showed that Mef2a 
expression is lower during embryonic development (E14), increasing just before the birth (E18) 
and reaching its highest levels 1 week after birth and remaining elevated at 1 month 
postnatally (Figure 4.4). A one-way ANOVA revealed a significant gene dosage effect in the 
mouse brain samples (F (3,8)= 4.734, p=0.035). Post-hoc analysis using Tukey shown that the 
change was significant only between E10 and 1 week after birth (p=0.031), which corresponds 
to human third trimester (Romijn, Hofman, & Gramsbergen, 1991) when the brain growth 
spurt occurs (Clancy, Finlay, Darlington, & Anand, 2007). Inspection of the dissociation curves 
for zebrafish mef2aa and mouse Mef2a expression in RT-qPCR experiments revealed a single, 
specific amplicon for each measurement (Figure 4.5). 
These findings are in general agreement with our results obtained while testing for Myt1l 
expression, when we observed significant increase in mRNA levels at stages E18 and 1 week 
postnatally (see Figure 2.10 in Chapter 2.4.3). To further elucidate the relationship between 
Myt1l and Mef2a expression, a Pearson correlation coefficient was computed. There was a 
strong positive correlation between the two variables (r=0.916, n=14, p=4.23E-06); increases in 
Myt1l expression were correlated with increases in Mef2a expression. This indicates that 





Figure 4.4. Graph representing stage specific expression of Mef2a during mouse brain development. 
The highest expression was recorded at post natal (P) week 1. Data from E14, E18, P1 week, P1 month 
and P6 months were calculated relative to the expression in the brain at E10. Statistical analysis 
(ANOVA) compared expression at E10, E18, 1 week and 1 month post natally. Tukey post hoc analyses 
showed significant increase in expression at 1 week after birth (*: p=0.035).  Error bars represent +/- 1SE 
of the mean.  
 
 
Figure 4.5. Confirmation of the specificity of mef2a RT-qPCR primers. Dissociation curves from qPCR 
analysis of Mef2a mRNA expression in zebrafish embryos (A) and in mouse brains (B) indicate a single, 
specific amplicon (i.e. one PCR product per primer pair). The additional peaks visible on both figures 







4.5.2. Testing the efficiency of the MEF2A shRNA in HEK 293T cells 
Before any attempts at knocking – down MEF2A were made, we needed to assess potential 
suitable cell lines that express MEF2A endogenously. Using qPCR, we have analysed SH-SY5Y, 
SK-N-SH, N2A and 293T cell lines for their endogenous expression of MEF2A. 293 T cells 
showed good expressions of MEF2A when their Ct values (Table 4.5) were compared to that of 
GAPDH (positive control). Although, the human neuroblastoma cell lines (SH-SY5Y and SK-N-
SH) and the mouse neuroblastoma cells (N2A) were available in the lab and could have been 
suited for the shRNA validation purposes, MEF2A expression level was low in those cell lines 
compared to 293T cell line (Table 4.5). Thus, the latter was chosen to test MEF2A targeting 
shRNA for its efficiency.  
 
Table 4.5. Ct values obtained from analysing MEF2A expression in four cell lines: SH-SY5Y, HEK 293T, 
SK-N-SH and N2A. Lower Ct values indicate higher levels of expression. The highest expression of MEF2A 





293T cells were infected with lentiviruses containing shRNA MEF2A and shRNA scrambled as a 
control. We obtained on average a 30% decrease in MEF2A expression (Figure 4.6) when 
compared to the control. One-way ANOVA showed a significant knock-down of MEF2A by this 
shRNA (F1,6=5.987, p=0.05).  
Cell line Mean Ct MEF2A Mean Ct GAPDH 
SH-SY5Y 37.28 +/- 0.73 30.82 +/- 0.08 
HEK 293T 29.86 +/- 0.14 17.06 +/- 0.46 
SK-N-SH Undetermined 16.36 +/- 0.15 





Figure 4.6. Relative fold expression of MEF2A mRNA in HEK 293T cells transduced with lentivirus 
silencing MEF2A. Cells were infected with virus carrying shRNA against MEF2A or scrambled shRNA, 
used as a control. Error bars represent +/- 1SE, *p=0.05. 
 
4.5.3. Effects of MEF2A knock-down on SPC-04 cells 
The human neural stem cell line SPC-04 was used as in vitro model for neural development. 
Firstly, we assessed endogenous MEF2A expression levels in SPC-04 at various stages of 
differentiation. By examining qPCR data of MEF2A expression during SPC-04 cells 
differentiation, we have found a good expression of this transcription factor across all the 
stages of stem cell differentiation (Figure 4.7), indicating endogenous expression of MEF2A 
mRNA in these cells. We detected a small decrease in expression at a pre-differentiation stage 
and 7 days of differentiation. A 1.5 fold increase at day 14 of differentiation compared to 
undifferentiated cells was observed. The small changes between the developmental stages 
were not significant when tested by one-way ANOVA (F(4,14)=0.114, p=0.975).  
Good endogenous gene expression across the developmental stages makes SPC-04 a good 
model to study gene silencing effects. We observed a lack of change in expression on mRNA 
level during the 14 day differentiation, which is in line with previous findings (S. W. Flavell et 
al., 2006; Steven W. Flavell et al., 2008; Scheschonka et al., 2007; Shalizi et al., 2006), which 
can suggest that unlike MYT1L, MEF2A might not be involved in the early stages of neural 
development but it might play a role later during synaptogenesis and post-synaptic neuronal 






Figure 4.7. The relative fold expression of MEF2A in SPC-04 cells at different stages of differentiation. 
The data indicated that MEF2A is endogenously expressed at all tested stages of differentiation in neural 
progenitor/stem cells and the changes observed between different stages were not statistically 
significant (ANOVA, p=0.975). The error bars represent +/-1 SEM. 
 
Having confirmed shRNA efficiency in 293T cells and endogenous expression of MEF2A in stem 
cells, SPC-04 cells were transduced with either MEF2A or non-silencing scrambled shRNAs and 
differentiated for 7 and 14 days. Microscopic examinations revealed a small change in cells 
morphology. Cells infected with shMEF2A (Figure 4.8 B,E) showed more developed neurites 
than the cells infected with a control shRNA (Figure 4.8 C,F). However, the phenotype is very 
subtle, and cells infected with MEF2A closely resemble uninfected, normally differentiating 
cells. Since this change is very subtle, it could be attributed to the effects of the virus alone, as 
we did not measure titers, therefore the virus containing control shRNA could have been more 











Figure 4.8. SPC-04 cells differentiation and transduction with lentivirus encoding shRNA MEF2A and 
scrambled shRNA. Each row represents a differentiation stage (7 or 14 days) and each column 
represents one condition obtained for this experiment. The first column contains phase-contrast 
pictures of normal differentiation occurring without transduction, second column represents cells 
treated with virus silencing MEF2A, and the last column corresponds to cells infected with scrambled 
shRNA. Figures 4.8. B-C and Figures 4.8 E-F are fluorescent microscope images indicating the GFP 
expression of transduced cells. Bar represents 200µm.  
 
 
4.5.4. MEF2 gene product suppresses expression of MYT1L 
The RNA harvested from transduced cells was first used to establish the knockdown efficiency 
of shMEF2A in SPC-04 cell line (3 samples at day 7 and 2 samples at day 14 of differentiation 
were analysed), which was on average a 40% reduction (Figure 4.9). The one-way ANOVA 
revealed a significant decrease (F(2,14)=4.041, p=0.046) of MEF2A expression in all our samples, 
however due to only two replicates at 14 days of differentiation, we were unable to perform 
statistical analysis for that time point alone. Subsequent t-tests performed on the data 
collected from cells differentiated for 7 days revealed a significant change in MEF2A expression 
(t (3)= -3.279, p=0.023).  































Figure 4.9. Relative fold expression of MEF2A mRNA in SPC-04 cells transduced with lentivirus 
silencing MEF2A for 7 and 14 days. Cells were infected with virus carrying shRNA against MEF2A or 
scrambled shRNA, used as a control. Error bars represent +/- 1SEM, *p<0.05 
 
Investigation of potential relationship between MYT1L and MEF2A was obtained by measuring 
MYT1L mRNA levels in MEF2A knocked-down and MEF2A control samples and by comparing 
the expression of the two genes. Indeed, we found that association between the two variables 
was significant (F(2,12)=7.029. p=0.01). Post-hoc Tukey revealed that MYT1L expression in 
MEF2A knock-down samples was significantly altered (p=0.013). In addition, the Pearson 
correlation coefficient was performed on data obtained from qPCR analysis of MEF2A knock-
down and MEF2A control samples to assess the directionality of the effect that MEF2A has on 
MYT1L expression. The data showed strong negative correlation between the expression of 
the two genes in the MEF2A knock-down samples (r=-0.820, n=15, p=1.82E-04), suggesting 
that the higher the MEF2A knock-down efficiency (i.e. lower MEF2A expression) the higher 
MYT1L expression is. When the data on MYT1L and MEF2A expression from MEF2A knock-
down experiments were plotted on the graph against each other, we found that MYT1L 
expression was dependant on MEF2A dosage.. For example, when MEF2A was silenced at 75%, 
MYT1L mRNA levels increased 27-fold, the trend followed the pattern that with lower MEF2A 






Figure 4.10. Graph representing MYT1L expression in MEF2A knock-down SPC-04 cells. MEF2A knock-
down efficiency was assessed together with MYT1L mRNA transcript levels. The trend line represents 
the negative correlation between the two variables. MYT1L expression increased upon MEF2A silencing. 
We observed that with the increase of MEF2A knock-down efficiency (decrease of MEF2A expression), 
MYT1L mRNA levels raised.  
 
We also checked if the relationship was mutual (i.e. if we observe altered MEF2A transcript 
levels dependent on MYT1L dosage), by measurement of the expression of MEF2A in the 
shMYT1L and MYT1L control samples. This analysis showed that in MYT1L knock-down 
samples, MEF2A levels remained unchanged (F(1,12)=1.361, p=0.266). These findings suggest 
that MEF2A is a regulator of MYT1L by repressing the expression of MYT1L and thus potentially 
regulates the pathways by which MYT1L operate, which is a point of high interest in this 






4.5.5. Differential gene expression analysis  
In order to identify potential transcriptional targets of MEF2A, microarray gene expression 
profiling was performed using extracts from SPC-04 cells transduced with shRNA MEF2A or 
scrambled shRNA as a control and differentiated for 7 days. The data is representative of three 
independent experiments.  
A total of 13 illumina probes detected significant (q < 0.05) differential mRNA expression 
between cells with silenced MEF2A and controls, which corresponded to transcripts from 11 
distinct genes all of which were upregulated (table 4.6). Interestingly, seven of those genes 
(highlighted in yellow, table 4.6) had significant (q<0.05) differential expression in the MYT1L 
knock-down dataset. Worth noting, all the common genes that are present in both data sets, 
were down-regulated (chapter 3.4.3, Table 3.7) upon MYT1L silencing and up-regulated upon 
MEF2A reduction. This finding is in line with our hypothesis that MEF2A suppresses MYT1L, 
and by extension it is possible that it suppresses genes that are co-expressed with MYT1L.  
 
Table 4.6. List of differentially expressed (FDR < 0.05) genes between SPC-04 cells with shRNA MEF2A 
and non-silencing controls. Relevant illumina probe, gene symbol and full name, log fold change, as well 
asuncorrected and corrected (FDR) p-values are listed for each gene. Genes are sorted according to 
pvalue; Highlighted in yellow are genes that were also DE in the MYT1L knock-down dataset. 
 
Probe ID Symbol Definition log fold 
change p-value FDR 
6450097 FAM69C chromosome 18 open reading frame 51 (C18orf51), mRNA. 1.79 6.92E-07 0.004589 
2750176 AQP4 aquaporin 4 (AQP4), transcript variant a, mRNA. 1.80 1.76E-06 0.005907 
1030021 SPARCL1 SPARC-like 1 (mast9, hevin) (SPARCL1), mRNA. 2.81 4.68E-06 0.011788 
2100446 BCAN brevican (BCAN), transcript variant 1, mRNA. 2.43 7.55E-06 0.015201 
2760239 RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) (RASGRP1), mRNA. 1.30 1.87E-05 0.0251 
1110048 SCRG1 scrapie responsive protein 1 (SCRG1), mRNA. 1.38 2.25E-05 0.0251 
520474 ODZ4 odz, odd Oz/ten-m homolog 4 (Drosophila) (ODZ4), mRNA. 1.85 2.39E-05 0.0251 
1090326 TIMP4 TIMP metallopeptidase inhibitor 4 (TIMP4), mRNA. 1.25 2.49E-05 0.0251 
3850059 LMO2 LIM domain only 2 (rhombotin-like 1) (LMO2), mRNA. 1.21 3.30E-05 0.030213 
460544 CHODL chondrolectin (CHODL), mRNA. 1.24 5.55E-05 0.04601 





4.5.6. Functional annotation clustering and pathway analysis 
The determination of whether the set of differentially expressed (DE) genes was enriched for 
any functional terms was performed by means of the functional annotation-clustering tool, 
which is part of the DAVID (v6.7) bioinformatic resource. As there is not a strong DE signal in 
this experiment, with only 11 significantly DE genes, the uncorrected p-value threshold of 
<0.005 was chosen as it is less stringent than both FDR corrected <0.05 cutoff. This way we 
generated a dataset containing 125 distinct genes, of which 107 were upregulated. 86 of those 
genes matched genes DE in MYT1L knock-down dataset (when dataset was widened to 
unadjusted p<0.005). All of the corresponding genes were upregulated in the MEF2A set but 
downregulated in MYT1L. These findings support our qPCR analysis suggesting that MEF2A 
may negatively regulate MYT1L.  
Of the 147 probes submitted to DAVID, 125 were recognised as probing distinct genes in the 
human genome. A total of 56 functional gene clusters were generated from these set of DE 
genes, 5 of which reached the significant level of enrichment score (es) >1.3 (p < 0.05). 
Interestingly, the top scoring cluster, with ES=1.89 pertained to mainly neuron development 
and differentiation, axonogenesis and neuron projection  (Figure 4.11). The enrichment score 
provides an indication of the biological significance of the gene groups being analysed. To 
better understand the details of enriched annotation terms associated with this gene list, 
functional annotation chart option in DAVID was implemented. When functional annotation 
chart option in DAVID was implemented it did not produce results that were significant after 
correction for a multiple testing. Briefly, the top ranked GO-term (GO:0030182)(Benjamini p= 
0.298) was neuron differentiation which included 10 genes. Among the top scoring terms was 
also biological adhesion (GO:0022610) (p=  0.305) made up of 13 genes. This list of enriched 
GO terms largely overlaps with what was observed earlier with MYT1L knock-down dataset. It 
corroborates our hypothesis that MEF2A is a regulator of MYT1L and its co-expressed genes. It 
also suggests that MEF2A is involved in neural development and growth. The presence of cell 
adhesion molecules on the list together with neuron projection can imply that MEF2A plays a 
role in synaptic formation and the establishment of neuronal connectivity, which is what we 
would expect based on previous studies (S. W. Flavell et al., 2006; Lyons et al., 1995; Shalizi et 





Figure 4.11. 2D view module from DAVID illustrating the top functional gene cluster pertaining mainly 
to neuron development, differentiation and neuron projection that was significantly enriched (ES>1.3) 
within the list of genes differentially expressed between SPC04 cells transduced with silencing MEF2A 




4.5.7. Ingenuity pathway analysis (IPA) 
An analysis was made to determine whether this set of DE expressed genes was enriched in 
any biological functions, pathways or diseases Ingenuity pathway analysis (IPA) was 
performed. The genes that showed significant DE at an unadjusted p-value <0.005 were used 
for this analysis. Here, the top associated network was cardiovascular system development 
and function, cell to cell signalling and tissue development as 18 molecules in this network had 
altered expression in the knock-down cells (Figure 4.12). This is not entirely surprising, as 
MEF2A was primarily discovered and described in context of cardiac muscles development 
(Dodou, Sparrow, Mohun, & Treisman, 1995; Naya & Olson, 1999; Olson, 2003). Interestingly, 
the top subcategory within ‘diseases and disorder’ was Neurological Diseases, as 24 molecules 
previously associated with neurological disorders had altered expression in the MEF2A knock-




to see that most of neurological disorders present on the list are of muscular nature (i.e. 
neuromuscular disease, movement disorders etc.). What is interesting is that 
neurodevelopmental disorders such as Schizophrenia and Rett Syndrome are also enriched 
with genes deregulated upon MEF2A silencing, suggesting that these disorders may be caused 
at least in part by disruption of MEF2A gene network. 
Table 4.7 Ingenuity analyses showing the top diseases and disorders with significant (p < 0.05) 
enrichment of genes deregulated in MEF2A knock-down SPC-04 cells. The corresponding p-value and 
relevant gene symbols are also included. 
 
Category























Alzheimer's disease 1.14E-02 DCX,GABBR2,GFAP,GLRX,MAPK8IP1
chronic fatigue syndrome 3.03E-02 BCAN,SPP1
















Figure 4.12. Top network in MEF2A knock-down SPC-04 cells representing cardiovascular system 
development and function, cell to cell signalling and tissue development. Green indicates genes which 
were significantly down-regulated in the MEF2A knock-down samples and red indicated genes which 
were significantly up-regulated in the MEF2A knock-down cells, compared to control cells. 
 
4.5.8. Enrichment for schizophrenia (SZ) or autism (SFARI) genes 
To further explore the potential relevance of deregulated genes in neurodevelopmental 
disorders, we analysed them for enrichment of genes that have previously been associated 
with ASD or schizophrenia (Table 4.9). The genes that showed significant DE at an unadjusted 
p-value <0.005 were used for this analysis. We have found 5 genes previously associated with 
ASD, 2 of them (HEPACAM and NFIA) were also DE in MYT1L knock-down dataset, however the 
enrichment wasn’t significant. We found no genes enriched for schizophrenia.  
Table 4.8. Enrichment of known ASD and SZ genes in the DE data set. The number of overlapping genes 
between the SFARI or SZ datasets and the DE genes list, and the p-values are included.   
 
SFARI (no. of overlapping genes) SFARI p-value SZ (no. of overlapping genes) SZ p-value





In the nervous system, MEF2 transcription factors have emerged as regulators of activity-
dependent neuronal survival and differentiation (S. W. Flavell et al., 2006; S. W. Flavell & 
Greenberg, 2008; Shalizi et al., 2006). The present series of experiments were designed to 
assess if MYT1L is a potential target gene of MEF2A during embryonic stem cells differentiation 
and development of zebrafish and mouse brain.  
In this chapter, we found that mef2a expression in zebrafish embryos is similar to that of 
myt1l. These results only confirm mef2a presence in zebrafish embryos, and that it is 
evolutionary conserved gene. However based on our study only, we cannot comment on brain 
specific expression of this gene, as we tested whole embryos, and mef2a in contrast to myt1l is 
not a brain specific transcription factor. From the literature we know that, in the zebrafish 
head, mef2a is expressed at 48hpf in the telecephalon, midbrain and hindbrain, areas that 
were also highlighted by our ISH with myt1l at this time point. Thus we can suggest an overlap 
of the expression between the two genes, and possibility of their interaction in the 
aforementioned regions. However, data on mef2a expression in the zebrafish nervous system 
development is limited, and it would be indeed beneficial to further examine localisation of 
mef2a at various time points during zebrafish embryonic development, as it could provide us 
with valuable information of its brain region specific expression patterns and the potential 
similarities to myt1l expression. We have also found that in the developing mouse brain, 
Mef2a expression gradually increased during embryonic stages, however the peak in 
expression was observed at 1 week postnatally. Transcriptional levels of Mef2a remained 
elevated at 1 month and 6 months after birth, implicating that this transcription factor might 
have a role in synaptogenesis. This finding supports previous studies performed on rat brain 
lysates, where MEF2A and MEF2D proteins were identified during embryogenesis, but their 
expression increased during the first 3 weeks after birth, a time during which synapses form 
and are remodelled (S. W. Flavell et al., 2006). Zebrafish embryos develop to fully swimming 
larvae within 5 days pfs, and since we only tested up to 3 days pfs, I can only draw very broad 
conclusions on the similarities in Mef2a expression between the two species.  
Results obtained from analysis of mef2a mRNA levels in the mouse brain are generally in 
agreement with the data obtained from fish embryos, as in both cases we observe gradual, 
modest increase in Mef2a expression, showing that the function of this gene is conserved in 




expression. We observed the highest expression of Myt1l gene just prior to birth (>6000 fold 
increase), but its levels remained significantly elevated at 1 week and 1 month postnatally, 
suggesting that both of those genes can play a role during neuronal maturation and 
differentiation. It is noteworthy that Myt1l expression seems to be more abundant in both 
mouse brain and in the zebrafish than Mef2a. This could be due to the fact that Myt1l is brain 
specific transcription factor, while Mef2a has been found in other tissues (i.e. muscle tissues 
(Liu et al., 2012; Zhao, Zhao, & Peng, 2012). This can suggest that Mef2a has a more diverse 
role than Myt1l and that its primary function is to activate genes involved in muscle 
proliferation and differentiation. 
We have also interrogated Gene Expression Nervous System Atlas (GENSAT) database (Gong et 
al., 2003) for possible presence of MEF2A or MYT1L however the expression of those two 
genes were not mapped in that database. The GENSAT project creates a library of bacterial 
artificial chromosome (BAC) clones that provide genetic access to each of the major cell 
populations in the mammalian brain, and it offers a collection of BAC transgenic mouse lines 
carrying fluorescent reporter genes that in turn allows further anatomical and physiological 
studies of these cells (Heintz, 2004). If Mef2a or Myt1l were present in the GENSET project it 
would help us to visualise and identify individual cell type expressing a gene of interest.  
To elucidate if MYT1L may be a direct or indirect MEF2A target, we performed lentiviral 
mediated MEF2A knockdown in differentiating human neural embryonic stem cells, which 
resulted in an average of 40% reduction in MEF2A expression. Firstly, qPCR analysis in these 
samples revealed that decrease in MEF2A levels resulted in increased expression of MYT1L, 
whilst MYT1L knock-down did not affect MEF2A expression, which indeed suggests that MYT1L 
may be a direct or indirect MEF2A target. Microarray analysis revealed 11 differentially 
expressed genes between cells transduced with shRNA targeting MEF2A and non-silencing 
controls. The top hit was FAM69C gene, which is a member of the FAM69 family of cysteine-
rich type II transmembrane proteins. It is found specifically in the brain and eye (Tennant-
Eyles, Moffitt, Whitehouse, & Roberts, 2011), however its function remains yet to be 
determined.  
Another gene that was deregulated upon MEF2A silencing was AQP4 (aquaporin 4). AQP4 is 
abundant in the mammalian brain and it is the predominant water channel in the brain 
(Jérôme Badaut, Verbavatz, Freund-Mercier, & Lasbennes, 2000). Altered levels of AQP4 have 
been associated with acute brain injuries, such as trauma (Ke, Poon, Ng, Pang, & Chan, 2001), 




haemorrhage (J. Badaut et al., 2003). It has been reported that AQP4 expression was rapidly 
up-regulated in the astrocyte endfeet in the early stages of stroke onset. This increase in AQP4 
was observed in the lesion site in a mouse stroke model, and the degree of its increase was 
temporally correlated with the degree of brain swelling (De Castro Ribeiro et al., 2006). Having 
AQP4 upregulated upon MEF2A silencing, can suggest that MEF2A may have a role in brain 
homeostasis. Interestingly, out of the 11 DE genes in MEF2A dataset, 7 were common to both 
datasets, MEF2A knock-and list and list of the DE genes generated from the MYT1L knock-
down microarray experiment. This finding alone can imply that MEF2A and MYT1L operate 
through the same regulator pathways.  
Gene set enrichment analyses were performed to ascertain whether differentially expressed 
genes were overrepresented in any particular biological functions, diseases, disorders, or 
canonical signalling pathways. The functional annotation analysis had shown that there are 
alterations in the expression of genes that have been previously associated with neuron 
projection, differentiation and development, indicating that MEF2A can play a role in neuronal 
differentiation through the regulation of those genes. Noteworthy, one of the genes 
repeatedly present in GO terms associated with neuron development and differentiation was 
NEUROD2. Neurogenic differentiation factor 2 (NeuroD2) is expressed exclusively in post-
mitotic neurons and research indicates that it mediates neuronal differentiation (McCormick 
et al., 1996). From our study point of view, this is very interesting finding, as NEUROD2, in 
combination with MYT1L and ASCL1, was reported to facilitate micro-RNA mediated 
conversion of human fibroblasts into neurons (Yoo et al., 2011). The link between NEUROD2, 
MYT1L and MEF2A strengthens our hypothesis that MYT1L is a target of MEF2A.  
Ingenuity Pathway analysis revealed that our set of deregulated genes was enriched for motor 
disorders. This finding is not surprising as MEF2 has been implicated in multiple aspects of 
muscle development (Potthoff & Olson, 2007). Our findings support previous studies on 
MEF2A, where MEF2A and MEF2D double knock-out mice showed deficits in motor 
coordination and enhanced short-term synaptic plasticity (Akhtar et al., 2012), whereas MEF2A 
and MEF2C were reported to be dysregulated in patients with myotonic dystrophy (Bachinski 
et al., 2010). We have also found genes that were previously associated with autism spectrum 
disorder, however most probably due to the sample size, the genes weren’t significantly 
enriched. Nevertheless, all these results taken together suggest a list of potential target genes 
of MEF2A and they bring the interesting possibility of MEF2A being a regulator of MYT1L. We 




MYT1L dataset, we also observed alterations in similar pathways or biological functions when 
the two sets were analysed. Furthermore, our results show that knock-down of MEF2A leads 
to increased expression of 107 genes and downregulation of 18 genes, which suggest that in a 
basal state those genes are maintained in a repressive state. Importantly, 87 of the genes 
upregulated upon MEF2A knockdown, were down-regulated by MYT1L silencing, but none was 
upregulated by the same treatment. These findings also suggest that upon reduction of MEF2A 
expression, genes belonging to the same regulatory pathway are activated to compensate for 
the loss of its function, whereas the same genes upon MYT1L silencing are also down-
regulated, meaning that MYT1L can act like a regulatory ‘switch’ for those genes.   
Previous studies have shown that MEF2s are required for neuronal survival and differentiation 
(Lyons et al., 1995; Mao et al., 1999). It has been shown that the reduction in MEF2s also 
prevents a metaplastic shift (i.e. activity-dependent regulation of neuronal plasticity), and 
reduction in MEF2 alone is sufficient to trigger a shift in plasticity responses (Chen et al., 2012). 
Thus, suggesting that MEF2 is a regulator of the plasticity threshold and implies orchestration 
of downstream effectors through altered transcriptional regulation. Here, by employing 
genome wide microarray analysis, we revealed target genes with diverse roles in neuron 
projection development and growth and neural differentiation.   
 
There are some limitations to this study. The first limitation stems from microarray findings 
itself. We only found 11 genes that were significantly deregulated in the cells transduced with 
MEF2A shRNA compared to cells with scrambled shRNA.  Similarly to MYT1L, we could not 
confirm results of reduced MEF2A in the cells transduced with shMEF2A compared to cells 
transduced with non-silencing shRNA. Thus, we were unable to confirm the efficiency of this 
transcription factor knock-down by microarray analysis. Although, we found by qPCR that 
MEF2A expression was altered in SPC-04 cells, our knock-down efficiencies were relatively low 
and fluctuating between the experiments, which could explain the microarray findings, and 
suggest little change between the two groups. One possible solution would have been to 
measure lentiviral concentrations and use a given concentration rather than certain quantity 
of the virus. This is an oversight on our part, as we performed experiments without the certain 
viral titer. The second limitation in this project is corroboration of microarray findings. Due to 
time constrains of these thesis, we were unable to validate any of our findings by qPCR. 




MEF2A down-regulation, it would be interesting to characterise neuronal properties of the 
cells with deregulated MEF2A.  
In terms of future experiments, efforts should be made to construct a more reliable knock-
down with a stable efficiency and known titer to corroborate our initial findings. Considering 
that increasing MEF2 expression decreases the number of dendritic spines and excitatory 
synapses in vitro (S. W. Flavell et al., 2006), and blocks increases in spine density normally 
observed after repeated cocaine administration in rat nucleus accumbens neurons in vivo 
(Pulipparacharuvil et al., 2008), it would be interesting to study cell morphology and cellular 
properties of neurons past 7 days of differentiation. It remains unknown, how downregulation 
of MEF2A leads to increased levels of MYT1L and co-expressed genes. The mRNA experiments 
described in this chapter do not address whether MYT1L or the genes identified are direct or 
indirect targets of MEF2A. To determine which of these genes are directly regulated by MEF2A 
and to provide additional confirmation that our knock-down and microarray experiments have 
indeed identified MYT1L as a MEF2A target, chromatin immunoprecipitation (ChIP) could be 
performed. Also, our studies concentrated only on in vitro approach, therefore it would be 
important to extend our results to in vivo studies to further elucidate MEF2A function and to 
examine whether the candidate MEF2A target genes identified in these experiments are also 
deregulated upon MEF2A silencing in live neurons in the brain.  
 
Dysregulation of transcription factor activity has been linked to various neuropsychiatric 
disorders, from substance abuse to neurodegenerative disorders (Steven W. Flavell et al., 
2008; Eric M. Morrow et al., 2008; Pulipparacharuvil et al., 2008). It has been suggested, that 
MEF2A might be involved in such disorders, by for example regulating cocaine-induced 
changes in dendritic spines (Benjamini & Yekutieli, 2001), however the mechanisms that 
regulate MEF2A remain unknown. Determination of such mechanisms is required to unravel 
the roles of this transcription factor in neuronal and brain development in health and disease. 
 
In conclusion, our study investigated the role of MEF2A on MYT1L expression during stem cell 
differentiation. It provided new insights into molecular interplay of these two transcriptional 
factors. To date, this is the first study that has showed a strong negative correlation between 




are deregulated upon both MEF2A and MYT1L knockdown suggesting that they could be part 






The general aim of this thesis was to investigate the functional role of a transcription factor 
MYT1L. This protein-coding gene is highly expressed in the brain, where it has been detected in 
neurons at the early stages of differentiation, but not in the glial lineage. This suggests that 
MYT1L has a role in the neurodevelopment (Armstrong et al., 1995; J. G. Kim et al., 1997). 
Additionally, studies have associated this gene with various neurodevelopmental and 
psychiatric disorders, such as autism (K. J. Meyer et al., 2012), schizophrenia (Y. Lee et al., 
2012; Van Den Bossche et al., 2013; Vrijenhoek et al., 2008),  intellectual disability (Bonaglia et 
al., 2009; S. J. Stevens et al., 2011) and major depressive disorder (T. Wang et al., 2010). The 
role of MYT1L in regulating neuron differentiation is further underlined by a recent 
breakthrough study showing that this protein, in conjunction with transcription factors Ascl1 
and Brn2, is essential for inducing functional mature neurons in a mouse induced pluripotent 
stem cell model (T. Vierbuchen et al., 2010). However, the specific role of this gene and its 
mechanisms of action are not fully understood. To expand our knowledge about this 
transcription factor, the expression patterns were assessed in zebrafish and mouse brains, 
followed by gene silencing in vitro using differentiating stem cells as a model for 
neurodevelopment. 
 
5.1.  Role of myt1l in vertebrate brain development 
In order to examine Myt1l expression patterns during embryonic development in vertebrates, 
zebrafish and mouse brains were used as a model. 
The mechanisms underlying CNS development and specification of neuronal identity are well 
conserved across all vertebrates (Hauptmann & Gerster, 2000; Wilson & Houart, 2004) and 
development of the zebrafish is very similar to the embryogenesis in higher vertebrates, 
including humans. The short generation time, the large number of offspring and the 
transparency of the embryos make the zebrafish a good model organism to study the 
development using a genetic approach.  
The patterns of expression of zebrafish myt1l were analysed using in situ hybridisation. myt1l 
expression was first detected at 24hpf in the telencephalon region. The telencephalon is 
involved in the zebrafish, as in other vertebrates, in high brain functions such as memory, basic 




have extended axons and formed a simple scaffold of axon tracts and commissures connecting 
adjacent subdivisions. These first neurons are termed “primary neurons” and can be 
distinguished from later developing neurons. The first neurons of the telencephalon form 
shortly after 16hpf (Hjorth & Key, 2002), and they form a dorsorostal cluster and by 24hpf cells 
from this cluster extend their axons to create a new dorsoventrally directed tract (Ross, 
Parrett, & Easter, 1992).  
As the fish development progressed, at 36, 48 and 72hpf, the expression of myt1l became 
more and more widespread and it was found in many regions of the brain, but it was restricted 
only to brain. The expression of myt1l during zebrafish development was also measured 
through quantitative RT-PCR experiments on pools of embryos at 18SS, 24, 48 and 72hpf. 
Myt1l mRNA levels remained low during the first 24hpf of development and then strongly 
increased between 24 and 72hpf.  It is accepted that the fish hatches at 3days post fertilisation 
and it is called a larvae after that. During the hatching period the embryo continues to grow 
and morphogenesis of many organs is complete (Charles B. Kimmel et al., 1995). These results 
suggest that myt1l may play a pivotal role in brain development and that it might be involved 
in the process of neurogenesis. The data on zebrafish myt1l provided an insight into the 
embryonic expression profile of this gene. 
 In mouse and rat embryos Myt1l is solely transcribed in the developing central nervous 
system where it plays role in neurogenesis (Jiang et al., 1996; J. G. Kim et al., 1997; Weiner & 
Chun, 1997). In rodents, Myt1l is expressed predominantly in differentiating, postmitotic 
neurons, including those in the cerebral cortex, thalamus, hindbrain, and dorsal root ganglia (J. 
G. Kim et al., 1997). To investigate if Myt1l expression followed similar pattern in higher 
vertebrates, RNA extracts from mouse brains at various developmental time points were 
analysed.  The analysis showed a very low expression at the early stages of development with 
the highest expression just before the birth. Although gradually decreasing, the mRNA levels 
remained elevated up to 6 months (last data point tested) after birth.  
The mouse data corroborate findings obtained from the zebrafish model, suggesting that the 
most prominent role of Myt1l is just before birth, when neural development is most active 
with the peak of synapse formation and cortex development (Workman, Charvet, Clancy, 
Darlington, & Finlay, 2013). Unsurprisingly, MYT1L has been highly conserved during evolution 
with the human protein being 95% and 92% identical to mouse and rat Myt1l respectively (J. G. 




vertebrates. These results also demonstrated that Myt1l is not only important for embryonic 
development, but it may also play role during post-natal brain development.  
 
5.2. MYT1L gene targets 
The pivotal role of MYT1L in regulating neuron differentiation is underlined by a recent study 
showing that the protein, in conjunction with Brn2 and Ascl1, is sufficient for to directly 
reprogram embryonic and postnatal fibroblasts into functional neurons (T. Vierbuchen et al., 
2010). Ascl1 alone was able to produce cells with immature neuronal features, but co-infection 
with Brn2 and Myt1l was required to produce cells with more mature neuronal features. 
Interestingly, these Myt1l-induced neurons resemble excitatory cortical neurons of the 
forebrain, mostly forming excitatory synapses (T. Vierbuchen et al., 2010). Moreover, Myt1l, in 
conjunction with Ascl1, Brn2, and NeuroD1 (Z. P. Pang et al., 2011), or with Ascl1, NeuroD2, 
miR-9/9* and miR-124 (Yoo et al., 2011) can directly convert human fibroblasts into neural 
lineages. These induced human neurons show neuronal morphology and express multiple 
neuronal markers (Z. P. Pang et al., 2011; Pfisterer et al., 2011). They are able to generate 
action potentials and to receive synaptic contacts and can be directed towards distinct 
functional neurotransmitter phenotypes, such as dopaminergic neurons (Pfisterer et al., 2011) 
or glutamatergic neurons or 
GABAergic neurons (Z. P. Pang et al., 2011; Thomas Vierbuchen & Wernig, 2011; Yoo et al., 
2011).  
All of the aforementioned studies imply regulatory functions of MYT1L in neurogenesis, 
however, at present, there are no studies investigating the direct role of MYT1L in 
neurodevelopment. Many transcription factors are downstream targets of signalling pathways 
and integrate different signalling inputs that control cell behaviour (Armant et al., 2013). 
Although the concept of a key lineage-specifying transcription factors referred to as master 
regulators has been suggested (Oestreich & Weinmann, 2012; Yang et al., 2004), a growing 
body of research indicates that transcription factors act in a combinatorial fashion and the 
interplay between these factors determines the final outcome of the gene-expression profile 
(Davidson et al., 2002; Ravasi et al., 2010).  
Our study is the first identifying possible target genes of MYT1L. Among the genes showing 




genes belonging to cell adhesion and the top scoring cluster consisted of genes involved in 
synaptic transmission and regulation. Among the various proteins involved in the 
establishment of the neural networks, cell adhesion molecules play a pivotal role in the 
identification of the appropriate partner cell and the formation of a functional synapse (Brose, 
1999). These findings suggest a role for MYT1L in processes such as neurite outgrowth, 
synaptic formation and neural migration. Further research is now required to verify and refine 
these initial findings.   
Gene expression profiling revealed a list of potential targets of MYT1L, most of which were 
down-regulated upon MYT1L silencing, implying that the MYT1L regulates the expression of 
those genes. Perhaps underlying the potential role of MYT1L in neurodevelopment comes 
from close examination of the deregulated genes: WNT7A and NLGN3. WNT7A is a member of 
the Wnt family of signaling molecules and it has been shown to play an important role in axon 
development, guidance, and synapse formation (Lorenza Ciani et al., 2011; Gogolla, 
Galimberti, Deguchi, & Caroni, 2009; A. C. Hall, Lucas, & Salinas, 2000). Wnt7a induces axonal 
remodeling and synaptogenesis in cerebellar granule cells and in adult hippocampal neurons 
(Gogolla et al., 2009; A. C. Hall et al., 2000). Moreover, loss of Wnt7a expression led to reduced 
neural stem cell self-renewal, increased the rate of cell cycle exit in neural progenitors and 
reduced numbers of newborn neurons in the hippocampal dentate gyrus of adult mouse 
brains (Qu et al., 2013). In addition, the gene encoding a member of a family of neuronal cell-
adhesion proteins, NLGN3, was downregulated upon MYT1L knock-down. Mutations in this 
gene have been identified in patients with ASDs (Jamain et al., 2003; Sudhof, 2008; Tabuchi et 
al., 2007). Autism is thought to arise from functional changes in neural circuitry and to be 
associated with an imbalance between excitatory and inhibitory synaptic transmission, 
however precise mechanism of action remain unknown (J. L. R. Rubenstein & Merzenich, 
2003). Studies suggest that a defect in NLGN3 may alter formation of specific synapses 
essential for the communication processes that are deficient in individuals with autistic 
spectrum disorder (Jamain et al., 2003). Recently it was found that induced neuronal (iN) cells 
that were derived from fibroblasts using Ascl1, Brn2 and Myt1l, when produced from a 
previously described mouse mutant in neuroligin-3, exhibited a phenotype similar to that 
observed in neurons with Nlgn3 mutation (Chanda, Marro, Wernig, & Südhof, 2013). This study 






5.3. Repressive function of MEF2A on MYT1L 
MEF2A plays multiple roles in neuronal development, including neuronal survival (Mao et al., 
1999), dendritic differentiation (Shalizi et al., 2006), synaptic density of hippocampal neurons 
(S. W. Flavell et al., 2006), spine density in nucleus accumbens (Pulipparacharuvil et al., 2008), 
and both synapse weakening and elimination and synaptic strengthening (Steven W. Flavell et 
al., 2008). A previous microarray study, conducted on differentiating stem cells (Desrivieres et 
al., 2014), revealed a set of genes that followed the same expression pattern as MYT1L. An 
examination of genes co-expressed with MYT1L during stem cells differentiation, led to the 
observation that the majority of them were enriched with MEF2A transcription factor binding 
sites. Based on that data and the hypothesis that MEF2A influences MYT1L expression,  
chapter 4 aimed at investigating regulatory role of MEF2A on MYT1L. One of the most 
intriguing questions raised by this study was whether MEF2A could act as a transcriptional 
repressor of MYT1L. To address this question the lentiviral-mediated MEF2A knockdown in 
differentiating human neuronal stem cells was used. Gene expression profiling experiments 
were performed on cells differentiated for 7 days. After successful validation of shRNA MEF2A 
knockdown efficiency, MYT1L mRNA levels were measured. Most interestingly, it was 
discovered that MYT1L levels were indeed dependant on MEF2A expression. A strong negative 
correlation was reported between the two genes, showing that MYT1L expression was 
enhanced upon MEF2A silencing. MYT1L levels responded increasingly to decreasing levels of 
MEF2A. It is very important to note that those correlations were observed only in MEF2A 
knock-down samples, as MYT1L silencing did not affect MEF2A expression, suggesting that 
MYT1L is a MEF2A target and not the other way around. Subsequent microarray analysis 
revealed a small number of differentially expressed genes in the MEF2A knock-down cells, all 
of which were upregulated. The DE analysis revealed that majority of genes deregulated upon 
knock-down of MEF2A were also de-regulated by knock-down of MYT1L, suggesting that both 
genes operate through similar or possibly the same regulatory pathways. Furthermore, the DE 
genes in this dataset were enriched for genes previously implicated in autism spectrum 
disorder, suggesting that MEF2A may be involved in key pathways related to these disorders.   
 
Previous studies have shown that knockdown of MEF2A and MEF2D in cultured hippocampal 
neurons increases the number of excitatory synapses and the frequency of miniature 




MEF2A in cerebellar granule neurons results in a decrease in the number of dendritic claws 
(Shalizi et al., 2006). Moreover, knock-out of the MEF2A-related transcription factor MEF2C in 
NSCs produced neurodevelopmental defects similar to ASD (Lipton et al., 2009). Additionally, 
mice with MEF2C conditionally knocked out at the NSC stage exhibited fewer, smaller, and 
more compacted neurons, similar to findings in Rett syndrome (Lipton et al., 2009). When 
MEF2C was knocked out later in development, neurogenesis was not affected, although 
synapse formation was altered (Lipton et al., 2009). Knockdown of MEF2A increases the 
density of orphan presynaptic sites in primary granule neurons and in the cerebellar cortex in 
rats (Yamada et al., 2013). Interestingly, the gene encoding synaptotagmin I (Syt1) has been 
recently found to be a novel direct repressed target gene of MEF2A in neurons (Yamada et al., 
2013). It has been demonstrated that Syt1 repression mediates the ability of sumoylated 
MEF2A to eliminate orphan presynaptic sites (Yamada et al., 2013). These findings can possibly  
explain MYT1L relation to MEF2A. Findings from this thesis suggest another MEF2A target gene 
– MYT1L, where both MEF2A and MYT1L are components of a novel transcriptional pathway 
that orchestrates neuronal development. 
 
5.4.  Study limitations 
Study limitations specific to each chapter has been discussed in the corresponding sections 
and they will not be recounted here.  
One potential limitation to this thesis is that almost all of the work presented comes from in 
vitro studies. It would have been beneficial to assess the effects of MYT1L downregulation in 
vivo. Culturing cells in vitro provides a method of studying cells in a controlled environment. 
The major advantages of this system include the added control. However in vitro systems 
cannot recreate the complexity of in vivo biology. Currently, the extensive interactions among 
cells and tissues cannot be completely duplicated in a non-animal model. Most cell systems are 
representing only one cell type (no cell–cell interactions), often monoclonal in origin. Culture 
conditions are not homeostatic (i.e. exchange of media and continuous depletion of nutrients). 
However, using in vivo method isn’t without flaws. The models require relative large amounts 
of test substance. The use of inbred-strains does not reflect natural variances (Hartung & 
Daston, 2009). Additionally, some of the genetic perturbations can be lethal to an organism, 
however in tissue culture the effects are much easier manipulated. In vitro models are 




established. Also, novel technologies are quickly emerging which include image technologies 
as well as the diverse range of “omic” technologies. Taken together, the combination of in 
vitro and in vivo methods and findings can provide more evidence for gene function.  
Another limitation to this thesis comes from qPCR experiments performed in the present 
study.MYT1L and MEF2A ΔCt values were normalised against the expression levels of only one 
housekeeping gene. Data normalisation in real-time q-PCR is a crucial step in gene 
quantification analysis. The appropriate choice of the internal controls (e.g. housekeeping 
genes) is critical for a meaningful quantitative RNA analysis. The most important characteristics 
of housekeeping genes are that they are present in all cells and that their expression levels 
remain relatively constant in different experimental conditions (Janssens, Janicot, Perera, & 
Bakker, 2004).  However, in the present studies, stable expression of a control gene (such as 
GAPDH or RPL18) was only presumed and it was not verified experimentally. There is a 
growing body of evidence suggesting that at least two or three housekeeping genes should be 
used as internal standards because the use of a single gene for normalisation could lead to 
relatively large errors, as the expression of control genes may vary depending on the tissue 
types, experimental conditions and chosen time points (Vandesompele et al., 2002). GeNorm 
is commonly used software that utilises an algorithm for selecting the best candidate 
reference gene for a given experimental design (Vandesompele et al., 2002). The geometric 
mean of multiple carefully selected housekeeping genes has shown a vast improvement in the 
normalisation procedure (Vandesompele et al., 2002). Thus, the use of a single control gene in 
our experiments may not have been an optimal normalisation procedure, therefore future 
research with multiple housekeeping genes selected using the GeNorm algorithm to validate 
these findings would prove valuable.  
 
5.5.  Future directions 
Due to lack of success in the identification of interacting partners for human MYT1L protein, 
future research should continue with this line of work. Most biological processes involve the 
action and regulation of multi-protein complexes. Protein-protein interactions regulate the 
activities of cells, therefore identifying them is critical to understanding cellular processes. 
Mass spectrometry techniques have been developed for large-scale screening to identify 




with the identification of interacting partners for MYT1L and should enable the formulation of 
hypotheses concerning MYT1L protein function and stimulate further research. 
In chapter 2, we characterised myt1l expression during embryonic development of zebrafish. 
We used in situ hybridisation to localise myt1l. However, due to overstaining we were not able 
to determine exact expression patterns of myt1l gene product past 24hpf. One way to 
overcome this would be to look at the sections of brain tissue. To determine the specific brain 
regions and times at which myt1l is active in those regions would provide us with valuable 
clues of its possible role in neural development. Also, our findings from analysis of RNA from 
mouse brain suggest Myt1l involvement during post-natal development. In the zebrafish, we 
have only examined time points referred to embryonic development.  It would be of interest 
to investigate the gene expression patterns in the fully developed zebrafish to assess myt1l 
levels and its distribution in adult zebrafish.  
Additionally, it would be of interest to perform immunocytochemistry to investigate the 
consequences of MYT1L/MEF2A down-regulation on the SPC-04 cells differentiation potential.  
This technique would allow us to confirm expression of key neural stem cell marker. To 
achieve these cells would be stained with different markers alongside differentiation. Possible 
markers to use would be Nestin (neuronal stem cell marker), Glial fibrillary acidic protein 
(GFAP; marker of astrocytes), O1 (for oligodendrocytes), βIII-tubulin (for neurons) and Tau 
(mature neurons). These results would further expand our knowledge of the role of 
MYT1L/MEF2A during neuronal differentiation.  
It remains unknown how MEF2A regulates expression of MYT1L. The mRNA profiling 
experiments described in these theses do not address the question whether the genes 
identified are direct or indirect targets of either MEF2A or MYT1L. To determine which of these 
genes are directly regulated by MEF2A/MYT1L and to provide additional confirmation that our 
microarray experiments have indeed identified MYT1L as a target of MEF2A, chromatin 
immunoprecipitation (ChIP) could be performed.  
Lastly, our studies concentrated only on in vitro approach, therefore it would be important to 
extend our results to in vivo studies of further elucidate MYT1L role in brain development and 
to examine whether the candidate target genes identified in these experiments are also 
deregulated upon MYT1L or MEF2A silencing in live neurons in the brain. Manipulation of 
MYT1L expression in the brain will enable us to investigate the consequence of its absence in 




5.6.  Conclusions  
Despite the advances in science, molecular mechanisms underlying proper and abnormal brain 
remain largely unknown. Therefore, there is a need to identify genes and pathways involved in 
these processes. To summarise, using zebrafish as a model organism this thesis have shown 
when and where in brain MYT1L starts being expressed. Using lentiviral-mediated gene 
knockdown, effects of altered gene expression in differentiating stem cells were explored. As a 
result, this study provided foundations for dissecting role of MYT1L in neurodevelopment and 
its possible modes of action. This study has also supplemented the knowledge of the possible 
downstream targets of MYT1L during brain development.  This is also the first study showing a 
direct link between MYT1L and MEF2A, demonstrating that MYT1L together with group of 
genes could be regulated via MEF2A. Therefore, the findings presented throughout this thesis 
contribute towards a better understanding of MYT1L role, function and its molecular 
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Table A1. All differentially expressed (FDR < 0.05) genes between MYT1L knock-down and non-
silencing shRNA controls in SPC-04 cells. Relevant illumina probe, gene symbol and a name, log fold 
change (FC) for cells differentiated for 7 and 14 days, as well as uncorrected and FDR-corrected p-values 
are listed for each gene. Genes are sorted according to p- value; lowest to highest. 









520474 ODZ4  odz, odd Oz/ten-m homolog 4 (Drosophila) (ODZ4), mRNA. -1.65 -1.97 8.27E-07 0.0039 
4890181 RAP1GAP  RAP1 GTPase activating protein (RAP1GAP), mRNA. -1.40 -2.24 2.42E-06 0.0039 
5490019 GPX3  glutathione peroxidase 3 (plasma) (GPX3), mRNA. -0.75 -1.07 1.38E-06 0.0039 
6620008 KAL1  Kallmann syndrome 1 sequence (KAL1), mRNA. -2.17 -1.94 8.19E-06 0.0088 
4050025 0  mRNA; cDNA DKFZp686J23256 (from clone DKFZp686J23256) -2.03 -1.67 7.58E-06 0.0088 
3930026 RASL10A 
 RAS-like, family 10, member A 
(RASL10A), transcript variant 2, 
mRNA. 
-1.02 -2.04 9.52E-06 0.00921 
2100446 BCAN  brevican (BCAN), transcript variant 1, mRNA. -3.19 -2.53 1.83E-05 0.0129 
7050575 PPAP2B 
 phosphatidic acid phosphatase 
type 2B (PPAP2B), transcript 
variant 1, mRNA. 
-1.52 -1.07 2.00E-05 0.0129 
3370162 SPON1  spondin 1, extracellular matrix protein (SPON1), mRNA. -0.39 -1.43 1.96E-05 0.0129 
2570564 HLA-DRA 
 major histocompatibility 
complex, class II, DR alpha (HLA-
DRA), mRNA. 
-0.58 -1.82 2.37E-05 0.01435 
6110152 C21orf62  chromosome 21 open reading frame 62 (C21orf62), mRNA. -1.07 -1.51 2.52E-05 0.01436 
110333 LOC440585 
PREDICTED:  hypothetical 
LOC440585, transcript variant 3 
(LOC440585), mRNA. 
-1.76 -1.67 2.93E-05 0.01522 
4060433 MAOB 
 monoamine oxidase B (MAOB), 
nuclear gene encoding 
mitochondrial protein, mRNA. 
-1.74 -2.05 3.17E-05 0.01522 
3310307 C21orf63  chromosome 21 open reading frame 63 (C21orf63), mRNA. -1.45 -1.71 3.27E-05 0.01522 
3780092 TNFRSF21 
 tumor necrosis factor receptor 
superfamily, member 21 
(TNFRSF21), mRNA. 
-1.33 -0.70 3.30E-05 0.01522 
1410403 LRRN2 
 leucine rich repeat neuronal 2 
(LRRN2), transcript variant 2, 
mRNA. 
-0.41 -0.92 4.35E-05 0.0191 





 radial spoke head 1 homolog 
(Chlamydomonas) (RSPH1), 
mRNA. 
-1.28 -1.33 0.0001 0.01921 
4220468 ATP1B1 
 ATPase, Na+/K+ transporting, 
beta 1 polypeptide (ATP1B1), 
transcript variant 2, mRNA. 
-1.08 -1.01 9.53E-05 0.01921 
3520039 NLGN3  neuroligin 3 (NLGN3), mRNA. -1.07 -0.85 8.87E-05 0.01921 
1980246 MYO5C  myosin VC (MYO5C), mRNA. -0.98 -0.90 9.68E-05 0.01921 
3850059 LMO2  LIM domain only 2 (rhombotin-like 1) (LMO2), mRNA. -0.97 -1.65 7.73E-05 0.01921 
2600465 SH3GL2  SH3-domain GRB2-like 2 (SH3GL2), mRNA. -0.97 -1.08 5.38E-05 0.01921 
6620538 UBL3  ubiquitin-like 3 (UBL3), mRNA. -0.96 -1.07 6.04E-05 0.01921 
2760239 RASGRP1 
 RAS guanyl releasing protein 1 
(calcium and DAG-regulated) 
(RASGRP1), mRNA. 
-0.95 -1.10 6.05E-05 0.01921 
6900630 ATP2B4 
 ATPase, Ca++ transporting, 
plasma membrane 4 (ATP2B4), 
transcript variant 2, mRNA. 
-0.94 -0.70 7.39E-05 0.01921 
1230521 0  mRNA; cDNA DKFZp686N1644 (from clone DKFZp686N1644) -0.90 -1.01 7.48E-05 0.01921 
6100482 ATP2B4 
 ATPase, Ca++ transporting, 
plasma membrane 4 (ATP2B4), 
transcript variant 1, mRNA. 
-0.83 -0.79 9.12E-05 0.01921 
4210411 NDRG2 
 NDRG family member 2 
(NDRG2), transcript variant 6, 
mRNA. 
-0.73 -1.00 9.00E-05 0.01921 
6040500 WDR16  WD repeat domain 16 (WDR16), transcript variant 2, mRNA. -0.72 -1.16 0.0001 0.01921 
7050333 HEPACAM  hepatocyte cell adhesion molecule (HEPACAM), mRNA. -0.68 -1.56 5.28E-05 0.01921 
6060482 ATP1B1 
 ATPase, Na+/K+ transporting, 
beta 1 polypeptide (ATP1B1), 
transcript variant 1, mRNA. 




O) sulfotransferase 15 (CHST15), 
mRNA. 
-0.60 -1.07 6.32E-05 0.01921 
110239 CALCR  calcitonin receptor (CALCR), mRNA. -0.56 -0.98 8.81E-05 0.01921 
1690403 PMP2  peripheral myelin protein 2 (PMP2), mRNA. -0.36 -1.40 5.93E-05 0.01921 
6040451 SLC47A2 
 solute carrier family 47, member 
2 (SLC47A2), transcript variant 1, 
mRNA. 
-0.15 -1.15 6.29E-05 0.01921 
4780563 GABBR2 
 gamma-aminobutyric acid 
(GABA) B receptor, 2 (GABBR2), 
mRNA. 
-1.81 -0.73 0.00011 0.01938 
5960475 RHPN2  rhophilin, Rho GTPase binding protein 2 (RHPN2), mRNA. -1.24 -1.34 0.00011 0.01938 





 diazepam binding inhibitor 
(GABA receptor modulator, acyl-
Coenzyme A binding protein) 
(DBI), mRNA. 
-0.43 -0.99 0.00013 0.02175 
4760747 TPST1  tyrosylprotein sulfotransferase 1 (TPST1), mRNA. -0.90 -1.16 0.00014 0.02179 
5360689 PROX1  prospero homeobox 1 (PROX1), mRNA. -0.70 -0.68 0.00014 0.02181 
5360301 LMO3 
 LIM domain only 3 (rhombotin-
like 2) (LMO3), transcript variant 
1, mRNA. 
-1.53 -1.15 0.00015 0.02261 
4780044 LOC389386 PREDICTED:  misc_RNA (LOC389386), partial miscRNA. -0.52 -0.99 0.00015 0.02261 
870048 PHYHIPL 
 phytanoyl-CoA 2-hydroxylase 
interacting protein-like 
(PHYHIPL), mRNA. 
-1.77 -0.95 0.00017 0.02434 
940630 MOBKL2B 
 MOB1, Mps One Binder kinase 
activator-like 2B (yeast) 
(MOBKL2B), mRNA. 
-1.26 -0.90 0.00018 0.02434 
4180452 ATP1B1 
 ATPase, Na+/K+ transporting, 
beta 1 polypeptide (ATP1B1), 
transcript variant 1, mRNA. 
-0.90 -1.05 0.00017 0.02434 
460767 BGN  biglycan (BGN), mRNA. -0.56 -1.02 0.00018 0.02434 
6100356 ALPL 
 alkaline phosphatase, 
liver/bone/kidney (ALPL), 
transcript variant 1, mRNA. 
-0.24 -0.91 0.00017 0.02434 
6550070 LPAR4  lysophosphatidic acid receptor 4 (LPAR4), mRNA. -0.68 -0.99 0.00018 0.02446 
540326 NCAN  neurocan (NCAN), mRNA. -1.90 -1.01 0.0002 0.02578 
2320047 NFIA  nuclear factor I/A (NFIA), mRNA. -1.79 -1.41 0.00024 0.02578 
3190608 SLC6A9 
 solute carrier family 6 
(neurotransmitter transporter, 
glycine), member 9 (SLC6A9), 
transcript variant 3, mRNA. 
-1.29 -1.46 0.00025 0.02578 
2600554 BTBD17  BTB (POZ) domain containing 17 (BTBD17), mRNA. -1.08 -1.44 0.00023 0.02578 
4180047 C1orf194  chromosome 1 open reading frame 194 (C1orf194), mRNA. -0.99 -1.30 0.00024 0.02578 
7550358 NELL2  NEL-like 2 (chicken) (NELL2), mRNA. -0.97 -1.66 0.00023 0.02578 
4570253 DTNA  dystrobrevin, alpha (DTNA), transcript variant 6, mRNA. -0.90 -1.15 0.00025 0.02578 
4560707 FAM183A 
 family with sequence similarity 
183, member A (FAM183A), 
mRNA. 
-0.86 -1.04 0.00025 0.02578 
4210678 PCSK1N 
 proprotein convertase 
subtilisin/kexin type 1 inhibitor 
(PCSK1N), mRNA. 
-0.76 -1.12 0.00022 0.02578 
1090326 TIMP4  TIMP metallopeptidase inhibitor 4 (TIMP4), mRNA. -0.76 -0.99 0.00021 0.02578 
1710020 SMOC1 
 SPARC related modular calcium 
binding 1 (SMOC1), transcript 
variant 1, mRNA. 




1570487 WDR16  WD repeat domain 16 (WDR16), transcript variant 2, mRNA. -0.66 -1.05 0.00021 0.02578 
1980484 EFHD1  EF-hand domain family, member D1 (EFHD1), mRNA. -0.63 -1.26 0.0002 0.02578 
4230195 NAV2  neuron navigator 2 (NAV2), transcript variant 2, mRNA. -0.62 -1.26 0.00022 0.02578 
2900626 SRI  sorcin (SRI), transcript variant 2, mRNA. -0.62 -1.15 0.00025 0.02578 
270168 HLA-DRA 
 major histocompatibility 
complex, class II, DR alpha (HLA-
DRA), mRNA. 
-0.27 -1.28 0.00024 0.02578 
5860039 CALB2  calbindin 2 (CALB2), transcript variant CALB2c, mRNA. -1.19 -0.62 0.00025 0.02586 
1660019 SNCAIP  synuclein, alpha interacting protein (SNCAIP), mRNA. -1.54 -1.25 0.00027 0.02606 
6220097 PPAP2B 
 phosphatidic acid phosphatase 
type 2B (PPAP2B), transcript 
variant 2, mRNA. 
-1.02 -0.68 0.00026 0.02606 
4780463 RAB6B  RAB6B, member RAS oncogene family (RAB6B), mRNA. -0.95 -1.29 0.00027 0.02606 
2450367 LRIG1 
 leucine-rich repeats and 
immunoglobulin-like domains 1 
(LRIG1), mRNA. 
-0.86 -1.07 0.00027 0.02606 
6770392 SRI  sorcin (SRI), transcript variant 1, mRNA. -0.68 -1.20 0.00026 0.02606 
240086 PHGDH  phosphoglycerate dehydrogenase (PHGDH), mRNA. -0.54 -1.30 0.00026 0.02606 
6040066 36403  septin 3 (SEPT3), transcript variant B, mRNA. -1.50 -1.21 0.00029 0.02706 
2750176 AQP4  aquaporin 4 (AQP4), transcript variant a, mRNA. -1.57 -1.97 0.00032 0.02909 
130754 PTPRZ1 
 protein tyrosine phosphatase, 
receptor-type, Z polypeptide 1 
(PTPRZ1), mRNA. 
-0.85 -0.99 0.00032 0.02909 
6550681 IGSF5  immunoglobulin superfamily, member 5 (IGSF5), mRNA. -0.80 -0.85 0.00032 0.02909 
150474 CA12  carbonic anhydrase XII (CA12), transcript variant 1, mRNA. -0.64 -1.88 0.00031 0.02909 
6220397 SC5DL 
 sterol-C5-desaturase (ERG3 
delta-5-desaturase homolog, S. 
cerevisiae)-like (SC5DL), 
transcript variant 1, mRNA. 
-0.51 -0.87 0.00032 0.02936 
1110048 SCRG1  scrapie responsive protein 1 (SCRG1), mRNA. -1.08 -0.31 0.00033 0.02936 
7000685 C1orf192  chromosome 1 open reading frame 192 (C1orf192), mRNA. -1.15 -0.83 0.00034 0.02965 
520324 REEP5  receptor accessory protein 5 (REEP5), mRNA. -0.54 -0.72 0.00035 0.0297 
4610672 FLJ14213  protor-2 (FLJ14213), mRNA. -0.57 -0.92 0.00035 0.02991 
360296 CRMP1 
 collapsin response mediator 
protein 1 (CRMP1), transcript 
variant 1, mRNA. 





 kelch repeat and BTB (POZ) 
domain containing 11 (KBTBD11), 
mRNA. 
-0.87 -1.16 0.00038 0.03189 
4210746 PACRG  PARK2 co-regulated (PACRG), transcript variant 3, mRNA. -1.00 -0.98 0.00039 0.03191 
2940189 LRRC4C  leucine rich repeat containing 4C (LRRC4C), mRNA. -0.57 -0.57 0.0004 0.03234 
2120707 CETN2  centrin, EF-hand protein, 2 (CETN2), mRNA. -0.81 -0.76 0.0004 0.03254 
1850242 ARMC3  armadillo repeat containing 3 (ARMC3), mRNA. -0.70 -1.03 0.00043 0.03354 
5490768 GPR56 
 G protein-coupled receptor 56 
(GPR56), transcript variant 3, 
mRNA. 
-1.22 -0.98 0.00043 0.0337 
1990079 FBXO32  F-box protein 32 (FBXO32), transcript variant 2, mRNA. -1.57 -0.42 0.00045 0.03461 
4590102 WRB  tryptophan rich basic protein (WRB), mRNA. -0.73 -0.47 0.00045 0.03461 
3940095 NAV2  neuron navigator 2 (NAV2), transcript variant 2, mRNA. -0.27 -0.83 0.00047 0.0358 
6420630 SCARA3 
 scavenger receptor class A, 
member 3 (SCARA3), transcript 
variant 1, mRNA. 
-0.32 -0.85 0.00049 0.03706 
7330544 ALDOC  aldolase C, fructose-bisphosphate (ALDOC), mRNA. -0.42 -1.75 0.0005 0.03723 
4220672 MT1F  metallothionein 1F (MT1F), mRNA. -1.62 -1.08 0.00051 0.03752 
1710736 DOCK10  dedicator of cytokinesis 10 (DOCK10), mRNA. -1.06 -0.70 0.00053 0.03849 
6020682 RGMA  RGM domain family, member A (RGMA), mRNA. -2.01 -1.78 0.00053 0.0387 
4290097 CD99  CD99 molecule (CD99), transcript variant 1, mRNA. -0.59 -0.90 0.00056 0.03986 
2630519 RSHL3  radial spokehead-like 3 (RSHL3), mRNA. -1.59 -1.46 0.00058 0.04023 
2850301 AGT 
 angiotensinogen (serpin 
peptidase inhibitor, clade A, 
member 8) (AGT), mRNA. 
-1.28 -1.26 0.00058 0.04023 
1090246 BCAN  brevican (BCAN), transcript variant 2, mRNA. -1.03 -0.68 0.00059 0.04023 
5960180 PRPH  peripherin (PRPH), mRNA. -0.92 -1.49 0.00059 0.04023 
1190673 LMAN2L  lectin, mannose-binding 2-like (LMAN2L), mRNA. -0.91 -0.42 0.0006 0.04034 
4490180 BEXL1 PREDICTED:  brain expressed X-linked-like 1 (BEXL1), mRNA. -0.70 -0.97 0.0006 0.04053 
270022 CEP135  centrosomal protein 135kDa (CEP135), mRNA. -0.94 -0.93 0.00061 0.0406 
1570184 KCNN3 
 potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 3 
(KCNN3), transcript variant 1, 
mRNA. 
-0.83 -0.90 0.00062 0.04085 





 zinc finger protein 36, C3H type, 
homolog (mouse) (ZFP36), 
mRNA. 
-1.08 -1.47 0.00067 0.04352 
4040471 RUFY3 
 RUN and FYVE domain 
containing 3 (RUFY3), transcript 
variant 2, mRNA. 
-1.05 -0.72 0.00067 0.04352 
1990333 ASTN1  astrotactin 1 (ASTN1), transcript variant 1, mRNA. -0.33 -0.83 0.00066 0.04352 
4780187 0  cDNA clone IMAGE:5263177 -0.84 -0.74 0.00068 0.04353 
2900390 VCAM1 
 vascular cell adhesion molecule 
1 (VCAM1), transcript variant 1, 
mRNA. 
-0.80 -1.24 0.0007 0.04384 
6420168 DBNDD2 
 dysbindin (dystrobrevin binding 
protein 1) domain containing 2 
(DBNDD2), transcript variant 3, 
mRNA. 
-0.78 -0.99 0.00071 0.04395 
2070161 AQP4  aquaporin 4 (AQP4), transcript variant a, mRNA. -0.49 -0.81 0.00073 0.04447 
270201 MEGF10  multiple EGF-like-domains 10 (MEGF10), mRNA. -0.97 -0.92 0.00074 0.04477 
870632 0  clone 23700 mRNA sequence -0.80 -0.79 0.00075 0.0451 
7320139 SOX8  SRY (sex determining region Y)-box 8 (SOX8), mRNA. -1.01 -1.13 0.0008 0.04697 
290239 NAV2  neuron navigator 2 (NAV2), transcript variant 2, mRNA. -0.55 -1.43 0.00079 0.04697 
5360370 SNTG1  syntrophin, gamma 1 (SNTG1), mRNA. -0.55 -0.69 0.00082 0.04771 
3610735 F12  coagulation factor XII (Hageman factor) (F12), mRNA. -0.43 -0.64 0.00086 0.04952 
4890241 GPR56 
 G protein-coupled receptor 56 
(GPR56), transcript variant 2, 
mRNA. 
-1.24 -1.30 0.00088 0.04994 
2810026 WNT7A 
 wingless-type MMTV integration 
site family, member 7A (WNT7A), 
mRNA. 
-0.66 -0.45 0.00087 0.04994 
1440014 MYO5B  myosin VB (MYO5B), mRNA. -0.59 -0.70 0.00089 0.05022 
4220068 CD70  CD70 molecule (CD70), mRNA. 1.36 1.11 2.33E-06 0.0039 
5270367 CTSC  cathepsin C (CTSC), transcript variant 1, mRNA. 1.48 0.49 2.01E-06 0.0039 
3450138 CTSC  cathepsin C (CTSC), transcript variant 1, mRNA. 1.66 0.80 8.90E-07 0.0039 
4290403 CMTM7 
 CKLF-like MARVEL 
transmembrane domain 
containing 7 (CMTM7), transcript 
variant 2, mRNA. 
0.86 0.80 4.63E-06 0.00639 
6250019 SHC1 
 SHC (Src homology 2 domain 
containing) transforming protein 
1 (SHC1), transcript variant 2, 
mRNA. 
1.11 1.25 1.35E-05 0.01186 
670386 ID1 
 inhibitor of DNA binding 1, 
dominant negative helix-loop-
helix protein (ID1), transcript 
variant 2, mRNA. 





 glycophorin C (Gerbich blood 
group) (GYPC), transcript variant 
2, mRNA. 
0.78 1.39 5.60E-05 0.01921 
2260196 LOC392437 PREDICTED:  misc_RNA (LOC392437), miscRNA. 0.80 0.69 8.94E-05 0.01921 
7320551 LYN 
 v-yes-1 Yamaguchi sarcoma viral 
related oncogene homolog (LYN), 
mRNA. 
0.82 0.49 7.00E-05 0.01921 
3830092 RGS10 
 regulator of G-protein signaling 
10 (RGS10), transcript variant 1, 
mRNA. 
0.93 0.73 0.00011 0.01921 
990300 CALCRL  calcitonin receptor-like (CALCRL), mRNA. 0.98 1.00 0.0001 0.01921 
7160253 LAMA4  laminin, alpha 4 (LAMA4), mRNA. 1.08 0.77 7.55E-05 0.01921 
6560301 SH2B3  SH2B adaptor protein 3 (SH2B3), mRNA. 1.17 1.78 9.13E-05 0.01921 
2640544 ASS1 
 argininosuccinate synthetase 1 
(ASS1), transcript variant 2, 
mRNA. 
2.14 2.21 0.0001 0.01921 
110433 ASS1 
 argininosuccinate synthetase 1 
(ASS1), transcript variant 1, 
mRNA. 
2.30 2.36 6.70E-05 0.01921 
610152 DAB2 
 disabled homolog 2, mitogen-
responsive phosphoprotein 
(Drosophila) (DAB2), mRNA. 
0.66 0.73 0.00011 0.01938 
2710730 PLS3  plastin 3 (T isoform) (PLS3), mRNA. 1.44 1.29 0.00012 0.01991 
6020286 FST  follistatin (FST), transcript variant FST344, mRNA. 0.39 1.47 0.00014 0.02258 
6250192 COL6A3 
 collagen, type VI, alpha 3 
(COL6A3), transcript variant 3, 
mRNA. 
0.28 1.02 0.00018 0.02434 
6020152 SH3KBP1 
 SH3-domain kinase binding 
protein 1 (SH3KBP1), transcript 
variant 1, mRNA. 
0.60 0.93 0.00018 0.02446 
2120053 CYP1B1 
 cytochrome P450, family 1, 
subfamily B, polypeptide 1 
(CYP1B1), mRNA. 
0.60 1.73 0.00022 0.02578 
7210768 0 17000531886861 GRN_ES  cDNA 5, mRNA sequence 0.76 0.39 0.00024 0.02578 
2340241 IMPA2 
 inositol(myo)-1(or 4)-
monophosphatase 2 (IMPA2), 
mRNA. 
0.91 0.63 0.00022 0.02578 
2060040 ADORA2B  adenosine A2b receptor (ADORA2B), mRNA. 0.97 0.73 0.0002 0.02578 
2190603 PLS3  plastin 3 (T isoform) (PLS3), mRNA. 1.38 1.12 0.0002 0.02578 
6040097 ARAP3 
 ArfGAP with RhoGAP domain, 
ankyrin repeat and PH domain 3 
(ARAP3), mRNA. 
0.77 0.67 0.00027 0.02606 
6580270 LOC646723 
PREDICTED:  similar to Keratin, 
type I cytoskeletal 18 
(Cytokeratin-18) (CK-18) (Keratin-
18) (K18) (LOC646723), mRNA. 





 glycophorin C (Gerbich blood 
group) (GYPC), transcript variant 
2, mRNA. 
0.73 1.31 0.00035 0.0297 
5130435 LAMA4  laminin, alpha 4 (LAMA4), mRNA. 1.05 1.03 0.00034 0.0297 
3930367 DAB2 
 disabled homolog 2, mitogen-
responsive phosphoprotein 
(Drosophila) (DAB2), mRNA. 
0.65 0.85 0.00039 0.03191 
2640768 CTSC  cathepsin C (CTSC), transcript variant 1, mRNA. 0.72 0.14 0.00041 0.0326 
7610433 SLC1A5 
 solute carrier family 1 (neutral 
amino acid transporter), member 
5 (SLC1A5), mRNA. 
0.79 1.13 0.00041 0.0326 
5050053 TXNDC5 
 thioredoxin domain containing 5 
(endoplasmic reticulum) 
(TXNDC5), transcript variant 1, 
mRNA. 
0.61 0.69 0.0005 0.03738 
3450059 SH3KBP1 
 SH3-domain kinase binding 
protein 1 (SH3KBP1), transcript 
variant 1, mRNA. 
0.49 0.82 0.00055 0.03926 
5720136 RAB34  RAB34, member RAS oncogene family (RAB34), mRNA. 1.14 0.93 0.00055 0.03926 
7160343 MYLK 
 myosin light chain kinase 
(MYLK), transcript variant 8, 
mRNA. 
0.58 2.34 0.00058 0.04023 
6520064 TMEM178  transmembrane protein 178 (TMEM178), mRNA. 1.38 1.73 0.00059 0.04023 
4070356 FLG  filaggrin (FLG), mRNA. 1.74 0.92 0.00069 0.04384 
4570255 LEF1  lymphoid enhancer-binding factor 1 (LEF1), mRNA. 0.85 0.91 0.0007 0.04384 
2630195 VAMP5 
 vesicle-associated membrane 
protein 5 (myobrevin) (VAMP5), 
mRNA. 
1.41 1.44 0.0007 0.04384 
3440338 RNF181  ring finger protein 181 (RNF181), mRNA. 0.75 0.87 0.00072 0.04395 
5360273 SNCA 
 synuclein, alpha (non A4 
component of amyloid precursor) 
(SNCA), transcript variant 
NACP112, mRNA. 
0.76 0.67 0.00071 0.04395 
1070121 LOC340274 PREDICTED:  misc_RNA (LOC340274), miscRNA. 1.49 1.68 0.00078 0.04637 
2690538 LOC341230 PREDICTED:  misc_RNA (LOC341230), miscRNA. 1.02 1.01 0.00081 0.04754 
5130438 PIPOX  pipecolic acid oxidase (PIPOX), mRNA. 1.40 0.68 0.00083 0.04779 
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